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In populations worldwide, the Hepatitis C Virus displays great 
diversity.  The capsid gene, however, is remarkably conserved and this has 
led to predictions of RNA secondary structure and an overlapping, 
alternative reading frame (ARF). We investigated a role of the ARF in HCV 
infection, by introducing four stop codons into the ARF of a genotype 1a 
H77 molecular clone. These changes did not alter the capsid protein 
sequence, but were predicted to disrupt the RNA secondary structures, SLV 
and SLVI. An infection was launched after inoculation of the mutant HCV 
RNA into an HCV naïve chimpanzee. The acute infection was attenuated 
with low peak viremia, minimal ALT elevation, and early virus control by a 
diverse adaptive immune response.  
Sequencing circulating virus revealed progressive reversions at the 
third and then fourth stop codon mutations. In cell culture, replication of a 
genome with the four stop codons was severely impaired, but the revertant 
genomes showed a marked improvement in replicative fitness. Consistent 
with the chimpanzee infection, reversions at stop codons 3 and 4 were also 
selected by passage of mutant, infectious HCV in cell culture.  
Genetic evidence for RNA structures that were disrupted by the stop 
codons was provided by structure-restoring compensating mutations that 
relieved the defective HCV replication. Further mutagenesis identified bases 
and secondary structure features critical for function; mutations in the top 
stem of SLVI severely impaired HCV replication. RNA bearing these 
mutations was less efficiently translated in cell free extracts. The effect of 
mutations in SLVI was reduced when the HCV replicase proteins were 
translated using a heterologous IRES. This data suggests that these RNA 
structures are important for translation from the HCV IRES and that the 
defective translation exhibited by the SLVI mutants contributed to their 
impaired replication. 
Thus, RNA structures within the capsid coding region are responsible 
for modulating translation from the HCV IRES, and do not encode an ARF 
protein as had been postulated. While dispensable for the viability of 
subgenomic replicons, strong selective pressure for the integrity of these 
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Chapter 1. Introduction. 
Identification of hepatitis C virus. 
 Forty years ago, one in three blood transfusions resulted in the 
recipient contracting hepatitis 3. After diagnostic tests identified the hepatitis 
A and B viruses, the unattributed disease was designated as non-A, non-B 
hepatitis (NANBH). Harvey Alter and others demonstrated that serum from 
NANBH patients conveyed hepatitis when injected into a chimpanzee, and 
the causative agent was recognized as an enveloped virus after transmission 
was shown to be due to a chloroform-sensitive, filterable agent 1, 139. The 
virus responsible for NANBH was identified by Michael Houghton’s group 
at Chiron using a random-primed complementary DNA library prepared 
from NANBH-infected chimpanzee plasma and screened with serum from a 
NANBH infected patient 27. In a 7 year effort, one out of one million cDNAs 
was recognized by the NANBH patient serum and proved to be derived from 
the etiological agent by detecting an RNA of approximately 10,000 
nucleotides in only NANBH infected patient serum. With the cloned agent 
sequenced, the newly identified hepatitis C virus (HCV) was classified and 
its genome organization disclosed. Knowledge of HCV proteins enabled 
new serological diagnostic assays to be developed. By 1996, the nation’s 
2
blood supply could be screened for hepatitis A, B and C viruses reducing the 
risk of transfusion delivered hepatitis to nearly zero 2, 4.   
 
Epidemiology and disease burden of HCV. 
An estimated 3% of the world population is infected with HCV, and 
an estimated three to four million persons are newly infected each year 159. 
Infection with HCV is rarely cleared by the host immune response. In 65% -
80% of exposures, a persistent, chronic infection is established for the life of 
the host 51. Although initial symptoms are often mild, chronic infection can 
lead to liver damage and hepatocellular carcinoma. Infection with HCV 
accounts for approximately 20% of cases of acute hepatitis and 70% of cases 
of chronic hepatitis.  HCV is responsible for 50-76% of all liver cancer cases 
and is the leading cause of liver transplants in the developed world 159. 
 The severity of HCV related liver disease is extremely variable 
between patients. Progression of liver fibrosis to cirrhosis and to 
hepatocellular carcinoma may take years or decades. Jaundice and fulminant 
hepatitis are very rare. More commonly, patients show an elevation in the 
aminotransferase levels and may have mixed cyroglobulinemia 120. 
Disease prevalence is below 1% in Australia, Canada and northern 
Europe, about 1% in the USA and most of Europe, and greater than 2%  
3
(often 5-10%) in many countries in Africa, Latin America and Central and 
South-Eastern Asia 159. Italy has areas of high prevalence rates of over 
12.6%. Egypt has an extremely high seroprevalence rate ranging from 20% 
for those 10-19 years to about 60% for those above 30 years of age 156. 
 
Diversity of HCV. 
 HCV displays remarkable sequence diversity at various levels. There 
are 6 major genotypes displaying greater than 30% diversity at the 
nucleotide level 128, 129. They correlate with geographical location and 
particular risk groups. Within each genotype are more closely related 
subtypes, conventionally denoted with a letter, which differ by 20-25% at 
the nucleotide level. The subtypes 1a, 1b, and 3a are generally found in 
Western countries but can show a wide geographical range as they have 
been dispersed through blood transfusions and injecting drug use (Figure 
1.1) 134. Over 90% of HCV patients in Egypt are infected with genotype 4a 
as it was introduced and spread during a campaign for schistosomiasis 
treatment reusing nonsterilized needles 32. Within an infected patient, the 
virus population exists as a quasispecies differing by 2-5% at the nucleotide 
level.   
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Figure 1.1 Phylogenetic tree of the principal genotypes of HCV. The 
tree was constructed by using the neighbour-joining method using 
Jukes–Cantor-corrected distances between complete genome 































 The standard of care for HCV is pegylated interferon-alpha (IFN-α) in 
combination with ribavirin 28. Successful treatment is considered a sustained 
virologic response (SVR) and indicates undetectable HCV RNA in the blood 
24 weeks after treatment has ended. Treatment outcomes can vary with 89% 
of patients achieving SVR if not coinfected with HIV, relatively healthy, and 
infected with genotype 2 or 3.  The SVR drops to 30% for patients infected 
with genotype 1 HCV, coinfected with HIV, or with advanced liver fibrosis. 
A predictor of responding to treatment is seen within the first 12 weeks in a 
2 log drop in virus load 89.  
 
Transmission. 
Transmission occurs through direct contact of infected blood. 
Hemophiliacs, hemodialysis patients, drug addicts and people transfused 
with inadequately screened blood are particularly at risk for infection 4. In 
the developed world, intravenous drug use remains the main route of 
transmission, accounting for almost 90% of new HCV infections 107. Sexual 
transmission is thought to be infrequent. Mother-to-child infection ranges 
from 3-15% and is believed to occur in utero.  
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Classification and genome organization. 
 Hepatitis C virus is the sole member of the genus Hepacivirus in the 
family Flaviviridae. The virus genome is a single RNA molecule of positive 
strand polarity 9, 74. The genome organization closely resembles the other 
genera of the pestiviruses and flaviviruses. Virions are 50 nm in diameter, 
spherical, and surrounded by a lipid bilayer as measured by filtration and 
electron microscopy. Virus particles display significant heterogeneity as 
particles isolated from acutely infected patients have a buoyant density in 
sucrose of 1.06 g/cm3 and particles from serum of chronically infected 
patients have a density of 1.15-1.18 g/cm3 49. This lower density of is thought 
to be a result of particle association with very-low-density lipoproteins while 
the higher density particles are associated with immunoglobulins in the 
serum. Cell culture derived virus produces a density of 1.14 g/cm3 but a peak 
of specific infectivity at 1.10 g/cm3. Passage of cell culture derived virus in a 
chimpanzee resulted in particles having a major peak at 1.10 g/cm3 and a 
smaller peak at 1.14 g/cm3 73.   
 The HCV genome is a single-strand, positive polarity RNA molecule 
of approximately 9,600 nucleotides in length (Figure 1.2). The genome 
organization closely resembles the other genera of the Flaviviridae, the 
pestiviruses and flaviviruses. The RNA is uncapped and encodes a 
7
Figure 1.2. A. The genome of HCV is flanked by 5’ and 3’NTRs and 
encodes one, long polyprotein, which is processed by host cell and virus 
proteases into individual virus structural and nonstructural proteins. B. 




polyprotein of about 3000 amino acids that is cleaved co- and post-
translationally by cellular and virus encoded proteases into at least 10 mature 
proteins 45. These proteins act to replicate the virus genome into minus 
strand intermediates and then plus strand genomes, which are then packaged 
by virus structural proteins.  
 
NTRs. 
 The HCV polyprotein is flanked by non translated regions (NTRs) at 
the 5’ and 3’ of the genome which display highly structured RNA elements 
conducting translation and replication. An internal ribosome entry site 
(IRES) in the 5’ NTR directs translation of the polyprotein in a cap- 
independent manner and will be discussed in detail 54. Replication signals 
are present at the 5’ end of the 5’NTR and overlap the IRES 41. RNA 
structures in the minus sense are thought to act as promoters for the virus 
replicase during plus strand synthesis (Figure 1.3). The 3’NTR contains two 
highly conserved elements, the poly U/UC tract and a three helical structure 
of 98 bases called the 3’-X at the end of the 3’NTR 15, 162. Both elements are 
required for replication and are thought to act as promoters for the replicase 
during minus strand synthesis. A kissing interaction is required between the 
SL2 of the 3’-X and a large stem structure in the coding region of NS5B 40, 
9
Figure 1.3. RNA secondary structures in the HCV genome. A. The 
5’NTR contains RNA structures required for replication, SLI, and 
signals for translation by the IRES. SLV and SLVI are in the capsid-
coding gene. B. RNA secondary structures in the 3’NTR participate in 




165. The length of the poly U/UC tract can influence replication and may 
contribute to the stability of the kissing interaction 40. Although still 
controversial, the 3’NTR may contribute to translation efficiency 135. 
 
Structural proteins. 
 The structural proteins are expressed in the amino terminus the 
polyprotein. The capsid protein is a highly basic RNA binding protein that 
forms the nucleocapsid 121. It is the most conserved virus protein and has 
been described to perform a multitude of functions to modulate the host cell. 
A hydrophobic signal sequence located at the carboxy terminus of capsid 
guides the polyprotein into the ER where it is cleaved by the host cell signal 
peptidase. Another cleavage event by the host cell signal peptide peptidase 
removes the signal sequence from the anchored capsid protein; nonetheless 
the capsid remains associated with the ER via an unknown interaction 86, 157. 
HCV encodes two envelope glycoproteins, E1 and E2, believed to be type I 
integral membrane proteins, which are incorporated into the virion and likely 
interact with cellular receptors and mediate viral entry. Both E1 and E2 
contain signals in their transmembrane domains that mediate localization to 
the endoplasmic reticulum when expressed in cell culture. p7 is a small 
hydrophobic protein of 63 amino acids and contains two transmembrane 
11
domains and small basic loop in the cytoplasm and is often found uncleaved 
from E2 71. It has been shown to have ion channel activity resembling the 
M2 activity of influenza and other viroporins 100. It is not essential for 
replication, but required at an as yet unknown stage of infectious virus 
function 46. There are also reports of a protein expressed by ribosome 
slippage into a -2/+1 frame of the capsid gene 6, 18, 150, 153, 161. This alternative 
reading frame (ARF) is a conserved overlapping reading frame present in all 
6 genotypes that could express a 125-160 amino acid protein. HCV infected 
patients have been shown to produce antibodies and express T cell epitopes 
to peptides from the ARF, but a role for an ARF protein is unknown 66. 
 
Nonstructural Proteins. 
  The remaining proteins are considered nonstructural proteins (NS 
proteins) and participate in virus protein processing and virus replication. 
NS2 acts in conjunction with the NS3 protease to autocatalytically cleave 
itself from NS3 44.  The catalytic domain of NS2 acts as a dimeric cysteine 
protease with a composite active sites derived from two monomeric chains 
80.  NS2 is not required for virus replication, and recent studies have shown 
adaptive mutations found in NS2 permit virus production 164. The N terminus 
of NS3 is a serine protease responsible for four downstream cleavages of the 
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polyprotein. The carboxy terminus contains RNA helicase and nucleoside 
triphosphatase (NTP) activity 10, 145. The 54-residue NS4A is a cofactor of 
the protease NS3 and is associated with the ER and NS5A. NS4B is a 27kDa 
hydrophobic protein predicted to span the ER with at least four 
transmembrane domains with amino and carboxy tails located in the 
cytoplasm11. NS4B also has no currently defined function, but is thought to 
participate as a membrane scaffolding protein for the virus replicase. Genetic 
interactions have been described between NS4B and NS5A influencing 
HCV replication 11. NS5A is a serine phosphoprotein with hyper and basal 
phosphorylated states and is the target of numerous cell culture adaptive 
mutations improving HCV replication in Huh-7 cells 68, 141. NS5A has also 
been reported to act with cellular trafficking and antiviral pathways 142. 
NS5B is the RNA-dependent RNA polymerase and is anchored to the ER 
via its 21 amino acid carboxy tail 90. It has been shown to initiate RNA 
synthesis in a primer independent manner, but is regulated by interactions 
with other virus replicase proteins and RNA secondary elements of the 






 Virus attachment to, and entry into, target cells occurs by a 
multifactorial, multi-step process the details of which are not completely 
understood. Direct binding does occur between the glycoprotein E2 and the 
cellular co-receptors CD81 and scavenger receptor class-B member-I (SR-
B1) 47, 104. CD81 is present on numerous cells types and functions via 
interactions with cell type specific proteins; however, the role of CD81 in 
hepatocytes is unknown. Claudin-1 is required for infection at a late stage 
possibly after CD81 binding 35. Other receptors have also been described 
such as the liver and lymph node-specific intercellular adhesion molecule-3-
grabbing nonintergrin (L-SIGN) and the dendritic cell-specific intercellular 
adhesion molecule-3-grabbing nonintergrin (DC-SIGN) 43 106. HCV entry 
presumably occurs through receptor-mediated endocytosis, that delivers 
viral particles to endosomes, where low pH initiates fusion between the viral 
and cellular membranes 146. Following membrane fusion, although the 
mechanism has not been studied, the nucleocapsid is disassembled, and the 
virus genome RNA is released into the cytoplasm (Figure 1.4). 
 To generate viral proteins required for replication, the virus RNA 
must first undergo translation. The virus genome associates with the cellular 
translation machinery via the highly structured IRES of the 5’NTR. 
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Figure 1.4. Lifecycle of HCV. Virions bind the cell surface and are 
internalized by interactions with host cell receptors. Virus RNA is 
released into the cytoplasm where it undergoes translation of the 
polyprotein. Membrane-associated replicase complexes are formed which 
synthesize virus RNA via a minus strand intermediate. Genomic RNA is 
undergoes subsequent rounds of translation and establishing replicase 
compartments. Eventually genomic RNA is packaged by virus structural 
proteins and released from the cell.
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Translation begins with the assembly of a minimal set of cellular intiation 
factors to synthesize the entire polyprotein, which is cleaved into the 
individual virus proteins 58, 98. The replicase complex is built along the ER 
membranes, and the translated virus RNA becomes the template for RNA 
synthesis. Little is known about the transition from translation to replication, 
or how the virus RNA is recruited into the membrane complex. The RNA 
polymerase initiates replication at the 3’terminus of the positive sense 
genome to synthesize a full length complementary minus RNA strand, which 
is in turn used as a template for synthesis of genomic plus strand RNA. RNA 
amplification through the minus strand has not been thoroughly described 
for HCV, but previous work on other classical flaviviruses suggests that the 
minus strand RNA is base paired with the genomic RNA strand. This is 
referred to as the double-stranded replicative form, RF. The RF serves as the 
template to produce multiple positive-strand RNA molecules creating an 
unequal ratio of 10-100 positive to 1 negative strand RNA molecule in the 
cell. 
 Since translation of the polyprotein expresses equal molar ratios of 
each virus protein, and no subgenomic transcripts are generated, researchers 
have hypothesized about additional functions for both the structural and 
nonstructural virus proteins possibly acting as scaffolding or shuttle proteins 
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coordinating the virus RNA between the two processes of translation and 
replication. Replication complexes can be isolated from cells harboring 
replicating HCV. In such complexes, both positive and negative strand virus 
RNAs were protected from nuclease digestion and, by using protease 
digestion, only a small fraction of nonstructural proteins were found to 
contribute to replication 108. This indicates that the majority of the expressed 
nonstructural proteins may have a role supplemental to that played in RNA 
replication.  
 The mechanism of virus assembly has only recently begun to be 
studied. The capsid protein functions in virus assembly and domains of the 
capsid protein required for self assembly have been described 86, 94. The 
capsid protein has been observed to associate with cellular lipid droplets to 
act in virus assembly 117. The E1 and E2 glycoproteins associate with each 
other through their transmembrane domains, but their interactions with the 
capsid protein or other structural proteins during the assembly process is 
undefined. Compensatory mutations have been found in p7 and NS2 that 
enable production of infectious virus 164. Neither protein is thought to be 
incorporated into virions, and thus act during the assembly process in a yet 
undetermined manner.  
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Model systems to study HCV. 
Animal models. 
The study of HCV has been a challenge due to the inability to isolate 
virus from infected patients into cell culture. In addition, HCV displays a 
host range restricted to humans and the chimpanzee. Chimpanzees become 
infected with HCV after inoculation with serum from infected humans or 
chimpanzees, direct hepatic inoculation of in vitro transcribed HCV RNA, or 
from tissue culture derived virus 83, 139. The chimpanzee was the key animal 
model used to identify the causative agent of NANBH as the RNA virus 
HCV; inoculation of a chimpanzee with RNA transcripts from an HCV 
cDNA consensus clone led to infection and hepatitis, proving HCV is the 
causative agent of disease 65. Direct intrahepatic inoculation of HCV RNA 
transcripts, is still the most stringent system to test the in vivo importance of 
HCV genetic elements. This method was used to demonstrate the necessity 
of p7 and the RNA element 3’X region for HCV viability 119. Ethical and 
expense considerations make the chimpanzee model less than ideal, but the 
similarities between human and higher primate immune systems have 
enabled categorization of HCV-specific T cell epitopes, the presence of 
neutralizing antibodies, and study how the diversity of the virus allows 
escape from the host defenses.  
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Many studies have followed infections launched with monoclonal 
HCV genomes generated from cDNA clones and have established that 
chimpanzee and human HCV infections share similar features. Circulating 
HCV RNA can generally be detected 7-10 days after infection 123, 126. During 
the acute phase of weeks 2-20, HCV RNA levels increase and liver damage 
becomes apparent within 7-10 weeks as indicated by a rise in serum alanine 
aminotransferase (ALT) 24. The chimpanzee liver also displays signs of 
pathology, with inflammation and focal necrosis, but chimpanzees do not 
progress as frequently to severe liver disease, such as fibrosis and 
carcinoma, as do humans.  Seroconversion occurs generally between 15-20 
weeks 111. Neutralizing antibodies have been isolated from both human and 
chimpanzee infections; but appear unable to clear the virus 144. Levels of 
circulating HCV RNA show great variability in both species. Chimpanzee 
infections usually generate 104 to 107 HCV RNA copies/ mL during the 
acute phase. Greater variability is detected in chronically infected humans 
ranging from 102 to 108 HCV genome equivalents/ mL 154. Like humans, 
chimpanzees fail to spontaneously clear the virus during the acute phase and 
progress to chronic infection 60-70% of the time 113.  
Spontaneous clearance has been associated with generation of a 
diverse adaptive immune response. CD8+ and CD4+ T cells have been 
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isolated from the periphery and the liver and HCV-specific epitopes have 
been mapped. A correlation has been proposed between the diversity of 
virus epitopes recognized by the host T cells and the frequency of clearance 
30, 112, 158. HCV specific, interferon gamma producing T cells have also been 
shown be present in the liver of chimpanzees that have cleared the infection 
116, 137, 143. Development of a response by both CD8+ and CD4+ T cells has 
been shown to contribute to HCV clearance 45, 127. In both chimpanzee and 
human infections, HCV displays a similar mutation rate of 1.44 – 1.92 x 10-3 
base substitutions per genome per year 95. The generation of virus sequence 
diversity is thought to allow epitope escape permitting chronic infection.     
 
Chimeric mouse. 
 Establishment of a small animal model would provide a more 
convenient and economical alternative to study HCV. HCV inoculation of 
other primate monkey species, such as marmosets and tamarins, and also of 
tupaia and mice have failed to yield a reliable model for HCV infection. A 
chimeric mouse, which can express transplanted human liver cells, has been 
shown to replicate HCV 87. In this system, an immunodeficient SCID mouse 
was crossed with a transgenic mouse carrying the urokinase-type 
plasminogen activator gene controlled by the albumin promoter (Alb-uPA). 
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The Alb-uPA transgene results in programmed cell death of endogenous 
hepatocytes in the homozygous mice, thus enabling repopulation by injected 
human liver cells. Inoculation of serum from human HCV patients resulted 
in infection of these chimeric mice for 15-17 weeks with titers of 104 to 106 
HCV RNA copies/ mL in the blood. HCV could also be passed to other 
chimeric mice. There are numerous limitations for this model as the mice are 
difficult to breed and maintain because of the precarious state of their 
immune system. In addition, the mice must undergo a successful transplant 
of human liver cells, and this procedure often results in death. Studies of the 
immune response to HCV are also compromised by the SCID status of the 
chimeric mouse.  
 
Cell culture systems. 
Cell lines. 
 The study of HCV replication in cell culture has been challenging. 
The parental Huh-7 and subcultured Huh-7.5 cell line can support the most 
efficient replication for HCV genomes of genotypes 1a and 1b. Nonhepatic 
cell lines such as HeLa and 293 and the hepatic cell line HepG2 have been 
reported to replicate genotype 1 HCV, but not to levels equivalent to Huh-7 
and the Huh-7.5 cells.  The 2a sequence JFH-1 has demonstrated robust 
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replication in Huh-7 and Huh-7.5 cells as well as HepG2, 293, HeLa, and 
even primary mouse liver cells 61, 148. Primary hepatocytes are notoriously 
difficult to faithfully culture as they often de-differentiate in culture and lose 
specific functions and markers. The development of stem cell derived liver 
cells and three dimensional culture systems have not been reproducibly 
shown to easily propagate HCV replication.  
 
HCV RNA replication in cell culture. 
 HCV replication in cell culture was first achieved with the use of a 
subgenomic replicon that contained only the replicase proteins NS3 to NS5B 
for the genotype 1b Con1 sequence (Figure 1.5). The replicon included the 
5’ and 3’ NTRs of HCV, and expressed a drug selectable marker by the 
HCV IRES. A second cistron expressed the HCV replicase proteins behind 
the encephalomyocarditis virus (EMCV) IRES. Expression of the selectable 
marker, neomycin phosphotransferase (Neo), conferred resistance to the 
drug G418 and thus enabled selection for cells capable of harboring HCV 
replication 79. Replication of these subgenomic, bicistronic replicons in Huh-
7 cells allowed selection of more fit genomes. Adaptive mutations were 
discovered in NS3, NS4B, NS5A, and NS5B that enabled a substantial 
increase in the number of Huh-7 cells selected to replicate HCV 12, 78. These 
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Figure 1.5. A. Diagram of the molecular clone of the full length 
HCV genome. B. Bicistronic replicons expressing either the 
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adaptive mutations, however, were shown to be specific only for replication 
in cell culture, and HCV genomes containing these mutations were not 
infectious in the chimpanzee 25. Using this strategy, HCV sequences from 
genotype 1a and other 1b isolates were shown to replicate in Huh-7 cells in 
the context of a bicistronic genome 79.  
  During the selection of subgenomic replicons, cell colonies were 
isolated and found to contain no adaptive mutations in the HCV sequence. 
These cells were allowed to expand, and “cured” of the HCV RNA by 
treatment with interferon gamma 14. This Huh-7 subculture line, designated 
as Huh-7.5, was shown to have an increased capacity to support replication 
of HCV. It is not entirely clear which cellular factors contribute to HCV 
replication or are absent to impede replication, but Huh-7.5 cells have been 
shown to be deficient in the RIG-I antiviral pathway 38.  
Bicistronic RNAs expressing the entire polyprotein of HCV behind 
the EMCV IRES were shown to replicate in Huh-7 cells, but at a much 
lower efficiency than the subgenomic RNAs. These full-length, bicistronic 
genomes did not produce infectious virus despite the inclusion of the 
structural proteins 8. Using the highly permissive Huh-7.5 cell line, transient 
replication could be measured for full-length genomes containing cell 
adaptive mutations, but lacking a selectable marker.  
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All HCV genomes shown to replicate in cell culture required adaptive 
mutations until the isolation of a genotype 2a sequence from a patient 
displaying fulminant hepatitis. This sequence, JFH-1 (Japanese Fulminant 
Hepatitis) could replicate without adaptive mutations and was subsequently 
shown to produce infectious virus in cell culture 151. The determinants for 
virus production in cell culture have yet to be revealed, but inter- and intra- 
genotypic chimeras have been shown to be infectious when structural 
proteins are fused to the replicase proteins of JFH-1 102.  
 
Translation of HCV. 
HCV replication can only begin after the genome has been translated 
to produce the necessary replicase complex. Host cell machinery initiates 
polyprotein synthesis from the IRES located in the 5’NTR. The 5’ NTR 
contains 4 stem loop domains and a pseudoknot mapped to positions 44-354 
(Figure 1.6). The first stem loop, 5-20, is required for replication, but not for 
translation and when deleted can actually enhance protein expression 41. The 
following region, 21-43, is predicted to be unstructured in the plus sense, but 
is thought to form an RNA element with SLI in the minus sense and act as a 
promoter for plus strand synthesis (Figure 1.7). SLII marks the beginning of 
the IRES between positions 38 and 43 and influences binding of the 40S 
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Figure 1.6. The 5’NTR of HCV and the initiation pathway. A. The IRES 
boundaries are demarcated with a yellow line. eIF3 binds the apical 
stem of SLIII, and the 40S subunit binds the basal stem of SLIIId. SLII 
induces a conformational change of the 40S subunit to position the 
ribosomal P site at the start codon positioned in the pseudoknot of SLIV. 
B. The 40S subunit binds the SLIII and is positioned at the AUG start 
codon. eIF3 and the ternary complex join by contacting the top of SLIII 
to form the 48S* complex. After GTP hydrolysis, the 60S subunit joins 
and forms the 80S complex.
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Adapted from Smith et al. 2002
Figure 1.7. Replication elements in the 5’NTR participate as promoters 
for plus strand synthesis. Predicted RNA secondary structure of the 3’ 
minus strand. The stem structures are numbered based on the RNA 
structures in the genomic sense (see small IRES structure).  
dent nuclease activity of S1 and T2. Qualitatively identical
patterns of nuclease cleavage were observed with the full-
length negative-strand RNA substrate (data not shown), sug-
gesting the absence of long-range intramolecular base-pairing
interactions between this region and upstream sequences.
Analysis of single-strand-specific RNase cleavage within the
negative-strand 3! terminus revealed patterns of nuclease sen-
sitivity characteristic of stable stem-loop structures. To further
analyze the RNA folding pattern, secondary-structure predic-
tion for the terminal 365-nt sequence was carried out with
mfold, version 3.1 (59). Inspection of the mfold energy dot plot
and p-num values (not hown) indicates that the 3!-terminal
217 nt are well determined, whereas upstream sequences can
adopt a variety of structurally diverse yet thermodynamically
equivalent structures. Analysis of the optimal structur (Fig.
2A) revealed that the terminal 220 nt fold into five stem-loops
(I!, IIz!, IIy!, IIIa!, and IIIb!; see Discussion for domain no-
menclature). The 5! aspect of the largest stem structure, IIz!, is
interrupted by 5-nt and 7-nt single-stranded bulges. Nucleo-
tides C320 to G363 also appear to form a relatively well-
defined stem-loop (IV!). The five terminal stem-loops and, to
a lesser degree, the internal stem-loop are retained among
optimal structures even when upstream HCV sequences are
included in the computation.
The poorly structured domain (IIIcdef!), comprising nt C222
to C320, is capable of forming a multilobed structure, as in Fig.
2A, but, in many foldings, participates in long-range base-
pairing interactions with various upstream or downstream se-
quences. This promiscuity of base-pairing results in notable
structural variation among the suboptimal mfold structures.
For exampl , the terminal stem-loop (I!, nt 5 to 20) is absent
from several structures (Fig. 2B); in those cases, nt 1 to 20
FIG. 2. Predicted secondary structure and observed nuclease cleavage of the HCV negative-strand 3! terminus. Secondary-structure energy
minimization of the 3!-terminal 365-nucleotide region was performed with the mfold program, version 3.1. (A) The thermodynamically optimal
folding configuration is shown, with sites exhibiting reproducible, dose-dependent endonuclease cleavage indicated on the nucleotide 5! of the
hydrolyzed bond. Cleavage sites for RNases T2 (squares), A (triangles), and T1 (circles) are reported as preferred (solid symbols) or minor (open
symbols). Preferred and minor sites for nuclease S1 are denoted by bold and italic type, respectively. (B) Alternative base-pairing configuration
for nt 1 to 20. (C) Positive-strand 5!-UTR/core region (nt 1 to 365) secondary-structure domains (40). An RNA pseudoknot structure, psk, is
formed by base-pairing of subdomain IIIf and sequences upstream of domain IV.
9566 SMITH ET AL. J. VIROL.
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ribosomal subunit and eIF3 77, 136. The 40S ribosomal subunit and eIF3 bind 
two separate stem loops of a four-way junction of SLIII 62. SLIV harbors the 
initiating AUG codon of the polyprotein and participates in an RNA 
pseudoknot 52.  
Translation from the HCV IRES has been compared to prokaryotic 
translation as the 40S ribosomal subunit binds directly to the IRES, which 
acts in a fashion analogous to a Shine-Dalgarno sequence, without the need 
for canonical eukaroytic initiation factors such as the eIF4F complex 50, 115. 
Initiation proceeds as the 40S subunit binds the basal SLIII d, and eIF3 binds 
the apical region of SLIII a,b,c. SLII induces a conformational change in the 
40S subunit to position the start codon into the ribosomal P site 115, 136. The 
ternary complex of eIF2-GTP-Met-tRNA joins to form the intermediate 
48S* complex 98. After GTP hydrolysis, eIF2 releases the initiator tRNA and 
disassociates.  A second GTP hydrolysis event with eIF5B allows the 60S 
subunit to join and form the 80S complex. Translation elongation proceeds 
without any scanning activity.  
Single particle cryo-electron microscopy has shown the IRES to 
mediate conformational changes in the 40S subunit that permit access of the 
A site to the AUG located in stem loop IV 136. Mutation of the AUG start 
codon to AUU or CUG does not affect IRES mediated translation and an 
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increase in Mg2+ concentration allows translation to proceed without the 
need for an initiating tRNA 69, 114. The HCV IRES differs from other virus 
IRES such as the polio and EMCV IRES, because the boundaries extend 
downstream into the coding sequence 122. The first 33 nucleotides of the 
downstream capsid sequence are required for efficient translation, but 
providing the full length of the capsid sequence can suppress cap 
independent translation 37, 124. It has been demonstrated that the sequence 
after the AUG must also be free of secondary structure 52. After docking, the 
40S subunit must melt the pseudoknot structure in SLIV to proceed into the 
polyprotein coding region. Stabilization of the pseudoknot has been shown 
to inhibit translation, indicating that this RNA structure provides a 
regulatory role 53. The pseudoknot has also been predicted in the related 
classical swine fever and GBV-B viruses. In the pestivirus bovine viral 
diarrhea virus (BVDV), lack of stable secondary RNA structure rather than a 
specific RNA sequence was important for optimal translation initiation 93.  
 
Influence of the capsid gene on translation. 
The initial 33 nucleotides of the capsid gene are required for efficient 
IRES activity 37. Inclusion of longer regions of the capsid gene after the 
HCV IRES has been shown to be repressive for translation of reporter 
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constructs and has sparked a debate over whether the capsid protein or the 
capsid gene has a role in regulating translation.  
Proponents of the capsid protein being the repressive element have 
cited the ability of the capsid protein to preferentially bind the HCV 5’NTR 
over other RNA sequences, specifically SLI, the unstructured region of 23-
41, and SLIIId of the IRES 17, 36, 124, 125, 140. When the capsid protein is 
expressed by a recombinant baculovirus in trans, translation of an HCV 
IRES driven reporter is reduced in cells 121. Another group reports capsid 
expression must occur in cis and insertion of a frameshift early in the capsid 
sequence alleviates the repression of translation.  
Proponents of the capsid sequence down regulating HCV translation 
argue the capsid protein interacts nonspecifically with RNA including other 
virus RNA, tRNA, and even ribosomal RNA. Other virus capsid proteins 
can also bind the HCV IRES as efficiently as the HCV capsid protein. 
Expression of β-gal from a recombinant baculovirus resulted in lower 
translation activity from the HCV IRES and introduction of a frameshift 
early in the capsid gene still conveyed less translation than a reporter with 




Conservation of the capsid gene. 
Prodigious numbers of HCV particles are generated in an infected 
individual, ~1012 per day. Due to error prone replication, HCV has a high 
rate of mutation, causing each replicated genome to bear at least one change 
from its template. Over time mutations accumulate, sequence diversity 
expands, allowing rapid evolution. Viruses must adapt to changing 
intracellular environments and evade host defenses while maintaining the 
functions necessary for replication. Compact genomes and multifunctional 
elements assist in meeting these demands, yet constrain regions from 
random mutation. In the face of such strong selective pressures, viruses are 
positively selected where only progeny with an adaptive mutation can 
survive. By comparing virus sequences from an infected individual, patient 
H in 1977 and in 1990 (referred to as H77 and H90), the evolutionary rate 
for HCV was estimated to be 2 x 10–3 mutations per site per year 95. A slower 
mutation rate of 4-7 x 10-4 sites/year was observed within a cohort of 
infected individuals 131. The error threshold is the mutation rate beyond 
which viral populations cannot be sustained due to accumulation of 
deleterious mutations and is inversely proportional to the genome length. 
Estimating the HCV genome to be 104 nucleotides, a 10-4 error threshold 
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value is predicted; thus HCV replication occurs at or beyond the critical 
error limit.  
Despite a high mutation rate, there are notably conserved regions of 
the HCV genome that must possess functions indispensable for the virus life 
cycle. Ina reported a low level of synonymous substitutions in the capsid 
gene of HCV and subsequent studies have confirmed this observation with 
more divergent sequences 57 (Figure 1.8). Pressure to maintain virus protein 
function would prevent an excessive number of nucleotide changes in the 1st 
and 2nd codon positions, but does not explain conservation of 3rd base 
positions that do not alter the amino acid sequence. Ina also noted a release 
of sequence constraint near the termination of the +1 capsid protein.  Smith 
et al confirmed suppression of sequence variability in the capsid gene and in 
addition noticed sequence constraints located in the NS5B region of the 
genome 133. It is interesting that both of these genes are adjacent to areas 
with highly conserved cis acting regulatory elements of RNA structure in the 
5’ and 3’ NTRs. The transition to transversion ratio was also higher in 
synonymous sites (16:1) than in nonsynonymous sites (1.4:1) of the capsid 
region, indicating that preservation of the type of nucleotide is important. 
Walewski et al reported that codons conserved at 3rd base positions in the 
capsid gene of all genotypes 153. Five clusters of conserved codon usage 
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Figure 1.8. Sequence conservation of regions in the HCV genome 
are shown by measuring the distance with an overlapping 150 bp 
window of the nonsynonymous/ synonymous mutation rate. This 
analysis reveals highly conserved regions in the 5' UTR and core 
regions, and high viral diversity in envelope genes and NS5A. 
Adapted from Smith et al. 2002.
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were found in the HCV genome with 22 conserved codons in the capsid 
region. Another study contradicts the phylogenetic evidence for an ARF-
encoded protein citing the distribution of stop codon between genotypes 
indicates a lack of functional constraints 31. These reports indicate that the 
conservation of codons could be attributed to the translation of the 
overlapping reading frame into a protein, or the presence of RNA secondary 
structure elements, that are essential for HCV viability.  
 
Evidence for an ARF protein in HCV replication and infection.  
In 1994, Ina first proposed the possibility of HCV using an 
overlapping reading frame to encode a protein as an explanation for the 
conservation of sequence in the caspid region. All HCV genotypes have an 
open reading frame in the +1 frame of the capsid gene beginning at 
nucleotide 346, with the polyprotein beginning at 342, but the length of the 
open frame varies between genotype (Figure 1.9). The +1 frame for 
genotype 1a is open for 486 bases and could produce a 17 kDa protein, 
genotype 1b is open for 429 bases potentially encoding a 15 kDa protein, 
and genotype 2a is open for 375 bases that could express a 13 kDa protein. 
The +2 frame contains numerous stop codons. Walewski et al have termed 
the +1 frame ARF for alternative reading frame, and the potential encoded 
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Figure 1.9. The proposed frameshift sites of the F and DF proteins. 
A. The F protein initiates at the start of the polyprotein and shifts 
into the ARF at codon 9-11. Translation terminates at a stop codon 
in the ARF. B. Translation of the DF protein also initiates at the start 
of the polyprotein, yet shifts further downstream into the ARF at 
codon 42. Translation continues until reaching a stop codon where 
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protein, ARFP. The synonymous substitution bias of the capsid gene 
preserves the amino acid sequence of the ARFP, and there is 65-82% 
identity between all genotypes. Walewski et al aligned and compared 255 
HCV sequences to conclude that the potential ARFP is as conserved as other 
conventional HCV proteins. ARFP has little amino acid identity with the 
capsid protein, 16%, but both are predicted to be very basic with a pI of 
approximately 12 153 152. Proponents of the evolutionary principle of gene 
overprinting, where a novel protein is created by utilizing an existing coding 
region, remark that the chemical composition of the overlapping protein is 
often polarized due to amino acid restrictions imposed by the original 
protein. The restrictions are due to the codon usage of the 2nd base position 
and could explain the similar amino acid composition.  
Experimental evidence for a protein encoded by the +1 frame can be 
traced to early studies investigating HCV polyprotein processing. There are 
two forms of capsid protein with sizes of 23/21 kDa and 21/19 kDa. The size 
discrepancy is due to ambiguous protein markers used between different 
laboratories. The full-length capsid protein has a hydrophobic region in the 
carboxy terminus that serves as a signal sequence to deliver the proceeding 
E1 protein into the lumen of the ER. The host cell signal peptidase cleaves 
capsid from E1 in the ER and the signal peptide peptidase cleaves the 
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remaining capsid protein from the ER. The smaller, completely processed 
form of capsid predominates in cell culture. While investigating these 
processing patterns, a smaller protein of about 16 kDa was occasionally 
detected in cell free translation reactions programmed with the capsid gene 
76. This 16 kDa protein was initially believed to be another processed form 
of the capsid protein, until the laboratory of James Ou began investigating 
the presence of the 16 kDa protein, named P16, by comparing two HCV 
genotype 1a sequences, HCV-1 and HCV-RH (Figure 1.10). HCV-1 is the 
first HCV sequence to be identified by Choo et al; HCV-RH is another name 
for the H77 sequence 27. Using in vitro translation assays, capsid gene 
sequences from HCV-1 produced only P16 whereas HCV-RH made only a 
21 kDa protein (P21). There are 4 amino acid differences between HCV-1 
and HCV-RH capsid protein sequences. Domain swapping experiments and 
site directed mutagenesis revealed that codon 9 was critical for P21 or P16 
production. At codon 9, HCV-1 expresses a lysine (codon AAA) and HCV-
RH an arginine (codon AGA). The adenine to guanine difference in HCV-
RH interrupts a stretch of 10 consecutive adenines present in HCV-1. HCV-
1 is the only isolate with 10 consecutive adenines at this position, in an 
otherwise conserved A-rich region. Tagging experiments determined that 
P16 and P21 initiated at the same AUG, but differ at the carboxy termini.  
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Figure 1.10. Comparison of the HCV-1 and HCV-RH genotype 1a 
capsid sequences. The sequence HCV-1 contain 10 consecutive 
adenines at positions 23-33, which are proposed to conduct a 
ribosomal frameshift event. The sequence of HCV-RH has a guanine 
at position 26,  interrupting the stretch of adenines and is not reported 
to frameshift. 
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Xu et al proposed that synthesis of P16 occurs by a ribosomal 
frameshift into the –2/+1 reading frame and renamed this the Frameshift or F 
protein (Figure 1.9) 161. Sequencing of the F protein did not precisely define 
the shift site, but suggested that it occurred at or near codon 11 and only 
required codons 8-14. Varaklioti et al measured the ability of HCV to 
frameshift by cloning the luciferase gene after HCV-1 and HCV-H77 capsid 
genes in all three reading frames 149. In cell free translation assays 
programmed with the HCV-1 sequence, ribosomal frameshift into the +1 
frame was detected 35% of the time. A –1 frameshift was also detected 6% 
of the time when only 9 A’s were in the slippery sequence. The HCV-H77 
sequence, which does not have consecutive adenines, only demonstrated 
frameshifting less than 1% of the time. Xu et al reported the ability of Huh-7 
cells to support ribosomal frameshifting 1-2% as measured by a luciferase 
reporter construct 161. A triple decoding strategy has also been proposed 
where both the +1 frame and the +2 frame are expressed. The +2 frame 
contains eight regularly spaced stop codons before amino acid 120 of the 
ARF, but using an in vitro translation system, a small 1.5kDa protein was 
detected 26.  
The downstream E1 gene has been implicated to have a role in P16 
production 75. When the capsid and E1 genes of HCV-1 were used in cell 
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free translation systems, P21 and P16 were produced, whereas HCV-RH 
again only expressed P21. Interestingly, both HCV-1 and HCV-RH were 
able to generate both P21 and P16 in a transient mammalian expression 
system in HepG2 cells. If the HCV sequence only contained the capsid gene 
and did not include E1, HCV-1 only made P16 and HCV-RH only made 
P21. Different cellular localizations were reported. P16 was found in the 
nucleus and P21 in the cytoplasm, but these systems also lacked the majority 
of the polyprotein 75. The HCV capsid protein has been reported to be 
transported to the nucleus when no other HCV proteins are coexpressed 56. 
Studies have investigated the cellular localization of the F protein in 
transient expression systems of HepG2 cells. The F protein was only 
detected if the sequence between codons 9 and 11 contained the consecutive 
adenines 118, 160.  
HCV infected patients also generate antibodies against the F protein. 
HCV patient sera have been used to detect P16 in the above translation 
assays and also immunoprecipitate recombinant F protein. Walewski et al 
reported 13/100 chronic HCV patient sera recognized peptides based on the 
+1 frame by western blot compared to 3 out of 104 healthy controls patients 
with non-HCV liver disease 153. Patients infected with different HCV 
genotypes (1a, 1b, 2b, and 4) have also been reported to produce antibodies 
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against F by ELISA 66. Another group sequenced the HCV capsid gene from 
HCC patients and found 3/10 had non-arginine codons at codon 9, but none 
had a lysine 96. When these sequences were expressed in an in vitro 
translation assay, P16 was produced.  
Another ARF protein was detected using the +1 overlapping reading 
frame of the capsid gene.  Boulant et al isolated a heterogeneous population 
of E.coli expressed capsid proteins using a carboxy terminal affinity tag. 
Protein sequencing revealed that a +1 frameshift had occurred at codon 42 
and upon encountering a stop signal, a –1 shift at codon 144 placed the 
ribosome back into the capsid reading frame to continue producing the 
polyprotein 18. This dual frameshift protein, DF protein, is the first detection 
of use of the overlapping reading frame usage by genotype 1b (Figure 1.9). 
Using a transient expression system, the authors showed expression of the 
DF protein in HepG2 cells.  
In summary, there are two reported proteins encoded from the +1 
frame of the capsid gene, both involving a translational frameshift. The F 
protein shares the first 9-11 amino acids of capsid and then moves into the 
+1 frame. The DF protein uses a frameshift site at codon 42 to enter the +1 
frame and shift back into the capsid sequence at codon 144 (Figure 1.9). 
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Summary of thesis work. 
 My thesis research began with a desire to learn classical virology with 
molecular methods to further our understanding the replication of an 
infectious agent important to public health. Focusing on HCV, I also wanted 
to examine a function of replication that was not specific for, or limited to, 
cell culture. Given the early difficulties of studying HCV replication, this 
attempt could have been very brief and without much success! However, I 
benefited from joining the field at an exciting time when advances in the 
methods to study HCV replication were rapidly evolving, and I was in a lab 
that quickly adopted these new practices and contributed novel systems to 
the field.  
The strong conservation of the capsid gene sequence, based on 
naturally occurring HCV isolates, was persuasive evidence that the capsid 
gene, and not simply the capsid protein, had functional significance in the 
HCV life cycle. Two lines of evidence were in the literature: an expressed, 
alternative reading frame and RNA secondary structures. I chose to test the 
requirement for an ARF in HCV infection as the mechanism of translational 
frameshift allows for many interesting studies of virus-host interactions. 
Translation from the HCV IRES was already shown to be novel during 
which a minimal set of initiation factors conduct expression of a ~3000 
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amino acid protein. The characterization of a newly identified virus protein 
also promised many questions to solve. The inability to identify a frameshift 
protein in cell culture hampered these efforts, and the focus shifted to an in 
vivo model.  
 Chapter 3 describes the investigation for a requirement of an ARF in a 
natural infection. This approach involved the introduction of silent point 
mutations conferring multiple stop codons in the ARF. In collaboration with 
Stephen Feinstone, an HCV genome with these Stop mutations was 
inoculated into a chimpanzee. Using the conventional sequence of H77, 
which has been the parent genome for over 20 chimpanzee studies, stop 
codons were introduced into the ARF without altering the capsid protein 
sequence. The Rice lab has been involved with numerous studies 
investigating the pathogenesis and molecular determinants of HCV infection 
in the chimpanzee model, and has shown this approach to provide definitive 
evidence for factors that are required for replication.  
An infection was launched, yet attenuated. The ARF was therefore not 
required for infection, but could be responsible for the low virus load and 
little signs of pathology. We measured the immune response in both the 
periphery and liver and detected a diverse set of HCV specific T cell 
epitopes corresponding with the time of virus decline. Sequence analysis of 
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the circulating virus RNA revealed a reversion at the site of one of the point 
mutations conferring a stop codon in the ARF. This reversion was selected at 
the beginning of the acute infection and became fixed in the population. As 
the infection progressed, additional reversions were identified and indicated 
selection of the capsid sequence as opposed to an ARF protein. 
Chapter 4 describes how mutations conferring the Stop codons in the 
ARF were shown to be detrimental to HCV replication in Huh-7.5 cells. 
Mutagenesis studies confirmed the silent mutations of the ARF stop codons 
actually disrupted an RNA structure. Two RNA structures had been 
proposed for the capsid gene based on covariant sequence analysis. 
Mutations in the structure of SLVI were shown to reduce HCV replication, 
with disruptions in the apical region of the SLVI resulting in the most severe 
effects. Altering the stability of the base produced a slight reduction in 
replication, but contributed to a further reduction when combined with 
mutations in the apical stem. Passage of Huh-7.5 cells transfected with HCV 
genomes containing a disrupted SLVI identified reversions selected to 
restore the RNA base pairs of SLVI. These reversions were identical to the 
reversions selected during the chimpanzee infection and indicated that 
comparable selective pressures exist to maintain a functional RNA structure 
during replication in cell culture and in vivo.  
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 Chapter 5 describes how the search for a mechanism of SLVI in HCV 
replication returned the focus on HCV translation. The capsid gene had been 
shown to have a potential role in regulation of translation, but a specific 
interaction had never been identified. The mutations in SLVI conveyed a 
reduction in IRES mediated translation. A 2- 4 fold reduction was observed 
in transfected Huh-7.5 cells and in cell free assays using rabbit reticulocyte, 
Huh-7, and Huh-7.5 cell extracts. Mutations in SLVI were shown to reduce 
translation independent of downstream capsid sequence or of the 5’NTR, 
contradicting published reports. We showed that the effects of SLVI depend 
on its position in the HCV genome. We can abrogate the reduced replication 
due to mutations in SLVI by expression of the replicase proteins in trans and 
out of the context of SLVI and the IRES.  
 We propose that mutations in SLVI reduce IRES-mediated 
translation, which consequently lowers the amount of replicase expression 
leading to a reduced level of synthesized RNA in the cell. The impact of 
mutations in SLVI is most evident at 24 hours post transfection, a time when 
translation and replication activity begins to accelerate. The lower efficiency 
of translation conveyed by mutations in SLVI becomes amplified during this 
period and if too severe, replication of the mutant cannot be sustained in the 
cell. Replication of mutant SLVI can proceed in a minor subpopulation of 
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Huh-7.5 cells, implying either a host factor or an infrequent state of the cell 









































Chapter 2. Materials and Methods 
Cell culture. 
Cell monolayers of the human hepatoma cell lines Huh-7 and Huh-7.5 
were grown at 37 °C, 5% CO2 in Dulbecco's modified minimal essential 
medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 
nonessential amino acids, 10% fetal bovine serum (FBS), 100 U of penicillin 
per ml, and 100ug of streptomycin per ml. Cells were passaged after 
treatment with 0.05% trypsin-0.02% EDTA and seeded at a dilution of 1:4. 
 
Plasmid construction.  
The HCV genotype 1a H77 infectious clone (GenBank accession 
number: AF009606) 65 was used to generate RNA for the chimpanzee 
infection. The HCV genotype 1a H77 full-length genome, pH/FL (L+I) 
[(P1496L) and (S2204I)] 13, genotype 1b Con1 (I) [S2204I], genotype 1b 
Con1 (GIT) [E1202G, T1280I, and K1846T] were used in cell culture 
replication assays. 
The genotype 2a chimera pJ6-JFH 72, genotype 2a chimera pJ6-
JFH/Rluc 146, genotype 1a-2a chimera pH-JFH/Rluc (V+T) [I348V/S1103T], 
genotype 1a-2a chimera bicistronic pH-EI-JFH (V+T) (Williams, D., 
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unpublished) were used in cell culture replication assays and to produce 
virus in cell culture.  
 The plasmid H-JFH/Rluc was created by generating a PCR product 
containing the Renilla luciferase gene and 2A protease from FMDV using 
oligos 7041 (5’ GGG GGA CGC GTT GGA CAC GAC TTC GAA AGT 
TTA TGA TCC AG 3’) and 7236 (5’ CCC CCA CGC GTC GGG CCC 
TGG GTT GGA CTC G 3’). This product creates MluI sites on either side 
and inserts the signal sequence for NS2 (amino acids LDT) prior to the 
Renilla luciferase gene. An extra G was inserted after the 2A protease to 
maintain the reading frame. PCR was performed by the Expand High 
Fidelity kit (Roche Applied Science, Indianapolis, IN), the product gel 
purified, and TA cloned (Invitrogen). The product was verified by 
sequencing and subcloned as a MluI fragment into plasmid pH-JFH-MluI/ 
V+T, which contains two base changes (A2768G and C2769T) generating a 
MluI site at the junction of p7 and NS2.   
 Plasmids containing deletions in the capsid gene were generated by 
two-step PCR. The first step amplified the flanking regions of the deletion 
site. A NotI site was included at the junction of the deletion site to allow the 
two PCR products to anneal. The second PCR step amplified the two PCR 
products creating a NotI junction at the site of deletion. The deletion of 
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amino acids 15-171 (pDel 15-171) was generated by PCR using the oligos 
6607 (5’ GAG TGT CGT GCA GCC TCC AGG ACC C 3’), 7243 (5’ ACC 
TGC GGC CGC GGT GTT ACG TTT GGT TTT TCT TTG AG 3’), 7244 
(5’ GCG GCC GCA GGT TGC TCT TTC TCT ATC TTC CTT CTG G 3’), 
and 7245 (5’ GCC CAG CGG TGG CCT GGT GTT G 3’). The deletion of 
amino acids 57-171 (pDel 57-171) was generated by PCR using the oligos 
6607, 7241 (5’ ACC TGC GGC CGC TTG CGA CCG CTC GGA AGT 
CTT CC 3’), 7244, and 7245. The plasmid pDel 57-171/ Stop 1,2,3,4 was 
created using the PCR strategy listed above, but with the template pH-
JFH/Stop 1,2,3,4. The fragments of AgeI – MluI were cloned into pH-
JFH/Rluc-MluI and their identity verified by sequencing. 
 The bicistronic plasmids of pH-neo/RRRI and pH-neo/RRRI (Stop 
1,2,3,4) were created by two-step PCR. The first reaction used oligos 4016 
(5’ CCC CAG TGC CAC GTT GTG AGT TGG 3’), 4015 (5’ CGT GCT 
CAT TAT TAT CGT GTT TTT CAA AGG 3’) and amplified the EMCV 
IRES with an extension to the capsid gene. The second PCR amplified the 
capsid with an extension for the EMCV IRES and used oligos 4014 (5’ CAC 
GAT AAT AAT GAG CAC GAA TCC TAA ACC 3’), and 4017 (5’ CGT 
GCT CAT TAT TAT CGT GTT TTT CAA AGG 3’).  The second step 
joined the two PCR products using oligos 4016 and 4017. For pH-neo/RRRI 
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the template for the capsid gene was pH/L+I. For pH-neo/RRRI/Stop 
1,2,3,4, the template was pH/L+I/Stop 1,2,3,4. The PCR products were 
purified using QIAquick spin column (Qiagen, Valencia, CA). The KpnI 
fragment was subcloned into pH-neo/L+I 13. The adaptive mutations were 
introduced by subcloning the fragment BsrGI-EcoRI from pH/RRRI 
[Q1067R, K1691R, K2040R, S2204I] 163.   
 VEE replicons expressing the HCV capsid (VEErepC) and C-NS2 
(VEErepC-NS2) from genotype 1a H77 sequence were generated by PCR 
creating SapI sites flanking the fragment using oligos 7043 (5’ TAA ATA 
AAG CTC TTC AAG CAC GAA TCC TAA ACC TCA AAG AAA AAC C 
3’), 7044 (5’ TTA TTT AGC TCT TCT TTT AGG CTG AAG CGG GCA 
CgG TCA GGC 3’), and 7240 (5’ TTA TTT AGC TCT TCT TTT AAT 
CAT TGG TGA CAT GGT AAA GCC C 3’). Products were verified by 
sequencing and the SapI fragment subcloned into pVEErepGFP-Sap 101.   
  
Site directed mutagenesis. 
 Point mutations were introduced using the QuikChange Site Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA). A small, intermediate plasmid 
containing EcoR-KpnI of the 5’NTR and capsid gene was cloned into pRS2 
and used as the template for the QuikChange PCR. Products were verified 
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by sequencing and subcloned using either AgeI-KpnI or EcoRI-KpnI 
fragments into the parent HCV genome. Table 2.1 lists the mutations 
introduced into HCV genomes. 
 
Detection and sequencing of HCV RNA.  
Quantitative real-time reverse transcription polymerase chain reaction 
(qRT-PCR; detection limit 200 RNA GE/ml) was performed with total RNA 
extracted from 100 ul serum. For nested RT-PCR, total RNA was isolated 
using QIAamp Virus RNA mini kit (Qiagen). RT-PCR was performed using 
Superscript III and Platinum High Fidelity One Step system (Invitrogen). 
RNA was denatured at 60°C for 5 min followed by reverse transcription at 
55°C for 40 min. PCR cycling conditions were 94°C 30 sec, 55°C 30 sec, 
and 68°C 1 min for 25 cycles. For samples requiring nested RT-PCR, 2 ul of 
the first reaction was used for semi-nested PCR using Pfx polymerase 
(Invitrogen). The cycling conditions were 94°C 15 sec, 55°C 30 sec, and 
68°C 1 min for 20 cycles. Reverse primer 5'-CCG CCT CGT ACA CAA 
TAC TCG (nt: 970-990) and forward primer 5'-GTG CCC CCG CAA GAC 
TGC (233-250) were used. Semi-nested PCR combined the forward primer 
above and an internal primer, 5'-GGT GAC ATG GTA AAG CCC CG (934-
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953). PCR products were either sequenced directly or cloned into pCR2.1 
(Invitrogen) and individual clones sequenced. 
 
Chimpanzee inoculation and sample collection.  
Chimpanzee 1602 was inoculated with 0.6 mg transcript RNA by 
direct intrahepatic injection 65. Peripheral blood was collected in acid citrate 
dextrose tubes for isolation of PBMCs, expansion of CD8+ T cells, and 
plasma. Liver tissue obtained by hepatic needle biopsy was placed in RPMI 
for T cell studies or flash frozen for later RNA analysis. Peripheral blood 
and liver needle biopsies were collected weekly for the first 12 weeks and 
monthly thereafter. Animal housing, maintenance, and care met the NIH 
requirements for the humane use of animals in scientific research. 
 
Isolation of PBMCs.  
PBMCs were isolated using Ficoll-Paque Plus (GE Healthcare 
BioSciences, Piscataway, NJ) density gradient and cultured in AIM-V 
(Invitrogen) and 2% heat inactivated human AB sera (Gemini Biosciences, 




Isolation of CD8+ and CD4+ T cells from liver bioposy 
To recover intrahepatic lymphocytes (IHL), liver biopsies were gently 
homogenized in phosphate buffered saline (PBS) containing 1% FCS. CD8+ 
T cells were enriched using anti-human CD8+ dynabeads (Dynal, Oslo, 
Norway) and expanded in bulk using anti-human CD3 antibody. CD8+, 
CD4+ and CD8-/CD4- cells were seeded in one well of a 24 well plate in T 
cell clone media: RPMI 1640 (Invitrogen) with L-glutamine (Invitrogen), 
5% T-stim culture supernatant without PHA (BD Biosciences, San Jose, 
CA), 50U/mL recombinant human IL-2 (Peprotech, Rocky Hill, NJ), 10% 
heat inactivated FCS, and antibiotics (penicillin and streptomycin). Cells 
were expanded using anti-human CD3 monoclonal antibody (clone X35) 
(Immunotech, Marseille, France) at 0.05 ug/ml in the presence of 2 x 106 
irradiated (3000 rads) human PBMCs per well as feeder cells. Cultures were 
fed every 3-4 days by replacing half of the culture media. Populations of 
CD4+ cells were confirmed to have 94.5% purity and CD8+ cells 98.5% 
purity by flow cytometry. 
 
Detection of HCV-specific CD8+ T cells by ELISPOT.  
IFN-γ ELISPOT kits (U-cytech, Utrecht, The Netherlands) were used 
to assay PBMCs and expanded CD8+ cells. 2 x 105 freshly isolated PBMCs 
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cells were incubated with HCV antigen at 2 ug/mL for 48H and then 
transferred to 96 well plate coated with anti-IFN-γ. For expanded CD8+ 
cells, 1 x 105 cells/well were in incubated with autologous irradiated PBMCs 
as APCs and HCV antigen for 48H before transferring to 96 well plates 
coated with anti-IFNγ. Plates were developed according to the 
manufacturer’s instructions.  
 
HCV recombinant antigen and peptides.   
HCV recombinant antigens C22-3 (core aa: 2-120), C33c (NS3 aa: 
1192-1457), C100 (NS4 aa: 1569-1931), C200 (NS3-NS4 aa: 1192-1931), 
and NS5A (aa: 2054-2995) were expressed as C-terminal fusion proteins 
with human superoxide dismutase in either yeast (Saccharomyces 
cerevisiae) or Escherichia coli and were a gift from Dr. M. Houghton 
(Chiron, Emeryville, CA). Peptides were synthesized by Genemed Synthesis 
(San Francisco, CA). Peptide pools were comprised of 15-20 mer peptides 
overlapping by 10 residues. Each pool was composed of peptides 
corresponding to residues, numbered from the beginning polyprotein: 1-214 
(pool 1); 205-766 (pool 2); 757-1055 (pool 3); 1046-1365 (pool 4); 1356-
1680 (pool 5); 1671-2009 (pool 6); 2000-2443 (pool  7); 2434-2735 (pool 
8); 2726- 3011 (pool 9). Peptides used to screen the ARF were composed of 
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amino acids 1-161 of the +1 frame, beginning with nucleotide 5 of the 
polyprotein (pool 10). 
 
Detection of HCV-specific antibodies. 
  HCV-specific antibodies were determined using the HCV EIA-2 assay 
(Abbott, Abbott Park, IL).  
 
Generation of CTL Lines.  
CD8+ T cells enriched using anti-human CD8 dynabeads (Dynal) as 
described above were cloned at a limiting dilution of 10 or 50 cells/well in 
96 well plates. CD8+ T cells were seeded in T cell clone media and 
expanded using anti-human CD3 monoclonal antibody (clone X35) 
(Immunotech) at 0.05 ug/ml in the presence of 5 x 104 irradiated (3000 rads) 
human PBMCs per well as feeder cells. Cultures were fed every 3-4 days by 
replacing half of the culture media. After 2 weeks, growing cell lines were 
transferred to 24 well plates and subjected to another round of anti-CD3 
antibody stimulation in the presence of 2 x 106 irradiated human PBMCs. 
Cultures were fed every 3-4 days as described above. 306 independently 
derived CD8+ T cell lines was tested for cytotoxicity against autologous 
independently derived CD8+ T cell lines (BLCL) targets infected with 
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recombinant vaccinia virus expressing the HCV genome (vv1-3011).  
Epitope fine mapping was performed by intracellular staining for IFN-
γ using peptide matrices spanning the antigen of interest. Peptides were 20 
amino acids long overlapping by 10 residues. 
 
CD4+ proliferation assay.  
Liver derived CD4+ T cell clones were tested for proliferative activity 
by incubating 5 x 105 CD4+ T cells with 5 x 105 irradiated (10,000 rads) 
autologous BLCLs in the presence of synthetic HCV peptide in AIM-HS 
media (AIM-V lymphocyte medium, Invitrogen) containing 2% human AB 
serum (Gemini Biosciences) in 96 well flat bottom plates. Four replicates 
were seeded for each CD4+ cell clone. Cultures were incubated at 37°C in 
5% CO2 for 2 days. Proliferating cells were labeled with 1uCi/well of [3H] 
thymidine (GE Healthcare BioSciences, Piscataway, NJ) for 18 hours. Cells 
were collected and washed on filters using an automated cell harvester 
(Tomtec, Hamden, CT) and the amount of incorporated thymidine measured 






Populations of lymphocytes were confirmed by 4- color flow 
cytometry using anti- CD3 (UCHT1) and subset-specific antibodies against 
CD4 (SK3), CD8 (SK1), and CD56 (B159) (all BD-Pharmingen, San Jose, 
CA). Cells were resuspended at 2 x 106 cells/mL in PBS containing 2% FCS 
and 0.02% sodium azide and incubated with the appropriate antibody for 1 
hour. After washing three times, cells were resuspended in 2% 
paraformaldehyde solution and analyzed on a FACS Calibur instrument 
using CELLQuest software. 10,000 events were acquired in the lymphocyte 
gate. The data was analyzed with program FlowJo (Tree Star, Ashland, OR).  
To detect HCV protein in transfected Huh-7.5 cells, a single cell 
suspension was prepared at a density of 2 x 106 cells/ml and fixed in a 2% 
paraformaldehyde solution in PBS for 20 min at room temperature. The cells 
were washed and permeabilized in 0.1% saponin- PBS for 20 min at room 
temperature and stained for 1H with an anti-NS5A monoclonal antibody 
(MAB7094P 1:50) (Maine Biotechnology, Portland, ME) or an isotype 
control (IgG2a) diluted in 0.1% saponin- PBS and 1% goat serum. Bound 
monoclonal antibody was detected by incubation for 1 h at room temperature 
with anti-mouse immunoglobulin G (IgG) conjugated to Alexa 488 
(Invitrogen) diluted 1:1,000 in 0.1% saponin- PBS and 1% goat serum. The 
58
stained cells were washed three times with 0.1% saponin- PBS and analyzed 
as described above. 
 
In vitro RNA transcription.  
Plasmid DNA for in vitro transcription was prepared from large scale 
bacterial cultures and twice purified by centrifugation in CsCl gradients. For 
the chimpanzee study, the cDNA plasmid pH/FL Stop1,2,3,4 was linearized 
by digestion with BsmI and 3’ overhangs converted to blunt ends with T4 
DNA polymerase. The reaction was terminated by Proteinase K digestion, 
phenol-chloroform extraction, and ethanol precipitation. RNA transcripts 
were synthesized at 37°C for 1.5H in a 200 ul reaction volume containing 40 
mM Tris-HCl (pH 7.5), 10 mM NaCl, 18 mM MgCl2, 2 mM spermidine, 10 
mM dithiothreitol (DTT), 3 mM of each NTP, 160 U of Superasin (Ambion, 
Austin, TX), 400 U of T7 RNA polymerase (Epicentre Technologies, 
Madison, WI), and 10 ug of linearized DNA. At the end of the reaction, 10 
U of DNase I (Ambion) was added and incubated at 37°C for 20 min to 
remove the DNA template. RNA was purified using the RNeasy Mini kit 
(Qiagen). An additional DNase treatment was performed on the column 
using an RNase-free DNase set (Qiagen).  The RNA was eluted in water and 
the integrity of RNA was confirmed by agarose gel electrophoresis. 
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Parental and mutant derivates of genotype 1a pH/L+I, pH-neo/RRRI 
were linearized with HpaI, genotype 1b Con1 (I) and Con1 (GIT) were 
linearized with ScaI, and genotype 2a and 1a- 2a chimeras pJ6-JFH, pH-JFH 
(V+T), pH-EI-JFH (V+T) were linearized with XbaI. RNA was synthesized 
by in vitro transcription as above using 2 ug of template DNA in a 50uL 
reaction or using 5 ug of template DNA in a 20 uL using the T7 MegaScript 
kit (Ambion). After incubation for 2H at 37°C, 2uL of TurboDNase 
(Ambion) was added to the reactions and incubated for 20 min at 37°C. The 
RNA was purified using the RNeasy kit (Qiagen) and eluted twice in a total 
of 100 uL of water. The yield of RNA was determined by absorbance at 
260nm and integrity verified by agarose gel electrophoresis. 
 
Electroporation of transcribed HCV RNA. 
Subconfluent Huh-7.5 cells were trypsinized, collected, and washed 
twice with ice-cold RNase-free phosphate-buffered saline. The cells were 
resuspended in PBS at 1.5 x 107 cells/ml and placed on ice. One to two 
micrograms of in vitro transcribed RNA was mixed with 0.4 ml of the Huh-
7.5 cell suspension, transferred to a 2 mm gap cuvette (BTX, Holliston MA), 
and pulsed with a BTX ElectroSquarePorator (820 V; five pulses; 99 usec 
pulse length, 1.1 sec intervals). After 10 min at room temperature, the cells 
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were transferred to 9.6 ml of DMEM-10% FBS. For Flow cytometry, 1x106 
cells were plated on 100 mm dish. For real time qRT-PCR, 7.5 x 105 cells 
were plated per well of a 6 well plate. 
For luciferase assays, a master dilution plate was generated using an 8 
x 12 rack of Titer tubes (BioRad, Hercules, CA). Two dilutions were made: 
3 x 105 cells/ mL and 1 x 105 cells/ mL. Transfers of 100 uL from the master 
plate to a 96 well flat bottom tissue culture plate were performed creating 
four replicate wells per RNA. Three 96 well plates were seeded at 3 x 104 
cells/ well to harvest at the early time points and three plates were seeded at 
1 x 104 cells/ well to harvest at later time points.  
 
Quantitation of HCV RNA by Real Time qRT-PCR. 
 A 100 ng aliquot of total RNA was used to quantify HCV-specific 
RNA levels using an ABI Prism 7700 sequence detector (Applied 
Biosystems, Foster City, CA).  qRT-PCR amplifications were performed 
using the Platinum Quantitative RT-PCR ThermoScript One-Step system 
(Invitrogen) and primers specific for the HCV 5' NTR: 5'-CCT CTA GAG 
CCA TAG TGG TCT-3' (sense, 10 uM); 5'-CCA AAT CTC CAG GCA 
TTG AGC-3' (antisense, 10 uM); and 6-carboxyfluorescein-CAC CGG AAT 
TGC CAG GAC GAC CGG (probe, 10 uM; Applied Biosystems). Reverse 
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transcription reactions were incubated for 30 min at 50°C, followed by 
inactivation of the reverse transcriptase coupled with activation of Taq 
polymerase at 95°C for 5 min. After cooling to 25°C for 2 min, 40 cycles of 
PCR were performed with cycling conditions of 15 sec at 95°C, 40 sec at 
50°C, and 30 sec at 72°C. The reaction mix contained the glyceraldehyde-3-
phosphate dehydrogenase detection mix from Applied Biosystems (VIC-
MGBNFQ) for normalization. Synthetic HCV RNA standards of known 
concentration were included with each set of reactions and used to calculate 
a standard curve. The real-time PCR signals were analyzed in a multiplex 
format using SDS software (version 1.6.3; Applied Biosystems). 
 
RNA secondary structure probing. 
One microgram of transcript RNA was treated with cobra venom 
nuclease V1 (Ambion) or RNase T1 (U.S. Biochemicals, Cleveland, OH) at 
0°C for 30 min. The reaction was carried out in a 10 ul reaction volume with 
10 mM Tris-HCl (pH 7.0), 0.1 M KCl, 10 mM MgCl2, 3 ug of yeast tRNA, 
and RNases. One or 0.1 U of RNase T1 and 0.1 or 0.01 U of RNase V1 was 




Primer extension analysis.  
Oligonucleotide used in the primer extension assay: (5'-CCA GGT 
CCT GCC CTC GGG CCG-3'). The oligonucleotide was gel purified and 5'-
end labeled with 10 U of T4 polynucleotide kinase (New England Biolabs, 
Ipswich, MA) and 100 uCi of [g32P]ATP (8,000 Ci/mmol; GE Healthcare) in 
a reaction mixture containing 70 mM Tris-HCl (pH 7.6), 10 mM MgCl2, 100 
mM KCl, and 1 mM ß-mercaptoethanol at 37°C for 30 min. The 
unincorporated radioisotope was removed by passing the reaction mixture 
twice through QIAquick silica gel (Qiagen). Cleaved RNAs were mixed 
with the 5'-end-labeled oligonucleotide (5 x 104 cpm as determined by liquid 
scintillation counting) in a 20 ul reaction volume containing 50 mM Tris-
HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, and 10 mM DTT, prewarmed to 
40°C for 2 min, and incubated for 50 min following addition of 100 U of 
Superscript II RNase H reverse transcriptase (Invitrogen). The cleavage sites 
on the RNA were determined by analyzing the reverse-transcribed cDNA 
products separated by denaturing polyacrylamide gel (12% polyacrylamide-
7 M urea) electrophoresis. Dideoxy sequencing reactions were carried out on 




TransMessenger delivery of RNA to Huh-7.5 cells. 
  Huh-7.5 cells were seeded at 8 x 104 cells/ well in a 24 well 
plate the day before. Next, 0.8ug of in vitro transcribed RNA was added to 
the diluted enhancer reagent and incubated for 5 min at room temperature. 
TransMessenger reagent (Qiagen) was added to the RNA and incubated for 
10 min at room temperature. OptiMEM media was mixed with the 
transfection mix. Cell monolayers were washed with PBS and the 
TransMessenger-RNA complexes added drop wise to the cells. Cells were 
either harvested or after 3H, DMEM with 10% FBS added to the wells.  
 
Immunohistochemistry.  
HCV-positive Huh-7.5 cells were visualized by immunohistochemical 
staining for NS5A. All washes and diluents consisted of PBS with 0.1% 
Tween20. Endogenous peroxide was quenched with 3% H2O2. Cells were 
incubated for 1H at 37°C with monoclonal antibody 9E10 diluted 1:200. 
After washing, bound antibody was detected with ImmPRESS peroxidase-
conjugated anti-mouse (Vector laboratories, Burlingame, CA) diluted 1:4 
and incubated for 30 min at 37°C. Peroxidase was detected with DAB 
substrate (Vector labs), and nuclei counterstained with hematoxylin 2. 
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Luciferase assay.  
 At the indicated time point post electroporation, media was removed 
and cell monolayers were washed twice with PBS. For cells in 96 well 
plates, 20 uL of lysis reaction was added to each well and the plate was 
stored at -80°C. To analyze luciferase activity, plate contents were thawed 
and 15 uL was transferred to a white polystyrene 96 well plate. For a dual 
luciferase reaction, 25 uL of LARII (Promega, Madison, WI) was added to a 
well, a 2 sec delay, and firefly luciferase activity read for 2-5 sec. Then 25 
uL of Stop and Glo (Promega) was added to the well, a 2 sec delay, and 
Renilla luciferase activity measured for 5-10 sec. For a Renilla luciferase 
assay, 25 uL of Renilla substrate was added to each well, a 2 sec delay, 5-10 
sec read, and then a 10 uL of 70% ethanol was added to quench the signal. 
 
Metabolic labeling of proteins and immunoprecipitation.  
Cell monolayers in 35 mm wells were incubated for 0.5 to 10H in 
methionine- and cysteine-deficient minimal essential medium containing 
1/40 the normal concentration of methionine,  10% FBS, and Express 35S-
protein labeling mix (140 uCi/ml;  NEN). Labeled cells were washed once 
with cold PBS and harvested in 200 ul of SDS lysis buffer (0.1 M sodium 
phosphate buffer [pH 7.0], 1% SDS, 1x complete protease inhibitor cocktail 
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[Roche Applied Science], 80 ug of phenylmethylsulfonyl fluoride [PMSF] 
per ml), and cellular DNA was sheared by repeated passage through a 27 
gauge needle. Equal amounts of protein lysates (50 ul) were heated at 75°C 
for 10 min and clarified by centrifugation prior to mixing with 200 ul of 
TNA (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.67% bovine serum 
albumin, 1 mM EDTA, 0.33% Triton X-100, 80 ug of PMSF per ml). One ul 
of HCV-positive serum (patient JHF) was added, and immune complexes 
allowed to form by incubation overnight at 4°C with rocking. Immune 
complexes were collected by adding 50 ul of prewashed Pansorbin cells 
(Calbiochem, San Diego, CA) and incubating for 1 to 2H at 4°C with 
rocking. Immunoprecipitates were collected by centrifugation and washed 
three times in TNAS (TNA containing 0.125% SDS) and once with TNE (50 
mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 80 ug of PMSF per 
ml), solubilized by heating at 80°C for 20 min in protein sample buffer, and 
separated on an SDS-10% polyacrylamide gel. Metabolically labeled 






Selection of reversions:  
Replication was launched following the electroporation protocol as 
described above with 10 ug of in vitro transcribed RNA for 6 x 106 cells. 
Cells were seeded at 1 x 106 cells in a 100 mm dish for passage, and 1 x 104 
cells in a 24 well plate for IHC. Upon reaching about 80% confluency, cells 
were split 1:5 into a 100 mm dish and one well of a 24 well plate. To test for 
virus infectivity, media was removed from the transfected cell culture, 
centrifuged to remove any cell debris, and added to naïve cells in a 24 well 
plate. HCV positive cells were visualized by IHC and HCV RNA was 
collected using RNeasy Mini columns (Qiagen) for cloning and sequencing.  
 
Huh-7 Translation Cell Extracts: 
Monolayers of Huh-7 cells were grown in ten P150 flasks to a density 
of 1 x 107 cells per plate. Media was removed and washed twice in ice cold 
PBS. Cells were dislodged from the dish in ice cold PBS using a flat edge 
cell scraper and centrifuged at 2000 x g for 20 min at 4°C. The supernatant 
was discarded and the cells were gently resuspended in 750 uL (1.5 the 
volume of cells) of low salt solution (10 mM HEPES [pH 7.4], 10 mM 
KoAc, 2 mM DTT). Cells were allowed to swell on ice for 10 min. Using a 2 
mL Dounce B homogenizer, cells were lysed with 30 strokes on ice and 
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transferred to two 1.5 mL microfuge tubes. To each tube, 125 uL of 10 x 
buffer (0.2 M HEPES [pH 7.4], 1.2 M KOAc, 50 mM DTT, 25 mM 
MgOAc) was added and mixed by pipetting. The lysates were centrifuged at 
3000 x g for 5 min at 4°C. The supernatant was transferred to a new 
microfuge tube and centrifuged at maximum speed for 20 min at 4°C. 
Avoiding a film of lipids at the surface, supernatant was transferred to a new 
microfuge tube. Micrococcal nuclease (0.067 U/ul) in 50% glycerol was 
added, followed by 1 mM CaCl to activate the nuclease The reaction was 
incubated at room temperature for 1H. 2 mM EGTA was added to stop the 
reaction and aliquots were flash frozen in liquid nitrogen before being 
transferred to -80°C.   
 
Translation using Huh-7 and Huh-7.5 cell extracts. 
 On ice, the reaction was assembled using 12.5 uL of cell extracts, 2.5 
uL of 10x Buffer (10 mM ATP, 2.5 mM GTP, 100 mM HEPES, 0.6 M KCl, 
12.5 mM MgOAc, 0.2 M creatine phosphate, 10 nM spermadine), 7.5 ug of 
creatine kinase, 0.04 mM amino acids.  Template RNA was added and the 





Translation using rabbit reticulocyte extracts. 
 The Flexi rabbit reticulocyte lysates were obtained from Promega. In 
a 25 uL reaction volume, 16.5 uL of lysates, 0.04 mM amino acids, 0.2 U 
superasin, 40 mM KCl, and MgCl2 added to a final concentration of 3 mM 
(depending on the endogenous amount in the lysates). Template RNA was 
added and the reaction was incubated at 30°C.  
 
Transfection of Huh-7.5 cells and selection with G418.  
Subconfluent Huh-7.5 cells were trypsinized, collected, and washed 
twice with ice-cold RNase-free phosphate-buffered saline. The cells were 
resuspended in phosphate-buffered saline at 2.5 x 107 cells/ ml. One 
microgram of in vitro transcribed RNA was mixed with 0.4 ml of the Huh-
7.5 cell suspension, transferred to a 2 mm gap cuvette (BTX), and pulsed 
with a BTX ElectroSquarePorator (0.82 kV; five pulses; 99 usec pulse 
length, 1.1 sec intervals). After 10 min at room temperature, the cells were 
transferred to 9.6 ml of DMEM with 10% FBS. To measure the efficiency of 
G418-resistant colony formation, the transfected cells were plated at a series 
of densities (106, 105, and 104 cells per plate). To maintain the total number 
of plated cells at 106 cells per 100mm dish, cells transfected with 
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polymerase-defective RNA were used as feeder cells. After 24H, the 
medium was changed to DMEM with 10% FBS supplemented with G418 
(Geneticin; Invitrogen) at 1 mg/ml. The medium was replaced every 4 days. 
After about 3 weeks, G418-resistant colonies were stained with 1% crystal 

















Table 2.1: List of mutations 
Name Position Genotype AA change AA ARF change 
Stop 1 C407A 1a None Stop 
Stop 2 T434A 1a None Stop 
Stop 3 G473A 1a None Stop 
Stop 4 C480A, C482G 1a None Stop 
Open 1 C407T 1a None L > S 
Open 2 T434C 1a None S > L 
Open 3 T471C, G473C 1a None S > W 
Open 4 G479C, C480A, 
C482G 
1a None S > C 
G > A 
Comp 3 C466T, C407A, 
T434A, G473A, 
C480A, C482G 
1a P42L Stop 




1a R39L Stop 
Comp 2 A502T, C407A, 
T434A, G473A, 
C480A, C482G 
1a E54V Stop 
Stop 1 C407A 1b None Stop 
Stop 2 C434A 1b None Stop 
Stop 3 C473T 1b None Stop 










1a None NA 
Mid Right C482A, C484G 1a A48G NA 
Mid Right 
Silent 
C482A, G485T 1a None NA 
Mid Left G452C, 
G455A 











Table 2.1: List of mutations, CONT. 
Name Position Genotype AA change AA ARF change 
Base Left T434A, T437A, 
A441T 
1a None NA 
Base Right T497A, 
C500A, 
A502T 





















2a None NA 





2a None NA 
J6 Stop 3,4 G472A, C479A, 
C481G 



















U26A 1a None NA 
5’NTR 
mut-E 





























Chapter 3.  The Alternative Reading Frame is not essential for infection. 
Aim. 
 An overlapping open reading frame is present in the capsid gene of all 
HCV genotypes. Using cell free translation assays as well as transient 
expression in cell culture, a protein product has been shown to be expressed 
from this alternative reading frame (ARF) 18, 149, 153, 161. HCV patients have 
also been shown to produce antibodies and cellular immune responses to 
ARF peptides indicating its expression during infection 66, 153, 161. To test if 
this ARF is required in an HCV infection, we introduced silent mutations 
that confer stop codons in the ARF, while preserving the capsid amino acid 
sequence, in an HCV molecular clone. This ARF-ablated genome was 
inoculated into a chimpanzee. We monitored the virus load, adaptive and 
humoral immune response, and virus diversity to determine if the ARF 
contributes to the HCV lifecycle in a natural infection.  
 
Introduction. 
Comparison of the capsid gene from divergent HCV isolates has 
revealed an unusually high level of nucleotide sequence conservation. 
Synonymous mutations are suppressed, suggesting a functional role for the 
nucleic acid sequence beyond simply encoding the capsid protein.  For all 6 
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HCV genotypes, an overlapping reading frame in the +1 frame of the capsid 
gene is present. In the same region, highly conserved RNA secondary 
structures have been predicted using phylogenetic analyses of covariant base 
pairs.  
The +1 frame of the capsid gene has been termed the alternative 
reading frame, ARF. Antibodies and cellular immune responses reacting to 
ARF-encoded peptides or recombinant protein have been detected in HCV-
infected patients.  These observations provide evidence for expression of the 
ARF in vivo; however, an ARF-encoded product has yet to be detected in 
infected tissue. Using cell-free translation and transient expression in cell 
culture, an ARF protein has, however, been reported for the prototype 
genotype 1a isolate, HCV-1. HCV-1 contains a stretch of 10 consecutive 
adenine residues where a +1 frameshift event moves translation into the 
ARF between codons 9-11 of the capsid gene to produce a frameshift 
product, termed the F protein 160. Another ARF protein has been reported for 
a genotype 1b sequence involving two frameshift events. This dual 
frameshift (DF) protein also begins translation from the AUG of the 
polyprotein and frameshifts further downstream after codon 42 into the ARF 
18. Translation continues in the ARF until a stop codon at position 144 is 
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reached, triggering either termination or an additional frameshift that 
restores translation into the polyprotein reading frame.  
 
Ablation of ARF-encoded gene products by site directed mutagenesis.  
Despite its high degree of conservation, the region of the capsid gene 
encoding potential ARF proteins is dispensable for RNA replication in cell 
culture. Since ARF-encoded proteins may function in other aspects of the 
HCV lifecycle such as virus assembly, virus-immune system interactions or 
pathogenesis, we used the chimpanzee model to examine the behavior of a 
mutant HCV genome with ablated expression of both the ARF-encoded F 
and DF proteins. The consensus genotype 1a H77 cDNA was chosen as the 
parent genome for our studies given the wealth of information obtained from 
chimpanzees infected with H77 RNA transcripts or with the acute-phase 
virus 82, 83, 84. Five nucleotide substitutions were introduced to the capsid gene 
that conferred four stop codons (Stop1,2,3,4) while preserving the amino 
acid sequence of the capsid protein (Figure 3.1). These mutations would also 
disrupt RNA secondary structures in the capsid gene (Figure 3.2). To 
minimize leaky protein expression due to read-through and reversion, two 
stop codons were introduced downstream from each reported frameshift site. 







Stop 1 Stop 2
Stop 3 Stop 4
Polyprotein
ARF
Codon 1 42 145
191
191
Dual frameshift (DF) protein
Figure 3.1. The proposed expression of the F and DF proteins are shown. 
Silent point mutations were introduced to convey stop codons in the ARF. 
Mutations for Stop 1 and Stop 2 would block expression of the F protein. 








































































































Figure 3.2. The predicted RNA secondary structures SLV and SLVI in the 
capsid gene. The point mutations conferring Stop 1,2,3,4 in the ARF are 
shown. Stop 2,3,and 4 would disrupt base paired interactions in SLVI.
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protein reportedly shifts into the ARF further downstream at codon 42 
(Figure 3.1). Stop 1 would permit expression of only the first 21 amino acids 
of the F protein, and Stop 2 follows 9 codons downstream. Stops 3 and 4 are 
located at codon 43 and 45 of the ARF to block expression of the DF 
protein. Stops 1, 2, and 3 each required one base substitution (C407A, 
U434A, G473A, respectively), whereas two base changes were required to 
generate Stop 4 (C480A and C482G). Only Stop 4 created a potentially 
leaky opal stop codon (UGA), but rather than C residue which promotes 
translational read-through, this codon was followed by a G 70.  
 
An HCV genome without F and DF expression is infectious in vivo. 
An HCV-naïve chimpanzee was inoculated with the HCV genome 
Stop 1,2,3,4 by direct intrahepatic injection of in vitro transcribed RNA. The 
animal became infected. Circulating HCV RNA was detected by nested RT-
PCR at 1 week post-inoculation. By week 2, HCV RNA levels could be 
quantified by real time qRT-PCR. HCV RNA levels rapidly increased and 
peaked at weeks 6 and 7 at 8 x 104 GE/ml (Figure 3.3). Circulating HCV 
RNA then declined rapidly and fell below the limit of detection at week 10. 
RNA was transiently measurable at week 12 (380 RNA GE/ml), and only 
detectable by nested RT-PCR for the subsequent weeks analyzed (through 
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      1  2  3  4  5  6  7  8  9  10 11 12     16   18  20      24   26   28  40
EIA                   -   -   -   -   -   -  -   -   -    -   +   +       +     +   +        +     +     +    +     
Nested PCR    +  +  +  +  +  + +  +  +   +   +   +       +     +   +        +     +   -/+  -/+
Week
  



















































































Figure 3.3. The infection profile of the HCV genome Stop 1,2,3,4 in a 
chimpanzee. The virus RNA levels are measured by Real Time qT-PCR 
and graphed on the inner left y-axis with the limit of detection as the origin 
of the x-axis. ALT levels are on the right y-axis. An HCV-specific immune 
response was measured by PBMCs and liver derived CD8+ in an 
ELISPOT assay. The frequency of secreted interferon gamma cells is 
shown on the outside left y-axis. An antibody response was detected by 
EIA and positive weeks indicated. 
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week 40). The animal seroconverted at week 11. No significant elevation in 
ALT was observed except for a slight rise of 20 U/ml above baseline during 
the peak of viremia (Figure 3.3). Compared to other monoclonal chimpanzee 
infections with the parental H77 sequence, Stop 1,2,3,4 infection produced a 
lower peak viremia by 1-2 logs. The mutant virus was also controlled earlier 
without apparent liver damage, suggesting that the ARF mutant may be 
attenuated.  
 
An immune response is detected in both the periphery and liver. 
Given that ARF-encoded products might function in modulating host 
immune responses to HCV, HCV-specific T cell responses were monitored 
both in the periphery and the liver. At weeks 10 and 12, HCV-specific 
responses were detected in peripheral blood mononuclear cells (PBMCs) and 
from intrahepatic CD8+ T cells by ELISPOT (Figure 3.3). PBMCs were 
stimulated from pools 3, 4, 5 and 6, representing peptides from E2 to NS4B, 
and HCV-specific CD8+ cell responses reacted to pools 2 and 3, which 
include peptides from E1, E2, p7, and NS2. The frequency of HCV-specific 
CD8+ cells was lower than observed for other chimpanzee infections 
launched with a genotype 1a virus, but we were able to detect a diverse 
response indicating active replication and interchange with a functional 
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immune system. We monitored the general population of CD4+, CD8+, 
CD3+, and CD56+ expressing cells in the PBMCs and found no change, thus 
indicating no evidence of immunosuppression during the infection.  
 
Unique epitopes are detected by direct cloning of T cells from liver biopsy. 
Since a response could not be detected after week 12 using the 
ELISPOT assay, we used a more sensitive approach and cloned intrahepatic 
CD8+ and CD4+ T cells from liver biopsies at week 16 and week 20 post 
inoculation. Analysis of 308 independently derived CD8+ T cell clones 
revealed that 31% were capable of killing target cells presenting HCV 
proteins. We then determined the epitope of 96 CD8+ and 7 CD4+ 
intrahepatic T cell clones, which revealed previously unseen CD8+ epitopes 
spanning proteins E1 to NS5. CD4+ cells proliferated in response to epitopes 
in NS4B at week 16 and epitopes in E2, NS3, NS5A by week 20 (Table 3.1). 
No T cell reactivity was detected against ARF-encoded epitopes. Thus, 
despite producing a low level of viremia, infection with Stop 1,2,3,4 
stimulated a diverse intrahepatic T cell response, first detectable by week 10, 
and presumably controlling the virus by week 20.  
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A. CD8+ T cell lines: 
Week 16  No. cell lines
 Pool 2 48
 Pool 3 39
 Pool 6 1
 Pool 7 4
 Pool 8 4
 Tested 308
B. CD4+ T cell clones:
Clone  Epitope   Protein AA sequence
Week 16
5F Pool 6 LFNILGGWVAAQLAAPGA    NS4B 1808-1825
9F Pool 6 LFNILGGWVAAQLAAPGA                      NS4B 1808-1825
Week 20
1C Pool 2 YANGSGLDERPYCWHY  E2 474-489
8C Pool 2 MVDYPYRLWHYPCTINY  E2 608-624
7E Pool 5 KLVALGINAVAYYRGLDV  NS3 1406-1423
3F Pool 5 YRLGAVQNEVTLTHPITK  NS3 1626-1643
7F Pool 7 EVSVPAEILRKSRRFARA  NS5A 2267-2284
Supplemental Data
Table 1
Table 3.1. CD8+ and CD4+ cells were extracted from liver biopsy at weeks 
16 and 20 and cloned in a limiting dilution assay. A. CD8+ T cell lines 
shown to generate a cytotoxic response upon stimulation with HCV 
peptides from the indicated pools. B. The epitopes of CD4+ T cell clones 
were mapped in a proliferation assay upon stimulation with the indicated 
HCV peptides.  
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The selection of revertants suggests pressure to maintain ARF RNA 
elements rather than F/DF protein expression.  
The low peak viremia and early control of the mutant virus could be 
due to the Stop 1,2,3,4 substitutions impeding HCV replication. Given the 
high mutation rate of HCV replication, reversion to the wild-type H77 
sequence and/or accumulation of compensating, fitness-restoring mutations 
would provide clues to the importance of F/DF expression or functional 
RNA elements in the ARF. At weekly or monthly (after week 12) time 
points, the 5'-NTR-C/ARF region of circulating HCV RNA was amplified 
by RT-PCR. Sequences were determined for both the population and 
multiple clones, to sample sequence heterogeneity.  
At week 1, the predominant HCV sequence was identical to the 
inoculated Stop 1,2,3,4 RNA transcript. Since we have never detected 
circulating input RNA using mutant transcripts with lethal (pol-) mutations 
65, this suggests that the Stop 1,2,3,4 mutant was able to replicate in vivo, 
albeit inefficiently. At week 2, coincident with a rise in circulating virus 
RNA to nearly 104 GE/ml, the parental H77 G473 was found in all HCV 
genomes sequenced (Figure 3.4). The reversion of Stop 3 (G473) remained 
















Stop 1 Stop 2 Stop 3 Stop 4
GGACGUAAAGU...UCGUAGGUG...GAUUAGGUGUGAGGGCG
407 434 473 480 482Position
Figure 3.4. Reversions detected in the circulation after inoculation with 
Stop 1,2,3,4 genome. At week 2, a reversion at 473 replaced the Stop 3 
mutation A with the H77 G. This reversion was the dominant sequence and 
became fixed in the population. At week 10, a mixed population was 
detected containing a second reversion of A480C. This second reversion 
became fixed at week 20. At week 40, a third reversion was detected, 
G482C.
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This reversion removed the Stop 3 ochre codon, but the downstream Stop 4 
opal codon was still present to block expression of DF.  
At week 10, we detected a second reversion at Stop 4 restoring A480 
to the wild-type C480 H77 sequence. This was not the dominant sequence, 
as virus with both reversions circulated with virus containing only the first 
reversion at Stop 3. The A480C reversion eliminated the Stop 4 codon, thus 
restoring possible expression of the DF protein. The capsid protein sequence 
remained unaltered as Stop 4 preserved capsid Arg47 by creating an 
alternative arginine codon (AGG, nucleotides 480-482) and the second 
reversion, A480C, yielded the capsid codon CGG. Virus with one or both 
reversions existed as a mixed population for the next 10 weeks. At week 20, 
virus with both first and second reversions was fixed in the population 
(Figure 3.4).  
A third reversion was detected at week 40 involving the second 
nucleotide substitution of Stop 4, with G482 being replaced by the wild-type 
H77 nucleotide, C (Figure 3.4). This third reversion was the only sequence 
detected, but may not necessarily represent the virus population since we 
succeeded in obtaining an RT-PCR product in only one of three attempts. 
This third reversion did not change the capsid protein sequence since C482 
restores the wild-type Arg47 codon (CGC, nt 480-482). Hence, the selective 
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force(s) favoring C482 are unclear. The possibility of codon preference for 
Arg CGC over CGG seems unlikely since they are used at approximately 
equal frequency in the HCV H77 ORF (38 versus 34 times, respectively). 
Since week 10, the presence of the first and second reversion could restore 
possible DF expression. The third reversion would not be expected to affect 
DF production, although it would alter the amino acid at position 5 of the DF 
frame from Gly (mutant) to Ala (wild-type). Alternatively, the reversion to 
C482 may restore an RNA element in the C/ARF region important for HCV 
replication. The results of the sequence analyses, where Stop 1 and Stop 2 
were maintained throughout infection, clearly demonstrate that F protein 
expression is not required for HCV H77 replication. 
 
Evidence for an RNA structure in the capsid gene. 
Two RNA helix forming stem structures, SLV and SLVI, have been 
proposed in the region containing the ARF stop codons and confirmed by 
enzymatic structure probing 147. The base change conferring Stop 1 is not 
predicted to alter a base pair interaction; however, substitutions for Stop 2, 
Stop 3, and Stop 4 could disrupt the upper stem in a large RNA helix of 
SLVI (Figure 3.5). A phylogenetic study of covariant base pairing shows 























































































































































































































































































































Figure 3.5. Reversions detected in the circulation indicate a selective 
pressure to improve replication by restoring an RNA structure. The top of 
SLVI is shown. The first reversion of Stop 3 would re-establish a Watson 
and Crick base pair below the loop of SLVI. The second and third 
reversion would restore two base pairs to the top  stem of SLVI. 
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(Figure 3.6). The sequence of the parental H77 was compared with 1274 
sequences including all 6 genotypes. The predicted RNA structures were 
compared by generating M-fold profiles and differences tallied with R-fold 
analyzer, kindly provided by Andrea Branch. The top of SLVI displays 
covariant conservation with base pairs likely to exist in 90% or more of the 
sequences shaded in Figure 3.6. Nucleotides conserved in all but one 
sequence out of the total 1274 analyzed are circled. The wild-type nucleotide 
of Stop 3, G473, is conserved in 1272 out of 1274 sequences, and the Stop 4 
mutations, 480 and 482, are conserved in 1256 out of 1274 sequences. 
Covariant base pairs are detected in 18 and 14 sequences for Stop 4 mutant 
positions 480 and 482, respectively. The first reversion at Stop 3 restores a 
base pair interaction at the base of the loop of SLVI, and the second and 
third reversions would repair two base pair disruptions in the stem of SLVI.  
 
Discussion. 
We have shown that an HCV genome containing 4 stop codons in the +1 
frame overlapping the capsid gene is capable of establishing an infection in a 
chimpanzee. The infection was, however, atypical with low peak viremia, 
short duration of the acute phase, and no appreciable liver pathology. A 















































Figure 3.6.  Phylogenetic analysis of the conserved nucleotides and 
covariant base pairs of SLVI. The sequence of the parental H77 was 
compared with 1274 sequences and include all 6 genotypes. Regions 
shaded indicate Watson-Crick or wobble base pairs likely to exist in 90% 
or more of sequences in all 6 genotypes. The nucleotides conserved in all 
but one sequence out of 1274 are circled. Covariant bases are counted 
adjacent to the structure, with the number of sequences with bases unable 
to pair (NP, not paired) indicated. The base mutations in the chimpanzee 
study are indicated by a square with the number of sequences with 
identical or different bases at each position indicated
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the periphery that coincided with a decline in circulating HCV RNA. During 
infection, a series of reversions emerged indicating a selective pressure for 
RNA sequence and predicted RNA structure rather than a frameshift protein. 
Base substitutions creating the two downstream stop codons were found to 
revert during the infection. These substitutions disrupt base pairing of a 
predicted RNA secondary structure in the capsid gene, implicating this RNA 
element in the modulation of HCV infection.  
Features of this infection differed from previous young naïve chimpanzee 
infections launched with this consensus H77 genome. The titer reached only 
8 x 104 GE/mL, 1-2 logs lower than previous studies 154. Also, circulating 
HCV RNA peaked at week 6 and was undetectable by week 12, several 
weeks earlier than a typical acute infection. The low level of circulating 
HCV RNA during acute infection may indicate that few hepatocytes became 
infected, low replication fitness of the mutant virus on a per cell basis, or 
both. Virus levels declined without elevated liver transaminases in the 
serum, signifying little liver damage. Again, this is atypical where an 
increase in serum ALT (usually to 100-200 IU/mL) coincides with immune-
mediated hepatocellular injury and a rapid decrease in circulating HCV 
RNA. We did, however, find a diverse adaptive immune response in both the 
liver and periphery at the time of virus decline and persisted as virus 
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disappeared from circulation. HCV specific CD8+ and CD4+ T cells 
detectable at low frequencies were capable of recognizing HCV peptides in 
5 of 10 pools representing the entire H77 polyprotein. No T cells targeting 
epitopes from the ARF were found. Thus, HCV lacking expression of an 
ARF protein established an infection, albeit with low levels of circulating 
virus and of short viremia. Infection with the mutant virus elicited a diverse 
adaptive immune response, though virus-specific CD4+ and CD8+ T cells 
were detected at a lower frequency. 
During infection, we detected a series of sequence reversions in the virus 
population. The predominant sequence in the first week of infection was the 
input mutant Stop 1,2,3,4. Since we have never previously detected carry 
over of RNA from inoculation in the circulation, this suggests that the input 
mutant was able to replicate.  The dominant virus during the acute phase 
harbored a reversion that eliminated the Stop 3 codon. Stops 1, 2 and 4 
remained intact, however, blocking the expression of both the F and DF 
proteins. A second reversion restored one of two nucleotide substitutions in 
Stop 4 and was selected at a time of immune stimulation. Finally, a reversion 
of the second substitution creating Stop 4 was selected as the dominant 
virus. Since the DF protein expression was possible after the second 
reversion, and at no time was there a change in the capsid amino acid 
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sequence, these results are consistent with selection to maintain the capsid 
nucleotide sequence rather than DF expression. Taken together, these data 
indicate that neither the F or DF proteins are required for HCV H77 
replication in vivo.  
RNA elements in both the non-coding and coding regions regulate 
translation and replication, but the functions of SLV and SLVI are unknown. 
The downstream boundary of the IRES does extend into the capsid-coding 
region, and IRES function can be influenced by both the capsid protein and 
RNA structures immediately downstream of the AUG start codon 52, 124, 155. 
The 5' base of the SLVI stem in the capsid gene has also been shown to base 
pair with a complementary region in the 5'NTR between SLI and the IRES, 
down modulating IRES function 55, 64. The base substitutions we used to 
create stop codons in the ARF do not affect the sequence proposed to base 
pair with the 5'NTR, but would disrupt the stem of SLVI itself. Also, a liver 
specific microRNA, miR122, can base pair with the same region in the 
5’NTR and enhance HCV replication 59. This interplay between cellular 
miR122, the 5’NTR, and SLVI may indicate that HCV translation and 
replication are regulated by competing higher order RNA structures.  
Our results clearly show that the F and DF proteins are dispensable for 
HCV replication in vivo and in vitro. We cannot exclude that functionally 
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important ARF products are expressed by internal initiation from regions 
downstream of the Stop 4 codon (ARF codon 46). In this regard, internal 
initiation has been proposed to occur between ARF codons 80 and 86, and 
the importance of such ARF-encoded products remains to be examined 6.  
In summary, a study designed to test the importance of the ARF-encoded 
F and DF proteins, instead revealed a new, functionally important RNA 
element in the HCV protein-coding region. This stem-loop structure (SLVI) 
resides in the ARF and capsid-protein coding region and may be part of an 
assemblage of higher order RNA structures that regulate HCV translation 

































Chapter 4.  An RNA structure in the capsid-coding region affects HCV 
replication in cell culture. 
Aim: 
 The course of a chimpanzee infection with an H77 genome containing 
mutations for Stop 1,2,3,4 differed from that with the wild type, parental 
genome. Low circulating RNA levels and a series of reversions that were 
rapidly selected, as early as the second week, imply that the mutant was 
attenuated. To determine if silent “Stop” mutations in the ARF affected 
HCV replication in cell culture, we engineered these mutations into an HCV 
genome that is replication competent in Huh-7.5 cells. The mutations were 
studied in a functional assay measuring HCV RNA levels and protein 
expression in cell culture. The regions of the capsid gene contributing to a 
replication defect were mapped and compared with HCV sequences from 
diverse genotypes. Using an HCV isolate capable of efficient replication and 
virus production in cell culture, we evaluated the selective pressure to 







 The region of the core gene encoding these Stop mutations is 
dispensable for replication of subgenomic replicons. These replicons 
undergo HCV replication with a minimum of genetic elements.  Both 
promoter-containing NTRs are present, and the replicase is expressed from 
the heterologous EMCV IRES. It was thus surprising to detect reversions for 
this region of capsid sequence during the infection. The first reversion was 
selected at the launch of the acute stage of the infection and was rapidly 
fixed in the population. Additional reversions were soon selected and 
dominated the circulating virus population. The appearance and shift in the 
population indicate a strong selective pressure, and the order of the 
reversions implies selection for an RNA element in the capsid gene.   
 RNA structures are known to conduct translation and replication in 
positive strand viruses. Virus families such as the Picornaviridae, in 
addition to the pestivirus and hepacivirus, use IRES-driven translation to 
express the virus proteins as well as RNA structures at the both ends of the 
genome to conduct replication via virus polyprotein precursors and cellular 
proteins 109. RNA structures at the carboxy terminus of the genome can often 
influence translation as well as enhance RNA stability. The tRNA-like 
elements of the family Bromoviridae are aminoacylated and require binding 
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of the capsid protein for replication 16. Cis- acting elements have been 
identified in plus and minus strands in almost all RNA viruses. RNA signals 
in the coding regions have been shown to act as frameshifting signals in 
genera as diverse as the retrovirs, coronaviruses, and astrovirus 22, 85. 
Minimal RNA structures as well as additional enhancer elements have been 
described as acting as packaging signals for the virus nucleocapsid in 
assembly. A role for the RNA structures SLV and SLVI of the capsid gene 
in HCV are unknown, therefore we measured the ability of HCV genomes 
with mutations in SLV and SLVI to replicate in cell culture.  
 
 The Stop mutations confer a replication defect in cell culture. 
The point mutations conferring Stop 1,2,3,4 in the ARF were 
introduced into an HCV genome capable of replicating in cell culture. The 
parent genome is identical to the genotype 1a H77 sequence used in the 
chimpanzee infection, with the exception of two amino acid differences in 
the replicase that confer replication in cell culture; one adaptive mutation in 
the helicase domain of NS3 (P1496L) and another in NS5A (S2204I) 13. All 
experiments were performed using an adapted cell line capable of increased 
HCV replication, Huh-7.5, which was derived from the human hepatoma 
cell line Huh-7 12. Replication was measured by electroporating in vitro 
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transcribed HCV RNA into Huh-7.5 cells and HCV RNA levels determined 
at successive time points by quantitative real time RT-PCR. RNA levels for 
the mutant constructs were compared to the wild-type (H/L+I) parent or a 
replication defective (pol-) control.  For the H/L+I parent, RNA levels 
declined slightly as input RNA was degraded, then rose to plateau by day 4 
as new RNA was generated (Figure 4.1). By day 3, pol- RNA remained 
detectable, but at levels more than 1000-fold lower than the H/L+I parent. 
The Stop 1,2,3,4 mutant was highly impaired with transient, low-level 
replication observed at 3 days, which then decreased to pol- levels by day 5. 
The defect in replication caused by five silent point mutations in the capsid 
gene was striking, as this region is dispensable for replication in subgenomic 
replicons, and therefore, thought not to participate in replication. To 
determine which mutations contributed to the defect, we made a further 
series of constructs and evaluated their capacity for replication. Mutations 
for Stop 1 and Stop 2 had no deleterious effect on replication; however, 
mutations for Stop 3 and 4 did impact replication levels (Figure 4.2). 
Individually, Stop 3 and Stop 4 reduced replication to 47% and 38% of wild 
type levels, respectively, and together they crippled replication to just 2% of 
wild type (Figure 4.2). Combining the mutations of Stop 3 with Stops 1 and 
2 also attenuated replication by 76%. Stop 4 yielded an even more dramatic 
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Figure 4.1. Replication of the Stop 1,2,3,4 genome is severely 
impaired. HCV RNA was measured by Real Time qRT-PCR and 
normalized with cellular GADPH RNA. Replication is indicated 
where HCV RNA levels are present above a polymerase defective 
control. 
Replication






























Figure 4.2. Replication of HCV genomes with point mutations for Stop 
codons 1-4. A. HCV RNA measured by Real Time qRT-PCR at days 3, 
4, 5 post electroporation. B. HCV RNA levels at day 5 post 
electroporation. The percent difference from wild type is shown above 
each bar. Data represent averages of two independent experiments with 

















































































































affect in combination with Stops 1 and 2 with 18% replication compared to 
wild type (Figure 4.2). These results imply that the Stop mutations 
compromised replication in the chimpanzee infection. Consistent with the 
results from the chimpanzee infection, the genome with all mutations was 
severely compromised, almost to the level of the pol- control, yet the 
genome mimicking the first reversion, Stop 1,2,4, replicated more efficiently 
although to only 18% of wild type. Furthermore, the second and third 
reversions in the chimpanzee removed both Stop 3 and Stop 4 mutations, 
and we found that this genome could replicate to wild-type levels.  
The replication defect was confirmed by detecting HCV antigen in 
transfected Huh-7.5 cells by flow cytometry. This allowed a measurement of 
HCV protein expression on a per cell basis, while the quantitative real time 
RT-PCR results were a study of RNA levels within the transfected cell 
population. At day 5 post electroporation, 19% of the cells transfected with 
the wild type H/L+I were positive for NS5A, whereas only 2% of cells were 
positive when transfected with the pol- control (Figure 4.3). Genomes with 
the mutations for Stop 3 (Stop 1,2,3 and Stop 3 alone) conveyed a 15% and 
14% antigen positive cell population, respectively. Fewer cells were positive 
when transfected with genomes with Stop 4 mutations. A four-fold 
reduction, 5% of the population, in the number of positive cells resulted 
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Figure 4.3. Flow cytometry of Huh-7.5 cells positive for HCV 4 days 
post electroporation. Histograms show percent cells stained with anti-
NS5A (red),  IgG2a (blue), and cells unstained (green). The percent 
positive for NS5A is indicated.

















































































































































from transfection with genomes with Stop 1,2,4 and Stop 4 alone (Figure 
4.3). Stops 3 and 4 together resulted in only 4% of the population being 
HCV positive. These results suggest that mutations for Stops 3 and 4 are 
deleterious for replication. This indicates that the reversions observed in 
vivo, which replaced the Stop 3 and 4 mutations with the original H77 
sequence, were selected because they improved the replication ability, and 
thus the fitness of the virus.  
 
The Stop mutations do not affect expression or cleavage of the polyprotein. 
 The mutations of Stop 3 and Stop 4 impair replication. We examined 
the ability of HCV RNA containing the Stop mutations to express and 
process the polyprotein. DNA plasmids with the HCV genome behind a T7 
promoter were transfected into Huh-7.5 cells. Subsequently, cells were 
infected with a recombinant vaccinia virus expressing the T7 RNA 
polymerase, which transcribed the HCV RNA in the cytoplasm of the cell. 
Translation was mediated by the HCV IRES, and the polyprotein was 
processed into the separate virus proteins. Newly generated proteins were 
35S-Met labeled, HCV proteins immunoprecipitated with serum from an 
HCV infected patient, and analyzed by SDS-PAGE and autoradiography. 
We compared the expression and processing of HCV proteins from genomes 
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containing the Stop mutations (Figure 4.4). No difference in the expression 
levels of NS3, NS4B, and NS5A could be detected except in the lane for 
Stop 3,4. The lower amount of radiolabeled HCV proteins correlated with a 
lower level of background contaminants therefore it appears the low level is 
due to a loading error.  In this system, the Stop mutations had no effect on 
HCV expression and polyprotein processing.  
 
The ARF is dispensable for HCV replication in cell culture. 
 The replication defect in genomes with silent mutations in the capsid 
gene, yet conveying Stop codons in the ARF, could be due to lack of 
expression of an ARF protein product. To address this possibility, HCV 
genomes were constructed with point mutations in the same location as the 
Stop mutations; however, these genomes were engineered with both the 
capsid and ARF reading frames open. These “open” substitutions did not 
alter the capsid amino acid sequence, but did change the coding of the 
alternative reading frame. The genome with Open 3 mutations contains two 
substitutions (T471C, G473C) and Open 4 consists of three substitutions 
(G479C, C480A, C482G). Open 1 and Open 2 both contain only one 
substitution each (C407T and T434C) (Table 2.1 and Figure 4.5). These 
substitution sets were introduced into the H/L+I parent, in vitro transcribed 
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Figure 4.4. The Stop mutations do not alter polyprotein processing. 
Immunoprecipitation of radiolabeled  HCV proteins expressed from 
genomes containing the Stop mutations. cDNA clones containing the 
HCV genome behind the T7 promoter were transfected in Huh-7.5 cells, 
and HCV RNA transcribed from the T7 polymerase provided by 
infection with the recombinant vaccinia virus vTF7-3. Proteins were 
radiolabeled with 35S-Met, and HCV proteins immunoprecipitated with 

















































































































































































































































































Figure 4.5. H77 SLV and SLVI with mutations for Stop and Open 
sets indicated. The mutations do not change the capsid protein.
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RNA transfected into Huh-7.5 cells, and replication measured as described 
previously. At day 5 post electroporation, the pol- genome measured RNA 
levels to 3% of the parental genome. Similar to the genomes with the Stop 
mutations, the substitutions of Open 3 and Open 4 were detrimental to 
replication. Genomes with Open 3, 4 alone, or in combination with Open 1 
or Open 2, replicated to just 1% of wild type (Figure 4.6); the same level as 
the genome with all five of the Stop mutations, Stop 1,2,3,4. Although both 
genomes were severely compromised for replication, Open 1,2,3,4 replicated 
to a two fold lower level than Stop 1,2,3,4. This could be due to the 
additional five substitutions in the Open 3,4 mutation set as opposed to the 
three in Stop 3,4. Interestingly, the mutations of region 3 and region 4, either 
Stop 3,4 or Open 3,4, had a dominant replication defect. The mutations of 
regions 1 and 2 had no effect independently; yet contributed a further 
reduction in the replication capacity when combined with the regions 3 and 
4 mutations. The genome with Open 3,4 substitutions was 100 fold reduced 
from wild type, yet Open 1,2,3,4 showed a 400 fold reduction. An identical 
pattern was observed with the Stop mutation set. Thus, mutations in regions 
1 and 2 exert a synergistic effect on the replication defect caused by 
mutation in regions 3 and 4. The replication defect in cell culture contributed 
by the Stop and Open mutations in the capsid gene indicated that either an 
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Figure 4.6. HCV replication of Open set of mutations. RNA levels 













































































ARF protein product does not participate in HCV replication or that the 
amino acid alterations introduced in the ARF were disruptive for replication.   
 
An RNA structure in the capsid gene sequence is involved in HCV 
replication.  
As discussed in chapter 3, the conservation of the capsid gene may 
indicate the use of an ARF or of functional RNA secondary structures.  Two 
helical stems, named SLV and SLVI, have been predicted by phylogenetic 
studies of codon usage and covariant base changes 133, 147. The substitutions 
conferring Stop codons designed to block expression of the ARF would also 
disrupt these predicted RNA secondary structures. The mutations of the Stop 
and Open substitutions would disrupt the large helix of SLVI, but, as 
mentioned above, we could not discriminate between an absent or 
dysfunctional ARF protein and an alteration of the RNA structure as the 
cause of the replication defect.  To address this, using the genome containing 
all five substitutions of Stop 1,2,3,4, we introduced compensatory mutations 
that would be predicted to restore the base pair interactions of SLVI (Figure 
4.7). Since the mutation for Stop 1 is located in the loop of SLV, no 
compensatory change was possible. The mutation for Stop 2 substituted an 
adenosine for a uridine at the base of SLVI, so we introduced the 
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Figure 4.7. HCV replication of compensatory set of mutations. RNA 
levels were measured by Real Time qRT-PCR 5 days post 
electroporation. Compensatory mutations of H77 SLV and SLVI are 













































































































































































compensatory substitution A502T. This change alters the amino acid of the 
capsid protein from a glutamate to a valine at position 54 (Table 2.1). The 
mutations for Stop 3 and Stop 4 disrupt three base pairs at the top helix of 
SLVI, therefore three mutations were introduced to restore these 
interactions. These mutations also change the capsid protein at P42L and 
R39L. The ARF remains blocked by the four original Stop codons. Genomes 
containing the Stop 1,2,3,4 mutations with individual or combinations of 
compensatory mutations were assayed for their ability replicate in cell 
culture. The replication level of the genome of Stop 1,2,3,4 was severely 
debilitated to 1% of wild type. On their own, the compensatory mutations 
for region 2 and region 3 (Comp 2 and Comp 3), did not restore replication. 
However, providing the compensatory mutation for Stops 2 and 3 together, 
Comp 2,3, replication did increase 25 fold over the parent Stop 1,2,3,4 
(Figure 4.7). 
Recall that replication for the genome with the Stop 1,2,4 mutations 
was debilitated to 18% of wild type, indicating that mutation of Stop 4 has 
the most severe replication defect of the tested mutations. The genome with 
Comp 3 alone could not restore replication of Stop 1,2,3,4 to the level of 
Stop 1,2,4, and required the addition of the Comp 2 mutation to replicate to 
levels 16% of the H/L+I sequence. In contrast, compensating the Stop 4 
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region allowed for more robust replication. Genomes with only the Comp 4 
mutations improved replication 27 fold above the parent. The benefit did not 
reach the level of Stop 1,2,3 mutations, which was 76% of wild type, but 
replication was improved to 18% of wild type. The addition of compensating 
mutations for Stop 2, Stop 3, and Stop 4 further improved replication: Comp 
2,4 showed an 88 fold increase and Comp 3,4 measured levels 93 fold above 
the Stop 1,2,3,4 parent. Genomes with the compensating mutations for Stop 
3, 4, Comp 3,4, could replicate to 60% of the H/L+I genome; however, did 
not restore replication to level of Stop 1,2 (which was equivalent to the wild 
type). These results imply that it is the defect of an RNA structure, and not 
the absence of an ARF protein, that debilitates replication.  
 
 RNA structure probing in solution reveals that Stop 3 and 4 mutations 
disrupt RNA secondary structure.  
 Genetic analysis revealed HCV replication is influenced by RNA 
secondary structures in the capsid region. Disruption of SLVI by the 
introduction of base pair breaking mutations, led to a decrease in the 
replication capacity of HCV genomes in cell culture.  Computer modeling 
programs of the thermodynamic folding of RNA, MFOLD, predicted the top 
of SLVI to be disrupted by the Stop 3 and Stop 4 mutations (Figure 4.8). We 
113
Stop 1 Stop 2
Stop 4
Stop 3
Figure 4.8. The  mutations for Stop 2,3, and 4 would predictably 
disrupt SLVI. The predicted RNA structures for Stop 1,2 and Stop 
3,4 generated from Mfold are shown. 
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wanted to confirm these predictions using the biochemical method of 
detecting paired and single stranded RNA in solution. Using the RNase T1, 
which cleaves the 3’ phosphate bond of single stranded guanine and the 
cobra venom nuclease V1, which cleaves double stranded RNA, we probed 
the RNA structure of the capsid region using primer extension analysis 
(Figure 4.9). The RNA containing Stop 1,2,3,4 mutations displayed different 
sites of T1 cleavage than the wild type. In the mutant RNA, T1 cleavage was 
detected at 481A and 482G, which are the locations of the Stop 4 mutations. 
T1 cleavage sites could also be detected on the other side of the stem bearing 
the Stop 4 mutations at positions 452G and 455G. This data demonstrates 
that the Stop 4 mutations disrupt RNA base paired interactions. Cleavages 
were also detected in the location of Stop 3 at 474G and 475G in both the 
wild type and mutant RNA indicating potential “breathing” of unpaired 
bases near the loop of the stem. V1 nuclease cleavage sites indicting helical 
RNA were infrequent, but we did detect cleavage in the wild type RNA 
464C and 465C, which is the base below the loop and at 478U, which lies 
below the G bulge in the top of SLVI. In the mutant RNA, a V1 cleavage 
site was detected in the loop at 476. Thus, the Stop 3 and Stop 4 mutations 
disrupted base pairing of the top of SLVI and may have induced base pared 
interactions within the loop of SLVI.   
115
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Figure 4.9. RNA structure probing reveals mutations in SLVI disrupt 
the top of SLVI. Cleavage with nucleases V1 (0.1U and 0.02U)  and 
T1 (1U and 0.2U) demonstrate that Stop 3 and Stop 4 mutations 
disrupt base paired interactions at the top stem of SLVI. 
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RNA structure in the capsid gene influences replication in diverse 
genotypes. 
 Replication studies of HCV in cell culture have been challenging. 
Currently, few sequences are capable of replication in Huh-7 cells and all 
but one requires cell culture adaptive mutations. The replication studies 
described so far have involved the full length H77 genome of genotype 1a 
containing the adaptive mutations L+I. To test if the mutations in SLVI 
impaired replication in sequences from other genotypes, we introduced the 
Stop mutations into the genotype 1b sequence of Con1 and the genotype 2a 
chimera J6-JFH. First, two Con1 sequences with different adaptive 
mutations were tested. The Con1/ I sequence contains the S2204I mutation, 
one of the same adaptive mutations in the H L+I genome, and the Con1/ GIT 
contains three adaptive mutations: two in NS3 (E1202G and T1280I) and 
one in NS4B (K1846T). As observed for the genotype 1a genome, the 
mutations for Stop 1,2 had no effect on, or actually improved, replication, as 
opposed to genomes containing mutations for Stop 3 and 4 which reduced 
replication to 20% of wild type (Figure 4.10). A dramatic reduction in 
replication, to 3 - 9% of wild type, again distinguished the genomes 
containing all five substitutions for Stop 1,2,3,4 (Figure 4.10). Recently, an 
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Figure 4.10. Stop 1,2,3,4 and Stop 3,4 convey a replication defect 
in Con1 sequence genotype 1b with adaptive mutations I and GIT. 
HCV RNA was measured by Real Time qRT-PCR after 5 days 
post electroporation with percent differences from wild type 
indicated above each bar. Two independent RNAs  were included 




















































































































HCV isolate, JFH-1, has proven to efficiently replicate without any adaptive 
mutations and produce infectious virus in Huh-7.5 cells. These remarkable 
features appear to stem from the replicase proteins of JFH-1, therefore 
chimeric genomes can be constructed where the 5’ NTR and capsid-NS2 
portions of the genome can originate from other genotype 2a sequences, 
such as the J6 sequence. Other genotype sequences may also be fused with 
the JFH-1 replicase proteins and 3’NTR and efficiently replicate; however, 
adaptive mutations are required for virus production.  
We wanted to test if the influence of SLVI is conserved in a genome 
with greater than 30% difference from the H77 sequence and if the 
mutations of SLVI also conveyed a phenotype in the more robust replication 
environment of JFH-1 60. The mutations for Stop 3 and 4 were introduced 
into the genotype 2a J6-JFH genome and replication was measured by 
quantitative real time qRT-PCR at 3 days post electroporation. Replication 
was compromised to 18% of wild type levels (Figure 4.11). The replication 
ability of the mutants was also tested in a genotype 1a-JFH-1 chimera where 
the 5’NTR to NS2 coding region from H77 is fused to the NS3 gene to 
3’NTR of JFH-1. While this chimera can replicate efficiently, it requires two 
adaptive mutations for virus production, (I348V/S1103T), hence is named 
H-JFH/ V+T. Consistent with previous observations, the mutations for Stop 
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Figure 4.11. Stop 1,2,3,4 and Stop 3,4 convey a replication defect 
in genotype 2a and 1a-2a chimeras. HCV RNA was measured by 
Real Time qRT-PCT at 72H post electroporation. Two RNAs were 
tested for each genome and averages shown. The percent 













































































J6-JFH pol- Stop 3,4
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1,2,3,4 contribute to a severe replication defect whereas mutations for Stop 
3,4 conveyed only a 17% reduction (Figure 4.11).   
 
The use of luciferase reporter genomes with the JFH-1 replicase. 
 Genomes with the JFH-1 replicase have increased our ability to easily 
detect replicating HCV RNA and allow us to test for virus assembly and 
infection in cell culture. A reporter genome was created that expresses the 
Renilla luciferase protein in the context of the HCV. The Renilla gene was 
cloned into the junction of the p7 and NS2 genes and included the 2A 
protease from Foot and Mouth Disease virus (FMDV) at the carboxyl 
terminus to allow proper processing (Figure 4.12). The Renilla gene and 2A 
protease were introduced into the parent genome of the H77- JFH chimera 
with the V+T adaptive mutations, H-JFH/ V+T, to create H-JFH/ Rluc. 
Insertion of the reporter and protease allowed efficient replication, albeit one 
log below the parent (Figure 4.12). Virus production was reduced from 6 x 
103 TCID50 /ml of the parent to 30 TCID50, but due to the sensitivity of the 
luciferase assay, virus infectivity was easily measured. Analysis of the 
infected monolayer by IHC revealed that about 5% of the cells were positive 
for NS5A antigen, therefore cells were not simultaneously infected and virus 
may spread during the analysis.  Since expression of the luciferase gene was 
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Figure 4.12. Genotype 1a genomes with a luciferase reporter 
between p7 and NS2 show similar replication kinetics, but with 
levels one log below the parental genome. A. Time course of 
luciferase activity of the reporter H-JFH/ Rluc. B. HCV RNA 
levels measured by Real Time qRT-PCR for the reporter and 
parental genomes.
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dependent on translation of the polyprotein, the luciferase signal increased as 
replication generated nascent RNA that was itself translated. This 
demonstrated the link between translation and replication. As the RNA 
entered the cell, either via electroporation or infection, translation occurred 
and expression of the polyprotein and luciferase reporter was evident for all 
genomes, including the pol- genome at 4H (Figure 4.12). As the input RNA 
degraded, the luciferase levels declined was monitored for the pol- genome. 
The logarithmic phase of replication is detected at 12H by measuring HCV 
RNA by real time qRT-PCR (Figure 4.12). At 16H, luciferase expression 
rapidly increased as HCV RNA was generated by the replicase and entered 
into subsequent rounds of translation. By 48H the pol- genome was 
degraded to background levels.  
Using these reporter constructs, we were able to monitor how 
replication and virus production were affected by mutations of RNA 
structures in the capsid gene. The mutations for Stop 1,2,3,4 and Stop 3,4 
were introduced into the H-JFH/ Rluc genome and replication measured. 
Initially, luciferase levels increased between 4H and 8H as the input RNA 
was translated and luciferase protein was accumulated (Figure 4.13). After 
8H, luciferase levels began to decline as luciferase degraded, with a half-life 
of approximately 6H. Replication could be detected at 16H as levels for the 
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Figure 4.13. Mutations for Stop 1,2,3,4 and Stop 3,4 show a 
reduction for replication at 16H post electroporation in the 
reporter H-JFH/ Rluc. Two RNAs were transfected and duplicate 
wells measured for luciferase activity for each genome. The 
averages are shown.
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pol- genome continued to decline yet the wild type genome began to rise. 
Following the initial translation from input RNA, the signal from the Stop 
mutants also declined, but not to pol- levels. After 24H, replication 
accelerated for the wild type genome. Levels of the Stop mutant genomes 
also rose, but did not reach wild type levels as the increase began from a 
lower point than the wild type. This lag in the exponential phase of 
replication could be due to numerous factors as the translation and 
replication processes overlap and interactions with the host cell or 
movement of RNA between replication and translation could alter the 
replication kinetics. Apparently, the mutations in the RNA structures 
contributed to a less than optimal transition between one or multiple 
components required for efficient replication. The result was a lower total 
level of HCV RNA and reporter expression. The reporter levels for the 
mutant genome Stop 3,4 was 1.7 logs below wild type, and Stop 1,2,3,4 
replicated 2.1 logs lower at 48H post electroporation.  
Using the luciferase reporter, we are able to detect virus infection of 
naïve cells. The sensitivity of the luciferase assay allows for consistent 
detection and quantitation of mutant HCV genomes that could not easily be 
studied using IHC or Real Time qRT-PCR. However, the requirement of the 
reporter to be translated and the ability of the genome to undergo replication 
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in infected cells, potentially complicates the result. If a mutant conveys a 
defect in translation or replication, differences in the luciferase activity in 
the infected cells may be a result of reduced translation, replication and virus 
production. In this regard, we refer to the luciferase activity measured from 
infected cells as “virus infectivity.” This general term is used to describe 
measurement of virus production, entry, and subsequent translation and 
replication in the infected cell. There was no measurable virus infectivity for 
the mutant Stop 1,2,3,4 and the Stop 3,4 genome, likely a consequence of 
the low levels of replication.  
 
The Open mutations impair replication and virus infectivity. 
As shown previously, the mutations consisting of the Open set were 
severely detrimental to HCV replication if located in the top of SLVI.  These 
mutations were engineered into the H-JFH/ Rluc parent and luciferase 
activity measured. All genomes with mutations in the top of SLVI, Open 3 
and Open 4, had impaired replication activity, even when present with the 
more robust JFH replicase (Figure 4.14). Again, there was a lag in the 
transition to the logarithmic replication phase and levels remained 1-2 logs 
below wild type. As in the H/ L+I parent, genomes with mutations Open 1 
and Open 2 alone did reach wild type levels. The failure of the mutants to 
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Figure 4.14. Mutations of Open 3 and 4 reduce replication and 
eliminate virus infectivity when both the capsid and ARF can be 
expressed. A. Time course of luciferase expression. B. Luciferase 
expression displayed as percent of wild type at 48H post 
transfection. C. Virus infectivity graphed as percent of wild type at 
48H post infection. Each genome was measured from duplicate 
wells of two transfected RNAs. Averages are shown.
Replication











































































































































accumulate a substantial amount of HCV RNA correlated well with virus 
production. Genomes capable of efficient replication were also able to infect 
naïve cells (Figure 4.14). These results show that the mutations of Open 1 
and Open 2 did not impede translation, replication, or virus infectivity.  
 
The mutations in SLVI do not alter RNA stability in Huh-7.5 cells. 
  The reduced replication of genomes harboring mutations in SLVI 
could be due to RNA instability and preferential degradation in transfected 
cells. The mutations of SLVI were introduced into a replication-incompetent 
genome. Luciferase expression and degradation were compared between the 
mutant and parental genomes and found to be equivalent indicating similar 
RNA stabilities in transfected cells (Figure 4.15).  
 
The loops of SLV and SLVI slightly influence replication and virus 
infectivity.  
 RNA structures are known to interact with virus and host proteins to 
coordinate replication and virus production. The predicted size of SLVI, 81 
bases, leads one to hypothesize that it may participate in these functions. We 
introduced mutations to change the nucleotide sequence of three bases in the 
loop of SLV and three bases in the loop of SLVI (Figure 4.16).  The 
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Figure 4.15. The replication defects contributed by mutations in SLVI 
and the 5’NTR are not due to RNA stability. Luciferase expression of 
mutant genomes with a defective polymerase show equivalent levels 
as a wild type genome with a defective polymerase. 
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Figure 4.16. Mutations of the loop in SLV and SLVI in the H77 
sequence. The mutation in the loop of SLV would change a lysine 
to a leucine in the capsid protein. The mutations in the loop of 
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mutations for the SLVI loop were silent for the capsid protein, but the 
mutations in SLV involved one amino acid change, a lysine to a leucine at 
position 23.  Replication and infectivity were measured by luciferase assay. 
Mutations in the loops reduced replication to 44% and 42% of wild type at 
48H post electroporation (Figure 4.17), but this reduction was not as severe 
as the replication defect observed for the mutations in the helices of SLVI. 
The difference between genomes with the mutant loops and wild type was 
apparent at an earlier time, 8H, when translation of the input RNA was 
occurring (Figure 4.17).  This difference was not due to a transfection or 
preparation in RNA discrepancy as a control firefly luciferase reporter was 
always used to equalize transfection efficiency and two independent RNA 
preparations were used for each construct in each experiment. The kinetics 
followed a similar pattern, yet failed to accumulate to wild type levels within 
two days. Infectivity of naïve cells was also reduced to 54% for the mutant 
loop SLV which may be a result of the lower level of accumulated HCV 
RNA, the change in the amino acid of the capsid protein, or an effect of the 
RNA structure (Figure 4.17). Infectivity was further reduced to 24% for the 
genome with the mutated SLVI loop despite replicating to a similar level as 
the mutated SLV. This difference was not due to changes in the capsid 
protein and may indicate a defect in virus assembly. The three mutations in 
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Figure 4.17. Mutations in SLV and SLVI slightly reduce replication 
and moderately reduce virus infectivity. A. Time course of luciferase 
expression. B. Luciferase expression displayed as percent of wild 
type at 48H post transfection. C. Virus infectivity graphed as percent 
of wild type at 48H post infection. Percent differences from wild 
type are noted above each bar. Each genome was measured from 





























































































































the loop of SLV conveyed a more detrimental replication effect than the 
single base change of Stop 1 or Open 1, both of which were located in the 
loop of SLV.  This data indicates a role for the SLV loop in replication, but 
this region may not be as critical as the helix of SLVI.  
 
 Mutations in the base of SLVI impair replication.  
 Structure predictions of the helix of SLVI reveal a large stalk of 81 
bases. We have demonstrated that the top helix of SLVI has a critical role in 
replication, while the loops of SLV and SLVI are also important, but to a 
lesser degree. To test the importance of the base of SLVI, we introduced 
three base mutations at the left side of the base of SLVI, called Base Left 
(Figure 4.18). All were silent for the capsid protein. We also created three 
mutations at the right side of the base to compensate for the left sided 
mutations (Figure 4.18). This mutant genome, Base Right, also generates an 
amino acid change at position 54 of the capsid protein with a glutamate to a 
valine substitution. The genome with both sets of mutations was named Base 
Left/ Right. Each set of mutations was tested in the parental H-JFH/ Rluc 
genome. Disruption of the base of SLVI reduced replication to 53% of wild 
type for Base Left and to 16% for Base Right at 48H post electroporation. 











































































































































































































































































































































































































































































Base Left Base Left/ RightBase Right
Base Left/ Stop 3,4 Base Right/ Stop 3,4 Base Left/ Right/ Stop 3,4
Figure 4.18. Mutations introduced at the base and top of SLVI in 
the H77 sequence.
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transition to efficient replication (Figure 4.19). The compensatory mutant, 
Base Left/ Right, was reduced to 45% of wild type, an improvement from 
the defect with the Base Right mutations alone. There was also reduced virus 
infectivity from genomes where the base of SLVI was disrupted. With the 
level of replication reduced to just half of wild type, virus infectivity was 
down to 32% for Base Left. The Base Right mutations eliminated virus 
infectivity (Figure 4.19). This could be a result from the amino acid change 
introduced at residue 54 in the capsid protein; infectivity was not restored 
with the compensation of Base Left/ Right. This mutant genome was also 
examined in a later study concerning its ability to produce infectious virus 
(Chapter 5). 
 
Mutations in the base of SLVI additively impair replication with mutations 
in the top of SLVI. 
 The base of the SLVI does influence replication, but not as drastically 
as mutations in the top stem of SLVI. To determine if the replication 
phenotype observed for the top of SLVI is influenced by the base structure 
of the stem, we combined the mutations of the base with those at the top of 
the helix, mutants Stop 3,4 (Figure 4.18). We found that mutations for Stop 
3,4 in the apical stem contributed to a more severe reduction in replication 
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Figure 4.19. Mutations in the base of SLVI reduce replication. The 
Base Right mutations, which change an amino acid of the capsid 
protein, eliminate virus infectivity. A. Time course of luciferase 
expression. B. Luciferase expression at 48H post transfection. C. 
Virus infectivity at 48H post infection. Percent differences are noted 
above each bar for B and C. Each genome was measured from 
duplicate wells of two transfected RNAs. Averages are shown. 
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than mutations in the base of the stem. Genomes with both mutations in the 
top and the base of the stem were additively suppressed for replication 
(Figure 4.20). The mutations for Base Right were more deleterious than the 
mutations for Base Left, 12% verses 36%, and the replication of each was 
further reduced when combined with the Stop 3,4 mutations. The genome 
with Stop 3,4 / Base Left was 199- fold below wild type levels, and the 
combination with the Base Right mutations further reduced replication (876-
fold below the parent). When base pairing was restored by the introduction 
of compensatory mutations, Stop 3,4/ Base Left/ Base Right, the replication 
defect was less pronounced (296- fold below wild type). Genomes with the 
compensatory mutations were still impaired, but not to the same levels as the 
Stop 3,4/ Base Right mutations (Figure 4.20). These results imply that while 
the top of SLVI has a critical role in replication, it is important to maintain 
the overall structure of SLVI for efficient replication.    
 
Mutations in the middle, c-bulge region and amino acids in the capsid 
protein that affect replication and infectivity.  
 The central region of SLVI shows remarkable conservation at both the 
nucleotide and amino acid level. Extending down from the top loop and just 
below the Stop 4 mutations, the region around the c-bulge at nucleotide 454 
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Figure 4.20. Mutations in the base of SLVI additively reduce 
replication in combination with mutations in the top of SLVI.  A. Time 
course of luciferase expression. B. Luciferase expression at 48H post 
transfection. C. Percent differences from wild type at 48H. Each 
genome was measured from duplicate wells of two transfected RNAs. 
Averages are shown. 
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is conserved in over 90% of sequences from all six genotypes. This region is 
predicted to be a foundation for the overall structure of SLVI. The program 
RNAmute predicted the area surrounding the c-bulge and specifically 
nucleotide 484 to be critical to maintain the structure of SLVI 29. To test if 
this region participates in replication, two mutations were introduced on 
either side of SLVI in the H-JFH/Rluc parent (Figure 4.21).  The mutations 
Mid Right, C482A and C484G, disrupt two base paired interactions and test 
the predicted critical base at 484. An amino acid is also changed at residue 
48 from an alanine to a glycine. The first mutation, C482A, was also one of 
the mutations in the Stop 4 mutant.  To alter the left side of SLVI, the 
mutations Mid Left, G452C and G455A, were introduced, and change 
residue L37F of the capsid protein (Figure 4.21). Genomes with both 
mutation sets, Mid Right/ Left would restore the base pairing of SLVI in this 
region according to the prediction models. Replication was measured in 
three separate experiments, each using two independent preparations of in 
vitro transcribed RNAs. At 48H post electroporation, genomes with the 
mutations Mid Left or Mid Right were reduced for replication to 34% and 
28% of wild type, respectively (Figure 4.22). Consistent with this, in a 
separate experiment, the genome with mutations for Mid Right gave lower 
levels of replication, 44% of wild type, than the genome with Mid Left, 
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Figure 4.21. Mutations in the middle region of SLVI in the 
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Figure 4.22. Mutations in the middle region of SLVI reduce HCV 
replication. Mid Right failed to make infectious virus. A. Time course of 
luciferase expression. B. Luciferase expression at 48H post transfection 
with percent differences from wild type noted above each bar. C. Virus 
infectivity 48H post infection with percent differences noted. Each 
genome was measured from duplicate wells of two transfected RNAs. 























































































































which was 30% of wild type (data not shown). By combining both sets of 
mutations in the genome Mid Right/ Left, replication was improved to 82% 
of wild type. This improved replication implied a restoration of a functional 
RNA structure, as the compensatory genome efficiently replicated, while 
harboring the two amino acid changes in the capsid protein. Virus 
infectivity, however, was reduced by the amino acid changes. While both 
genomes, Mid Right and Mid Left, replicated to similar levels, only the 
genome with Mid Left mutations produced infectious virus (Figure 4.22). 
This indicate that either the original residue, alanine, at position 48 is 
required for virus production/ infection or that the structure of SLVI that 
facilitates infection was not sufficiently restored. To address these 
possibilities, the genome with Mid Right mutations was examined in 
additional assays discussed later (Chapter 5).  
 To distinguish if the RNA structure or amino acid sequence 
contributed to the deficiency in infection, we created a genome with 
mutations in the Mid Right region, but without changing any amino acids 
(Figure 4.21). The first mutation was the identical to Mid Right, C482A, but 
the second mutation, G485T, was one base downstream of the “critical base” 
predicted by RNAmute. Unexpectedly, this mutant genome, Mid Right 
Silent, displayed a more dramatic reduction in replication than did Mid 
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Right. The genome Mid Right Silent could only replicate to 6% of wild type 
levels whereas Mid Right was moderately compromised to 34% of wild type 
(Figure 4.23).  This defect was barely apparent at 4H post electroporation, 
but was significantly delayed from the wild type level at the 16H to 24H 
transition window. Infectivity was reduced to 5% of wild type levels. This is 
probably a consequence of the reduced genomic RNA available for virus 
production due to the compromised replication. The replication defect by 
Mid Right Silent was observed repeatedly where the replication level was 
6% of wild type and infection was reduced to 1.2% (data not shown). This 
result is in contrast to the Mid Right mutant genome, which could efficiently 
replicate, but not produce infectious virus (Figure 4.22). The larger 
replication defect by Mid Right Silent, which differs from Mid Right by one 
adjacent nucleotide, may indicate a sensitive area for the RNA structure. The 
abrogation of infectious virus production from Mid Right while virus 
replication is still evident, implicates A48 to be critical for production of 






Figure 4.23. Mutations in the middle region of SLVI reduce HCV 
replication. A. Time course of luciferase expression. B. Luciferase 
expression at 48H post transfection with percent differences from 
wild type noted above each bar. C. Virus infectivity 48H post 
infection with percent differences noted. Each genome was 



































































































Mutations in the c-bulge region impair replication in the genotype 2a 
genome. 
 Mutations in the Mid region of SLVI were also examined in the 
genotype 2a J6-JFH/Rluc genome. This genome has similar levels of 
replication and virus infectivity as the H-JFH/ Rluc chimera but with a 
greater rate of replication from 24H to 48H (Figure 4.24). Replication was 
equivalent between the two genotypes at 72H post electroporation as were 
virus titers.  
Mutations at the c- bulge region were introduced into a genome with 
the Stop 3 mutation (Figure 4.25). We have previously shown the Stop 3,4 
mutations in J6-JFH to drastically reduce replication to 16% of wild type, 
and hypothesize the defect to be due to disrupting the RNA structure at the 
top of SLVI (Figure 4.11). To test the c-bulge region of SLVI in genotype 
2a, we combined the Stop 3 mutation (473A) and with mutations 481G and 
484T, located downstream from the Stop 4 mutations (479A and 481G). 
This genome, J6 Mid Right-B, was impaired for replication, although with 
some variation, at 37% and 5% of wild type in a two separate experiments 
(Figure 4.26). Virus infectivity was detected, but reduced to 8% and 4% of 
the wild type levels. These mutations are in the same location as the H-JFH 
Mid Right Silent genome, but change an adenine rather than a guanidine at 
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Figure 4.24. Comparison of replication kinetics of the 
genotype 1a-2a chimera reporter H-JFH/ Rluc and genotype 2a 
chimera reporter J6-JFH/ Rluc. Replication is indicted by 
HCV RNA levels measured by Real Time qRT-PCR.
Replication





























484 (485 in H-JFH numbering) to a uridine due to the covariant base usage 
between genotypes. Recall that H-JFH Mid Right Silent also showed a 
dramatic reduction in replication, 6% of wild type (Figure 4.23).  
We introduced mutations in the left side of the c-bulge region of 
SLVI. Silent mutations at 451 and 454 are on either side of the highly 
conserved C453 and in the same location as the H-JFH Mid Left genome 
(Figure 4.25) (see phylogenetic structure, Figure 3.6). Replication was also 
compromised, with some variability, with a range of being reduced 82-98% 
of wild type (Figure 4.26). Introduction of silent mutations in the 
downstream codon (449 and 451) in the genome J6 Mid Left-A, resulted in a 
minimal effect on replication (82% of wild type) and a modest reduction of 
virus infectivity (60% of wild type) (Figure 4.26). Mutations at the 
complementary side of SLVI, J6 Mid Right-A, also had a modest effect on 
replication, to 62 - 65% of wild type. However, virus infectivity was not 
detectable (Figure 4.26). The mutations in J6 Mid Right-A change the amino 
acid of an alanine to a glycine at codon 48. This could account for the 
elimination of virus infectivity, but also could be due to the reduced 
replication. This codon is conserved in all genotypes of HCV, except in the 































































































































































































































































































































Figure 4.25. Mutations in the middle region of SLVI in genotype 2a 
J6 sequence. Mid Right-A changes an amino acid of the capsid 
protein, A48G. 
148
Figure 4.26. Mutations in the middle region of SLVI in genotype 2a 
J6 sequence reduce HCV replication and virus infectivity. A. Time 
course of luciferase expression. B. Replication at 48H post 
electroporation with percent differences noted above each bar. C. 
Virus infectivity 48H post infection with percent differences noted. 
Each genome was measured from duplicate wells of two transfected 



















































































































































To evaluate the impact of this amino acid difference at residue 48, we 
introduced a single nucleotide change at position 482 that disrupts one 
predicted base pairing of SLVI and changed the J6 amino acid alanine at 
codon 48 to the JFH-1 threonine (Figure 4.27). This genome, J6 > JFH, 
replicated efficiently, 82% of wild type, but virus infectivity was 
compromised to 45% of wild type (Figure 4.28).  This result indicates that 
the amino acid at position 48 does contribute to virus production and/ or 
infection.  
 
Evolution of capsid protein mutants reveal a compensatory mutation at p7 
and NS2. 
 The genome with three mutations J6 Mid Right-A was capable of 
efficient replication, but failed to produce infectious virus in cell culture 
(Figure 4.26). In order to understand this defect, we subjected the virus 
genome of J6 Mid Right to continuous replication while monitoring the 
sequence for the selection of reversions or pseudo-reversions that enable 
virus production. It has been well established that the HCV polymerase has 
an estimated mutation rate of 10-3 to10-4 errors per generation 128. With a 
genome size of 9700 nucleotides, approximately one error will be 
incorporated in each genome generated. In addition, the T7 polymerase 
150
Figure 4.27. Mutagenesis to test differences between genotype 2a 
J6 and JFH sequence in SLVI. The single base substitution in the 
















































































Figure 4.28. Mutation differences between J6 and JFH in SLVI slightly 
reduce HCV replication and moderately reduce virus infectivity. A. 
Time course of luciferase expression. B. Replication at 48H post 
electroporation with percent differences noted above each bar. C. Virus 
infectivity 72H post infection with percent differences noted. Each 
genome was measured from duplicate wells of two transfected RNAs. 







































































































generates mutations with equal frequency during in vitro transcription, the 
source of HCV RNA in our replication studies. To discover adaptive 
mutations that can overcome the block in virus production caused by the 
mutations of J6 Mid Right-A, we electroporated in vitro transcribed RNA 
into Huh-7.5 cells and allowed the error prone replication to create a 
genomic diversity. Two preparations of each genome were tested in parallel. 
HCV replication diminishes as cell growth slows; therefore cells were 
seeded at low density in 100mm dishes and passaged as the monolayers 
approached 80% confluency. Replication was monitored by seeding cells in 
a separate 24 well plates and staining for NS5A expression by IHC (Figure 
4.29). Initially, 80% of the cell monolayers transfected with the parental J6-
JFH genome were positive for NS5A, while 50% of cells stained positive 
after transfection with the J6 Mid Right-A genome (Figure 4.29). Cells 
transfected with the J6-JFH genome maintained an approximately 80% 
positive culture while the percentage of J6 Mid Right-A positive cells was 
reduced after the first split. It has been observed that cells harboring HCV 
replication grow at a slower rate than naïve cells. Since the J6-JFH genome 
is capable of producing virus, the faster growing naïve cells become infected 
and thus maintain an HCV positive culture. Cells transfected with the virus-
impaired Mid Right-A genome were out competed by the faster growing 
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Figure 4.29. Selection for reversions increasing virus infectivity. 
Transfected cells were passaged upon reaching 80% confluency and 
monitored for HCV by immunohistochemistry staining for NS5A. After 
2 passages, cells with the wild type crashed, but cells transfected with 
the mutant showed an increase in the number of HCV positive cells. 
Infection of naive cells with media from the second passage revealed 




Split 1 Split 2






naïve cells and the percentage of positive cells was reduced to approximately 
5% in the monolayer (Figure 4.29). Within three days after the first split, 
cells harboring wild type J6-JFH became cytopathic and could no longer be 
cultured, but media was cleared of cell debris and used to measure virus. The 
culture of cells transfected with J6 Mid Right-A continued to grow without 
appreciable cell death and after the second split an increase in the number of 
positive cells was apparent, to about 30% of the population, is detected 
(Figure 4.29). 
 To determine if virus was being released, the media was removed, 
cleared of any debris, and transferred onto naïve cells for two days. Staining 
for NS5A revealed virus-infected cells in both the wild type and the J6 Mid 
Right-A genome after the second split. HCV RNA was isolated from both 
the transfected and infected cells and sequenced. From the J6 Mid Right-A 
cell population, no change was evident in the capsid gene, including the 
mutations in SLVI, but sequence analysis of the entire genome revealed an 
amino acid change in the p7 gene. This change was a transition from a 
thymidine to a cytidine at nucleotide 2667 in the polyprotein, which resulted 
in a phenylalanine to a serine at amino acid 776 in the polyprotein, the 26th 
residue of p7. One of the two cultures launched from independent RNA 
preparations contained a mixed population of both wild type p7 and the 
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776S change while the second culture contained only the 776S change. 
Media was passaged a second time for the J6 Mid Right-A culture onto 
naïve cells, again, HCV RNA was isolated and sequenced. Population 
sequencing of both J6 Mid Right-A cultures again found the p7 776S 
mutation; however one of the cultures contained an additional change in 
NS2. This mutation in NS2 involved a transition of a cytidine to thymidine 
at nucleotide 2937 and recoded a proline to leucine at the 53rd reside of NS2, 
which is amino acid 866 in the polyprotein.  Both cultures were passaged a 
third time and HCV RNA sequenced. One culture retained the 776S 
mutation in p7 and no other change in the polyprotein was detected. By the 
third passage, the second culture had completely reverted the 776S mutation 
in p7 back to the wild type codon and now only harbored the 866L mutation 
in NS2. The location of the pseudo-reversions occurred in very conserved 
regions for both p7 and NS2 (Figure 4.30 and 4.31). The F776 is conserved 
in 4 out of 6 genotypes while the proline at 866 in NS2 is conserved in the 
reference sequences for all 6 genotypes. No change was ever found in the 
capsid gene at any time during passage of either culture. Also, there were no 
changes detected at the population level in the wild type J6-JFH cultures.  
Continual replication of a virus-defective genome, apparently allowed 
amino acid changes in p7 and NS2 to become selected during passage. In 
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Figure 4.30. The amino acid in p7 involved in a pseudo-reversion 
restoring virus infection in an HCV genome with the mutation 
A48T in the capsid protein is conserved in 4 out of 6 genotypes. 
The p7 pseudo-reversion changes P866L. An alignment created 
by ClustalX of HCV reference sequences obtained from the 
HCV database (Los Alamos).
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Figure 4.31. The amino acid in NS2 involved in the second 
pseudo-reversion restoring virus infection in an HCV genome 
with a mutant capsid (A48T) is absolutely conserved in all 
genotypes. An alignment created by ClustalX of HCV reference 
sequences obtained from the HCV database (Los Alamos).
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Adapted from Yi et al. 2007
Figure 4.32. Position of compensatory mutations found in 
p7 (F776S) and NS2 (P866L) that restore virus infectivity 
of the mutant J6 Mid Right-A containing an amino acid 
change in the capsid protein at residue 48. Compensatory 
mutations in p7 and NS2 found by Yi et al. 2007 are also 
shown. 




order to confirm that these mutations were responsible restoring virus 
production, the 776S mutation for p7 was cloned into the wild type J6-JFH 
genome and the J6 Mid Right-A genome harboring the 48G capsid mutation. 
Replication of the J6-JFH/ 776S genome was comparable to the wild type 
J6-JFH with over 90% of cells positive for NS5A staining, whereas the 
genome J6 Mid Right-A (J6-JFH/ 48G) was only 50% positive. Combining 
both capsid and p7 mutations in J6-JFH/ 48G+776S enabled wild type level 
replication (Figure 4.33). To prove that the p7 mutation was selected as a 
compensatory mutation that repaired the virus defect conveyed by the capsid 
mutation of 48G, we measured virus infectivity by IHC. Using two 
independent RNA preparations for each construct, media was collected from 
transfected cells after 96H, transferred onto naïve cells, and stained for 
NS5A expression. The J6 Mid Right-A genome with mutation 48G failed to 
yield infectious virus (Figure 4.33). The J6-JFH/ 776S genome with the p7 
mutation was infectious, but with few cells in two infection foci. In contrast, 
the genome J6-JFH/ 48G +776S was capable of virus infection and infected 
larger number of cells with multiple foci (Figure 4.33).  This confirmed that 
the p7 mutation at 776S was able to rescue the virus defect contributed by a 
mutation in the capsid protein. We were thus able to identify compensatory 
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Figure 4.33. (next page) The compensatory mutation in p7, 
F776S, can restore virus infectivity in a mutant genome with an 
amino acid change in the capsid protein at residue 48. Introduction 
of the amino acid changes found in p7 into the molecular clones 
J6-JFH and J6-JFH/ Mid Right-A confirm that sequence changes 
found during the reversion analysis can improve virus infectivity 
and imply an association between residue 48 of the capsid protein 
and 766 of p7. IHC of cells either transfected with HCV genomes 
after 72H or naive cells infected with media from 72H transfected 





















































mutations for virus infection by increasing the pool of diverse genomes and 
selecting for mutations that restored virus infection. 
 
Evolution of RNA structure mutations in Huh-7.5 cells mimic reversions 
in vivo.  
 Given the successful selection of reversions that restored virus 
production in a genome with an amino acid mutation, we wanted to test if 
reversions that improve virus replication could be selected in cell culture. 
We have shown that mutations for Stop 1,2,3,4 severely compromise HCV 
replication by disrupting the RNA structure SLVI. During the infection of 
the chimpanzee inoculated with the Stop 1,2,3,4 mutant, reversions were 
selected that repaired the disrupted SLVI. Given the high mutation rate of 
HCV replication, a spectrum of diverse genomes is likely to be generated, 
but we did not know if reversions in SLVI would be selected in cell culture 
and how frequently reversions could arise when replication was drastically 
impaired. There appeared to be little cytopathic effect on cells harboring 
HCV genomes with attenuated replication, and therefore our strategy was to 
launch replication with a large amount of HCV RNA and monitor replication 
while passaging cells in culture. Replication is highly impaired by the Stop 
1,2,3,4 mutations and since the generation of diversity depends on the rate of 
163
replication, either adaptive mutations would be selected, improving 
replication, and the number of HCV positive cells increase, or HCV RNA 
would be lost from the population. The SLVI mutations were tested in the 
parent H-JFH genome that has a more robust replication and allows virus 
production. We have shown that mutations in SLVI initially affect 
replication, but that virus infection is possible if the defect on replication is 
not too severe. Using a genome that can produce virus, if replication occurs 
at a sustainable rate, virus spread and an increase in the number of cells 
harboring HCV replication should occur — increasing the likelihood of 
propagating a fitter genome as an adaptive mutation is selected.  
 To improve our chances of selecting an adaptive genome, we 
followed replication of two mutant genomes: H-JFH/ Stop 1,2,3,4 conferring 
impaired replication levels of 2% of wild type, and H-JFH/ Stop 3,4 which is 
moderately reduced to 16%. At four days post electroporation, over 90% of 
the population was positive for HCV antigen in the parental H-JFH/ V+T 
genome (Figure 4.34), but the mutant genomes were both reduced to less 
than 10% of the population. Cells were allowed to grow and passaged upon 
confluency. By day 5, the culture of the wild type genome displayed 
































Figure 4.34. Selection of reversions conferring an increase 
in replication of mutant H-JFH/ Stop 1,2,3,4 in Huh-7.5 
cells. (a–c) IHC staining of NS5A showing replication of 
H-JFH (a), a pol- control (b),and H-JFH/ Stop 1,2,3,4 (c) at 
day 2 post electroporation. (d–f ) Cells harboring H-JFH/ 
Stop 1,2,3,4 were passaged and stained for NS5A(brown) 
and nuclei (blue) at days 7 (d), 21 (e), and 41 (f).
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production, and could no longer be passaged. The cultures with the mutant 
genomes remained healthy.  
Initially, we sequenced HCV RNA at the population level. For the 
culture transfected with H-JFH/ Stop 1,2,3,4, there was no change in the 
capsid gene or the rest of the genome for the first 7 days post electroporation 
(Figure 4.35). By day 11, the chromatogram revealed a mixed population at 
473, the site of the Stop 3 mutation. The majority of the sequences contained 
the input mutation of adenine at 473, yet a minor population could also be 
detected with a reversion to the original H77 nucleotide of guanine (Figure 
4.35). No other sequence changes could be detected at the population level. 
The appearance of the reversion corresponded with an increase in replication 
as the number of NS5A positive cells increased (Figure 4.34). Sequence 
analysis at day 15 again showed a mixed population at the site of Stop 3, 
with the input 473A and revertant 473G, and another change in the 
population at 480, which was the first base of the Stop 4 mutations. This 
second change, A480C, was also a reversion to the H77 sequence and was 
present as a minor species in the population (Figure 4.35). By day 21, the 
number of HCV positive cells had increased to over 60% indicating a 
marked improvement in replication and/or virus infection. Sequence analysis 





















































































































































































































407 434 473 480 482Position
Figure 4.35. Sequence analysis of H V RNA during passage of cells 
transfected with H-JFH/ Stop 1,2,3,4. A. Sequence changes found in the 
passaged cells. B. The frequency of reversions found at the times 




































population. To measure the frequency of revertants in the population, we 
sequenced individual clones. This also enabled us to detect transient changes 
that may be present as minor species and therefore missed in the bulk 
sequence analysis. Initially, we only detected the input sequence containing 
the mutations Stop 1,2,3,4. In approximately half of the clones, we detected 
additional mutations in the amplicon region of the 5’NTR and capsid gene. 
These changes were not concentrated in one area and appeared to be 
transient changes in the population (Figure 4.35). By day 10, two out of six 
clones contained a reversion. One clone contained the A473G change and 
the other contained the A480C reversion indicating that these reversions 
were not on the same molecule, but arose independently. The input sequence 
was still the dominant genome of the population. By the third week, one-
third of the clones contained the 480C reversion while only one-tenth had 
the 473G reversion. The population shifted where the majority of clones 
possess a revertant, either 473G or 480C by week 4. In the following weeks, 
the revertant 480C steadily became the dominant genome. Replication 
showed a marked improvement as over 90% of the monoloayer was positive 
for HCV antigen (Figure 4.34). 
Following replication launched with the H-JFH/ Stop 3,4 genome 
showed the identical revertants emerging as for the genome with Stop 
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1,2,3,4, but with a different pattern. There was no sequence change detected 
in the population for two weeks post electroporation (Figure 4.36). At day 
14, all clones sequenced contained the reversion of Stop 3 to the H77 
sequence, 473G. This sequence change of the population corresponded with 
an increase in the number of HCV positive cells (Figure 4.36). During the 
following week, the second reversion of 480C was selected. This reversion 
was present on the same genome containing the reversion 473G. The 
frequency of genomes containing this second reversion remained only one 
out of ten clones for all time points after day 21, suggesting that a genome 
with Stop 1,2,3 and mutation A482 is more fit than the genome with Stop 
1,2,4. Indeed the mutant Stop 1,2,3 can replicate 58% more efficiently than 
mutant Stop 1,2,3,4 in both the H/L+I parent as well as in the H-JFH/V+T 
parent (Figure 4.2).  
HCV genomes with Stop 1,2,3,4 and Stop 3,4 mutations were both 
capable of at least low levels of persistent replication in Huh-7.5 cells. 
Reversions to the original H77 sequence were selected at the mutations of 
Stop 3 and 480 of Stop 4, indicating pressure to maintain a functional RNA 
structure of SLVI. The reversions selected in Huh-7.5 cells were identical to 
the reversions selected in the chimpanzee infection, demonstrating similar 
selective pressures in both the in vivo and cell culture systems. We conclude 
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Stop 3,4















Figure 4.36. Reversions found after passaging Huh-7.5 cells transfected 
with H-JFH/ Stop 3,4. HCV RNA was extracted and individual clones 
sequenced. A. Sequence changes found at times post electroporation and 
frequency of reversions detected in the cloned sequences. B. Reversions 
would restore the top of SVI. 
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that the genetic analysis defining the structure of SLVI in HCV replication 
in Huh-7.5 cells also describes the function of SLVI in a natural infection.  
 
Discussion. 
The Stop mutations convey a replication defect in Huh-7.5 cells. 
 A genome with mutations Stop 1,2,3,4 led to an attenuated infection 
in a chimpanzee. Within 2 weeks of the infection, a reversion at Stop 3 was 
selected and fixed in the population. Additional reversions of Stop 4 were 
soon selected and fixed in the circulating virus population. The order of the 
reversions and the speed of their selection indicate pressure to restore an 
RNA structure as opposed to open the ARF. As shown in the phylogenetic 
analysis, the mutations for Stop 3 and 4 disrupt three base pair interactions 
(Figure 3.6). The reversions restore the RNA structure for SLVI and indicate 
a role of this structure in the virus lifecycle. 
 We found that HCV genomes harboring the Stop mutations had a 
reduced ability to replicate in Huh-7.5 cells. The genome with Stop 1,2,3,4 
displayed a severe replication defect, with RNA levels greater than 2 logs 
below wild type. Comparing replication for genomes with different 
combinations of Stop mutations, we found that mutations for Stop 3 and 
Stop 4 conveyed the decrease in replication. Individually, the mutations 
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slightly reduced replication, but together a synergistic decrease in replication 
was observed. Genomes with mutations for Stop 1 and 2 showed no defect 
in replication; however, the genomes displaying the most impaired ability to 
replicate contain Stop 1,2,3,4. Even though the mutations of Stop 3 and 4 
disrupt the top of SLVI as predicted by the secondary RNA structure, 
tertiary interactions could also be disrupted and account for the additional 
replication defect with the inclusion of Stop 1 and 2. The defect in 
replication contributed by the Stop 1,2,3,4 mutations could be responsible 
for the selective pressure during the chimpanzee infection. Mutants of Stop 
1,2,4, mimicking the first reversion in the chimpanzee, showed an 
improvement of 205-fold compared to the Stop 1,2,3,4 genome. Reversions 
replaced the Stop 3 mutations with the H77 sequence and restored the top 
stem structure of SLVI. Since replication was reduced in the presence of the 
Stop 3 and 4 mutations, the reversions occurring in the natural infection 
indicate selection for a functional RNA element in vivo.  
 
Disruption of an RNA element impairs HCV replication. 
 By introducing mutations that allow both reading frames to be 
expressed, we confirmed that the Stop 3 and 4 mutations affect replication 
by disrupting an RNA structure rather than blocking expression of an ARF 
172
protein. These Open mutations also conveyed a replication defect when the 
helical stem of SLVI was disrupted. Since the Open mutations also 
introduced amino acid differences in the ARF protein, although silent for the 
capsid protein, the question if the ARF protein affects replication remained. 
We ultimately demonstrate that replication was affected by an RNA 
structure by introducing compensatory mutations in the genome with Stop 
1,2,3,4 that restore the structure of SLVI. Compensatory mutations restoring 
the base pairings of Stop 3 and 4 improved replication by 60%. The 
restoration of the top helix of SLVI and consequent improvement of 
replication strongly argues for a functional RNA element and not the use of 
an ARF protein in HCV replication in Huh-7.5 cells. Enzymatic structure 
probing confirmed that mutations for Stop 3 and 4 disrupt the helix base pair 
for an RNA structure.  
 
SLVI is conserved amongst diverse genotypes of HCV. 
 The importance of SLVI in diverse genotypes was demonstrated by 
comparing replication of genomes with Stop mutations in genotypes 1a, 1b, 
and 2a. Similar effects on replication were observed for each genotype. 
Mutations for Stop 1,2,3,4 reduced replication to below 8% of wild type 
levels and mutations for Stop 3 and 4 conveyed a replication decrease to 17-
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20% of wild type for all three HCV genotypes. This indicates that SLVI is a 
functional RNA element in sequences as diverse as 19% at the nucleotide 
level.  
 
Different regions of SLVI have varying importance in HCV replication.  
 To define the regions of SLVI that affect replication, we used a 
luciferase reporter genome that expressed the Renilla luciferase gene and the 
protease 2A from FMDV between the p7 and NS2 coding regions. The 
reporter was introduced into a chimeric genome of H-JFH allowing early 
measurements of translation, replication and virus infectivity. Point 
mutations in the loops of SLV and SLVI had a moderate effect on HCV 
replication; however mutations in the loop of SLVI dramatically reduced 
virus infectivity by 75%. The mutations did not alter the amino acid 
sequence of the capsid protein, thus implying the loop of SLVI has a role in 
virus assembly or infection.  
Mutations along the basal region of SLVI contributed to a minor 
reduction in RNA replication. When combined with mutations at the apical 
stem (Stop 3 and 4 mutations), however, an additional decrease in 
replication was observed. This implies the overall structure of SLVI 
influences replication, but it is the integrity of the top stem structure that is 
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critical. Mutations for Base Right in the base of SLVI, had a more 
significant impact on virus infectivity than on replication. These mutations 
were introduced to compensate for the Base Left mutation set, therefore 
restricting the position for the mutations. The Base Right mutations 
introduced an amino acid change into the capsid protein. This change was 
later found to be important for virus infectivity as it could be trans 
complemented by expression of the capsid, E1, E2, p7 and NS2 proteins 
(See chapter 5).  
Mutations in the middle region of SLVI had an effect on replication 
and indicated overlapping features of replication and virus infectivity. In the 
H-JFH/Rluc genome, mutations introduced along either side of the cytidine 
bulge of position 453, decreased replication to approximately 30% of wild 
type. By combining the left and right side mutations, replication was 
restored to 82% of wild type, by re-establishing the base pairing of SLVI. 
The mutations for Mid Right did alter the capsid protein and dramatically 
reduced virus infectivity. This mutant genome was also shown to be trans 
complemented for virus production by expression of the virus structural 
proteins and NS2 (Chapter 5). We found a critical base in the structure of 
SLVI that affects replication. The mutations for Mid Right Silent shared one 
substitution with Mid Right, 482A but also contained a mutation at 485T. 
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There was no amino acid change in the capsid protein. The genome Mid 
Right Silent was severely impaired for replication, to 6% of wild type 
whereas the similar mutant genome of Mid Right was only reduced to 34% 
of wild type. This difference in replication implied that the structure of SLVI 
may be considerably altered by the mutation at position 485 and may also 
indicate the existence of additional tertiary conformations not yet predicted.   
 We also compared mutations of the middle region of SLVI in the J6-
JFH/Rluc parental genome. Again, we found mutations of position 485 to 
contribute to a more severe reduction in replication than mutations of the 
adjacent positions. A comparable mutant to Mid Right in the H-JFH 
genome, Mid Right-A, was found to slightly reduce replication, but had a 
severe impact on virus infectivity. Mid Right-A involves three nucleotide 
substitutions at the top and middle region of SLVI and an amino acid change 
at residue 48. This genome could also be transcomplemented for virus 
infectivity by expression of the proteins capsid, E1, E2, p7 and NS2 
(Chapter 5). In addition, this genome was used in an analysis to detect 
reversions in Huh-7.5 cells.  
   The mutations for Mid Right-A changed the alanine at position 48 to 
a glycine. This position varies between J6 and JFH. In J6, as in all other six 
genotypes, residue 48 encodes an alanine, but in JFH, residue 48 is a 
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threonine. A genome with one base substitution conferring the JFH amino 
acid in the J6-JFH/Rluc parent only slightly reduced replication, but 
significantly reduced virus infectivity. This result describes another capsid 
amino acid critical for virus infectivity.  
 
Passage of a genome with a mutation in the capsid protein selects for 
second-site reversions in p7 and NS2.  
 The mutant genome Mid Right-A displayed a minor reduction in 
replication, but was significantly impaired in virus infectivity. After passage 
of Huh-7.5 cells transfected with this mutant RNA, we detected reversions in 
p7 and NS2 that coincided with an increase in virus infectivity. The first 
reversion was found in p7 and changed a phenylalanine to a serine at residue 
776 of the polyprotein. The F776 codon is not specific for genotype 2a, but 
is conserved in all 6 genotypes.  This residue is predicted to lie in the first 
transmembrane helix of p7. Introduction of the F776S pseudoreversion alone 
into the parental genome did not alter replication or virus infectivity, but 
when combined with the mutation A48G in the capsid protein, increased 
virus infectivity. A second pseudoreversion was selected after, and 
eventually replaced, the F776S mutation in the population. The second 
pseudoreversion is located within the first transmembrane helix of NS2 and 
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changes a proline to a leucine at residue 866. In a study investigating virus 
determinants for an H-JFH chimera, Yi et al. found similar compensatory 
mutations in p7 and NS2 164. Using an analogous approach of passaging cells 
transfected with replication competent chimeric genomes, virus infectivity 
was detected within 2 days, but increased by day 15. The compensatory 
mutations were found to also cluster in the transmembrane domains of p7 
and NS2, and the authors concluded that these mutations increased the 
specific infectivity of the particles rather than increase the number of 
released particles. In this study, we found genetic evidence for an interaction 
between residue 48 of the capsid protein and p7 at 776 and NS2 at 866 to 
restore virus infectivity. The residue of 48 of the capsid protein has not been 
specifically studied, but lies in a domain known to be involved with RNA 
binding activity and homo-oligomerization 86. Although not required for 
replication, p7 is essential for virus production. It has been shown to homo-
oligomerize and form an ion channel akin to other virus viroporins 100, 119. p7 
displays genotype compatibility indicating necessary interactions with other 
virus proteins, but there has been no description of a p7-capsid interaction 
164. The role of an ion channel activity or another mechanism of p7 in virus 
assembly has yet to be defined. Less is known for a role of NS2 in virus 
assembly, but an increase in virus infectivity was mapped in Con1-JFH and 
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J6-JFH chimeras, that implicates an interaction between the structural 
proteins of capsid, E1, and E2 and p7 and NS2 102. Shifting the junction of a 
J6-JFH chimera between the first and second predicted transmembrane 
segment of NS2 increased virus release and infectivity indicating sequence 
specificity for NS2. The second site reversions detected in p7 and NS2 could 
be a result of a general increase in fitness that compensates for the injury 
conveyed by the mutations in the capsid.  
 
Comparable selective pressures for the structure of SLVI are present in 
Huh-7.5 cells and in a natural infection. 
 The mutations in SLV and SLVI of Stop 1,2,3,4 severely reduced 
HCV replication, but low levels of replication persisted in transfected Huh-
7.5 cells. Reversions were identified after 7 days that restored the base 
pairing of SLVI and corresponded with an improvement of HCV replication 
in cell culture. Two reversions were found in the population, yet were not 
present on the same HCV genome. The reversion of 473G removed the Stop 
3 mutation and was also the first reversion found in the chimpanzee 
infection. The reversion of 480C involved one out of two mutations for Stop 
4 and was the second reversion selected during the chimpanzee infection. 
Both revertants arose simultaneously and were initially present at equal 
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frequencies. However the 480C revertant became the dominant genome in 
the population after 38 days in culture. This indicated that a genome with the 
Stop 1,2,3 mutations and G482 had an increase in replicative fitness over a 
genome with just Stop 1,2,4. This was indeed the case when replication was 
measured after electroporation where genomes with Stop 1,2,3 were 
compromised to just 76% of wild type and Stop 1,2,4 conferred a defect to 
18% of wild type (Figure 4.2).   
 Continued replication of genomes with mutants Stop 1,2,3,4 selected 
for reversions at either Stop 3 or the mutation 480 of Stop 4 in Huh-7.5 cells. 
A similar reversion pattern was observed in the chimpanzee infection where 
reversions for both Stop 3 and Stop 4 were selected. This demonstrates that 
there are parallel selective pressures to restore the structure of SLVI in both 
a chimpanzee infection and in a cell culture system. Replication in cell 
culture was impaired by the Stop mutations, which disrupt the RNA 
structure of SLVI. Given both systems selected reversions of mutants 
located at the top of SLVI, it is likely that reversions were selected to 


























Chapter 5.  The Role of RNA Structures in the Capsid Gene 
Aim: 
 We have shown that mutations in the RNA structures SLV and SLVI 
of the capsid gene reduce HCV replication, yet do not know what stage of 
replication is compromised. HCV, like many positive-stranded RNA viruses, 
conducts replication through interactions between virus RNA elements and 
host cell components. In this chapter, we demonstrate how mutations in 
SLVI affect translation and thus replication, and how virus proteins and 
cellular factors may participate.  
 
Introduction. 
Replication is dependent on the process and efficiency of translation, 
creation of membrane associated replicase complexes, and movement of the 
virus RNA between both of these sites. It is believed that translation of an 
HCV RNA molecule establishes a replicase complex that can only 
synthesize copies of the originally translated genome. 
Transcomplementation of a heterologous RNA that did not undergo 
translation for the replicase complex cannot occur 5 34. Nascent HCV RNA is 
released from the replicase complex and is translated to create new, 
independent replicase complexes that generate copies of their originating 
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genomes. This interdependence of translation and replication ensures that 
the fittest HCV genomes must possess elements that enable both of these 
processes to occur efficiently.  
 HCV translation requires a minimum sequence of bases 43-375 from 
the 5’NTR and capsid gene to form SLII, SLIII, and SLIV of the IRES 37, 41. 
The stability of SLIV requires the downstream sequence and also an absence 
of RNA structure immediately downstream 52. The secondary structure of 
SLIV, cofactors and contact points have been determined 39, 97, 105. The 
3’NTR is also thought to influence translation, potentially through 
interactions between proteins bound to RNA elements, but the exact 
mechanism of action is unknown and the IRES can conduct translation in the 
absence of the 3’NTR 67, 135. Translation initiation was monitored using 
purified 40S ribosomal subunits and eIF3 and comparing the kinetics of 
cofactors binding to mutant IRES RNA 58, 69, 98. The basal stem of SLIIId 
binds the 40S subunit and the apical SLIIIb binds eIF3. The ternary complex 
of eIF2-GTP-initiator tRNA joins eIF3 to form 48S*. In contrast to the 
canonical 48S complex, eIF4F does not bind the HCV IRES and this 
complex is therefore referred to as 48S*. SLII induces a conformational 
change in the 40S subunit, GTP hydrolysis releases eIF2 and the 60S subunit 
joins to form the 80S complex. In all of the above mentioned translation 
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studies, none have included the RNA structures of SLV and SLVI, therefore 
it is unknown how these RNA elements may influence IRES formation, the 
initiation of HCV translation, and thus replication.  
 Because HCV infection is persistent in vivo and noncytopathic in 
vitro, it is hypothesized that the virus must control the level of virus protein 
and RNA in the infected cell. Both the capsid protein and sequence have 
been described as modulating translation. The capsid protein reportedly 
down regulates translation by binding the IRES. Several studies claim the 
interaction with the IRES can occur in trans, yet another report claims the 
protein must be expressed in cis  17, 36, 124, 125, 140. Other studies suggest that it 
is the capsid gene sequence and RNA structures therein that decrease 
translation. The HCV capsid efficiently binds RNA, in a non-sequence 
specific fashion, and other virus capsid proteins, in addition to the HCV 
capsid protein, have been shown to bind the HCV IRES sequence 121, 155. In 
two contradictory studies, an identical frameshift was introduced early in the 
capsid sequence to conclude that it is the RNA sequence, and perhaps RNA 
structures of SLV and SLVI, that reduce IRES translation or that it is the 
capsid protein that is expressed in cis that reduces translation 124, 155. It should 
be noted that the frameshift would express the ARF protein. The specific 
elements of SLV and SLVI were never formally addressed in any of the 
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studies. Furthermore, the question of capsid protein or gene sequence acting 
as a modulating mechanism was never addressed in the context of HCV 
replication, with the exception of a study including the HCV IRES and 
capsid gene to drive translation of a chimeric poliovirus. In this context, the 
capsid gene was found to be essential for larger plaque size and titer 81, 166, 
167.  
 In this chapter, we defined when and how the RNA structures of the 
capsid gene affect HCV replication. Mutations in SLVI contribute to a 
defect in replication resulting in a lower steady-state level of HCV RNA 
compared to wild type genomes. The effects of mutations in SLVI are 
observed at a time when input RNA has decayed and initial replication 
activity accelerates. During this time, replicase complexes are formed, 
nascent HCV RNA synthesized, and translation of nascent HCV RNA 
establishes additional replicase complexes. We examined the possible effects 
of SLVI on HCV replication by measuring translation and assessing the 
effect of expression of virus proteins in trans, exploring the contribution 





Initial translation is affected by mutations in SLVI. 
  To determine if translation was compromised by the mutations in 
SLVI, a construct was created that expresses the Renilla luciferase gene near 
the C terminus of NS5A.  This position within NS5A was chosen based on 
another construct where a Flag epitope was randomly inserted into the 
replicase of genotype 1b, Con1 sequence with the adaptive mutations GIT 91. 
With the Flag epitope, replication was not affected, but when it was replaced 
with the Renilla luciferase gene, replication no longer occurred. We could 
however use this construct as a tool to measure translation in the absence of 
replication as the luciferase gene was expressed from the input RNA and 
declining levels indicate RNA degradation in the cell (Figure 5.1). We 
introduced the mutations in the capsid gene that were shown to significantly 
impair HCV replication by altering the RNA structure of SLV and SLVI. 
These mutations, Stop 1,2,3,4 and Stop 3,4, were introduced into the 
parental genome of 1bGIT/ RLuc (5A) as well as the Stop 1,2 mutations that 
do not confer a replication defect. In vitro transcribed RNA was 
electroporated into Huh-7.5 cells and luciferase expression at early time 
points was measured. At 4H, the wild type, pol-, and genome with Stop 1,2 
showed equivalent levels of luciferase expression, but a significantly lower 
(about 9 -fold less) luciferase activity was observed from the Stop 1,2,3,4 
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Figure 5.1 Mutations for Stop 1,2,3,4 reduce translation 4H after 
electroporation in a replication-defective genome. A. Time course of 
luciferase activity. B. Differences of mutant genomes from wild type 
at each time point.
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and Stop 3,4 genomes  (Figure 5.1). At subsequent time points, all genomes 
were capable of comparable levels of translation of the polyprotein and 
luciferase reporter gene. These results indicate a dysfunction at an early 
stage of translation, but not a complete inability to translate the input HCV 
RNA. Since replication does not occur, only translation of the input RNA 
was measured and levels declined as the RNA undergoes degradation in the 
cell.  
 We repeated this experiment and included additional time points early 
after electroporation. Any transfection differences were controlled by 
coelectroporating a capped, poly-adenylated transcript expressing the firefly 
luciferase gene with the HCV genomes containing the Renilla luciferase 
reporter and expressing the results as a ratio. No significant differences in 
transfection efficiency were observed. Again, the genomes with mutations 
Stop 1,2,3,4 and Stop 3,4 showed a markedly lower translation compared to 
wild type and the Stop 1,2 genomes (Figure 5.2). The genome with the Stop 
1,2,3,4 mutations showed a 3-4 fold reduced level of luciferase expression 
immediately after electroporation (0H) as well as the early times 2H and 4H 
post electroporation. Reduced translation was also observed for the genome 
with Stop 3,4 mutations at levels 2-3 fold below wild type (Figure 5.2).  
188
Translation




















































Figure 5.2 Mutations for Stop 1,2,3,4 reduce translation 4H after 
electroporation in a replication-defective genome. A. Time course of 
luciferase activity. B. Differences of mutant genomes from wild type 




 Electroporation may alter the state of the cell and may accentuate the 
mutant genomes’ defect in translation. To study the early translation events 
and differences contributed by mutations of SLV and SLVI, we tested 
another delivery method of HCV RNA to Huh-7.5 cells. Using a lipid-based 
RNA delivery, the TransMessenger system, HCV RNA was transfected to 
Huh-7.5 cells and luciferase expression measured. A capped firefly 
transcript was included to normalize any transfection efficiencies between 
RNAs. The firefly luciferase and HCV Renilla luciferase RNA were mixed 
and incubated with the TransMessenger reagent, and then applied to the 
Huh-7.5 cell monolayer. Without an additional incubation period, cells were 
washed and lysed at the time points indicated in Figure 5.3. After 75 
minutes, translation was comparable for all genomes, with wild type slightly 
higher.  As translation continued, and more RNA taken up by the cells, 
luciferase levels increased for the wild type, pol- and genome with the Stop 
1,2 mutations. Despite being transfected with equal amounts of RNA and 
normalized to the firefly luciferase control RNA, luciferase expression 
barely increased for the genomes with Stop 1,2,3,4 and Stop 3,4 mutations 
(Figure 5.3) over the 6H time frame. Luciferase expression was above 
background indicating a low level of translation did occur. We conclude that 
while the wild type, pol-, and Stop 1,2 genomes could efficiently launch 
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Figure 5.3 Mutations for Stop 1,2,3,4 reduce translation after RNA 
delivery by lipid mediated TransMessenger delivery. A. Time course 
of luciferase activity after RNA delivery. B. Differences of mutant 




translation and luciferase expression increased with time, this process was 
defective in the genomes with Stop 1,2,3,4 and Stop 3,4 mutations. The 
disrupted RNA structure could cause this phenotype in many ways, by 
altering cellular localization of the incoming RNA, association with 
inhibitory proteins, or perturbing the normal HCV IRES.  
 
Mutations in SLV and SLVI reduce translation in vitro. 
 The low level of luciferase expression at early time points of RNA 
delivery indicates the RNA structure of SLVI may participate at the stage of 
translation initiation or early events localizing the virus RNA with the 
translation machinery. To ask the question is translation per se altered by 
mutations in SLVI, and to remove the potentially complicating events 
occurring in cell culture, we compared our mutant genome containing the 
Stop 1,2,3,4 mutations with a wild type genome in a cell free translation 
reaction using rabbit reticulocytes extracts. Both genomes contain the 
Renilla luciferase gene near the carboxy terminus of NS5A to facilitate 
measurement of translation. Initial translation at 15 minutes was equivalent 
between the wild type and mutant genomes indicating no defect with 
translation initiation. The mutant genome however did not maintain wild-
type translation levels (Figure 5.4). Between 45 and 90 minutes, translation 
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Figure 5.4. Mutations for Stop 1,2,3,4 reduce translation in 
rabbit reticulocyte lysates. A. The wild type and mutant 
genome with Stop 1,2,3,4 mutations were measured for 
luciferase activity with three concentrations of input RNA and 
two concentrations of  magnesium. The amount of Renilla 
luciferase activity indicating IRES dependent translation of the 
HCV genomes was normalized to activity from  a capped, poly 
adenylated firefly luciferase message RNA B. Difference of 
luciferase activity measured from the mutant RNA from the 




of wild type had outpaced the mutant. The reaction was programmed with a 
standard 15nM of HCV RNA as well as ten-fold dilutions to 0.015nM to 
ensure that we did not saturate the translation system. Compared to the wild-
type, the mutant displayed a reduced translation in all four dilutions of input 
RNA indicating that the phenotype was independent of RNA levels in the 
system. Previous studies of HCV IRES dependent translation have shown 
Mg2+ to have a beneficial effect in the rabbit reticulocytes system. Increasing 
the Mg2+ concentration from 2mM to 3mM increased translation for both 
genomes (Figure 5.4). Again the mutant and wild type RNA were translated 
equally at 15 minutes, yet in this system, a difference was observed earlier, 
at 45 minutes, as the mutant genome failed to increase translation to wild 
type levels. Again, this was true for all dilutions of input RNA.  
The mutant genome exhibited a 2 -3 fold decrease in translation after 
90 minutes in the standard reaction, and a 2 -3.5-fold difference when the 
system was enhanced with the addition of Mg2+ at 45 min (Figure 5.4). This 
difference was consistent as we extended the time measuring translation up 
to 20H to determine the end point of the reaction. The maximum level of 
translation was detected at 4H followed by a decline in luciferase activity 
presumably as the input RNA and luciferase protein degraded, and necessary 
translation factors are exhausted (Figure 5.5). The mutant and the wild type 
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Figure 5.5. End point measurement of translation of wild type 
and mutant HCV RNA. A. Translation of the mutant RNA 
shows a reduction after 45 minutes and remains below wild 
type as the reaction ends for all concentrations of input RNA. 
B. The difference in translation between mutant and wild type 
is 2 - 3 fold for all RNA concentrations and are similar for 
each time point.
3mM Mg2+

























































levels declined at a similar rate indicating RNA degradation does not 
account for the differences in luciferase expression. This will be addressed 
more formally in the next sections. The mutant genome with SLVI disrupted 
can engage in translation, yet lags as compared to wild type. This could be 
due to a defect either in the efficiency in initiation, elongation, or 
termination and thus recycling of the ribosomes. The defect in translation 
found in the cell free system (2-3 fold of wild type) was similar to that 
measured in transfected cells (2-4 fold of wild type).  
  
Differences in translation are not due to RNA degradation.  
 While HCV genomes with mutations in SLVI can initiate translation, 
they fail to reach the activity of genomes with unaltered RNA structures. 
This disparity could be a result of different rates of RNA degradation, either 
due to the RNA being lethally misfolded in the cell or the chance of carrying 
a contaminant that degrades the RNA during the reaction. To address this 
concern, HCV RNA was transcribed in the presence of 32P-CTP for the wild 
type, the genome containing the Stop 1,2,3,4 mutations, and a genome 
containing a frameshift in E2, which prevents expression of the luciferase 
reporter from the start of the polyprotein. The radiolabeled RNA was used to 
program a standard cell free translation reaction in rabbit reticulocyte lysates 
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and RNA extracted. A short, 6KB radiolabeled RNA was added to the 
reaction prior to extraction as a control for any loss during the phenol 
chloroform extraction process. Radiolabeled products were separated by 
denaturing agarose gel electrophoresis and visualized by autoradiography. 
No differences in the amount or length of RNA were detected between any 
of the HCV genomes at all time points (Figure 5.6). Degradation does occur 
as less HCV RNA is present at later times, but was consistent for all three 
genomes. Thus, the observed defects in translation are not due to different 
rates of RNA degradation in the reaction.  
 
Visualization of radiolabeled protein products reveals a difference in 
translation at late time point. 
Translation was quantified by expression of a luciferase gene 
positioned within NS5A, the next-to-last gene of the HCV genome. It was 
previously shown that the mutations in SLVI do not affect polyprotein 
processing (Figure 4.4, Chapter 4). To verify that the mutations in SLVI 
contributed to IRES-dependent translation differences and were not due to 
faulty expression of the polyprotein, we radiolabeled the protein products 
during in vitro translation using rabbit reticulocytes extracts. Processing of 
the polyprotein was inefficient in rabbit reticulocyte extracts, despite the 
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Figure 5.6. The reduced translation observed from HCV genomes with 
mutations in SLVI is not due to RNA degradation. Labeled HCV RNA for 
the wild type (wt), mutant (mut) and frameshift (fs) genomes was 
extracted from rabbit reticulocyte lysates at time points indicated and 
integrity visualized on a denaturing agarose gel. A control RNA was added 
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addition of microsomal membranes, creating difficulties when visualizing 
the individual products.  To simplify the system, we truncated a genome by 
removing 7580 nucleotides between E1 and NS5B. This construct, 
Delta7580, is a genotype 1a H77 sequence and encodes a protein product of 
approximately 54kDa. The mutations Stop 1,2 and Stop 1,2,3,4 were 
introduced into the capsid gene of Delta7580 and RNA generated by in vitro 
transcription. HCV RNA was added to the rabbit reticulocytes extracts and 
protein products labeled with 35S-methionine. The truncated HCV protein 
could be visualized faintly by 15 minutes. The protein product also appeared 
to be identical in size for all genomes. By the 90 minutes, it was apparent 
there was less translated protein encoded by the genome harboring the Stop 
1,2,3,4 mutations (Figure 5.7). Again, this demonstrates the mutations in 
SLVI cause a translation defect evident at a later time point in translation.   
 
In vitro translation using extracts from Huh-7 and Huh-7.5 cells. 
 HCV efficiently replicates only in Huh-7 cells and more efficiently in 
Huh-7.5 cells. Although there are several reports noting the differences of 
Huh-7 and Huh-7.5 cells it is still unclear what causes these lines to support 
HCV replication. Given the ability of Huh-7 cells to support HCV 
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Figure 5.7. Mutant Stop 1,2,3,4 produces less radiolabeled translation 
products in an in vitro translation assay. Rabbit reticulocyte lysates 
were programmed with HCV RNA templates and translation products 
labeled with 35S-Met for the time indicated. A capped, polyadenylated 
















































replication, our lab and others developed a cell free translation system using 
Huh-7 and Huh-7.5 cell lysates (Marcotrigiano, J., unpublished, 138). 
Since Huh-7 cell lines harbor a beneficial environment for HCV 
replication and we have shown that mutations in SLV and SLVI cause 
deficient HCV replication in these cells, we asked if the SLV and SLVI 
mutants have a translation defect in these cells. Using the genotype 1b 
genome with the Renilla luciferase reporter in NS5A, we compared genomes 
with the Stop 1,2,3,4 mutations to the parental genome. To detect any 
aberrant translation that allowed expression of the downstream luciferase 
gene in a non-IRES dependent manner, a frameshift was introduced in the 
E2 gene, which should terminate translation of the polyprotein at residue 
571. Translation was measured from the three genomes, the wild type (wt), 
mutant with Stop 1,2,3,4 mutations (mut), and the frameshift genome (fs) 
using three concentrations of input RNA. Initially, translation occurred with 
a lower level of luciferase expression and at a slower rate in Huh-7 extracts 
than in rabbit reticulocytes; therefore, we monitored translation over a longer 
period of time (Figure 5.8). We included a capped, poly- adenylated RNA 
expressing the firefly luciferase gene as an internal control. By 3H a 
substantial difference in translation was detected between the mutant and 
wild type RNAs. This difference was observed for all three concentrations of 
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Figure 5.8. An HCV genome with mutation in SLV and SLVI is translated 
less efficiently in Huh-7 and Huh-7.5 cell free extracts. A. Translation in 
Huh-7 cell extracts of the wild type (wt), mutant SLVI (mut) and 





























































template RNAs with a 3- 4 fold reduction at the 15 nM concentration and 4.5 
-6 fold reduction at the lower concentrations of 1.5 nM and 0.15 nM. 
Luciferase expression was measured for the frameshift genome, but at 130 -
170- fold lower level than wild type. This indicates that either IRES-
independent translation can occur, but at a very low frequency or there is a 
read through of the stop codon at residue 572. 
 We also compared translation in extracts generated from Huh-7.5 
cells.  Following a similar preparation protocol, the Huh-7.5 cell lysates 
showed a reduced ability to translate even the capped firefly transcript. In 
Huh-7.5 cells, the peak of wild type genome translation was 1.5 logs below 
that observed in the Huh-7 cell extracts. Despite the lower translation 
capacity of the Huh-7.5 extracts, there was a difference in luciferase 
expression between the wild type RNA and the genome harboring the 
mutations in SLVI (Figure 5.8).  At the 3H time point, the mutant genome 
was reduced 2- fold at the 15 nM concentration and 4-fold reduced for at the 
lower concentrations of input RNA. The genome with the frameshift did 
express luciferase, but again at a level 160- fold below wild type. 
Consistently, the mutant genome with an altered SLVI demonstrated a defect 
in translation of 2- 4 fold below that of wild type.  
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Huh-7.5 cells contribute to an inhibitory factor versus Huh-7 cells. 
 The lower level of in vitro translation from Huh-7.5 cell extracts is in 
contrast to the replication ability of these cells. To understand the 
differences in translation between Huh-7 and Huh-7.5 cells, translation was 
measured when the extracts were combined. This would indicate if one of 
the cell lines contained a beneficial or inhibitory factor. In the same reaction, 
we measured cap- dependent translation of a firefly transcript, and IRES-
dependent translation of a wild type or SLVI mutant genome, HCV genome 
containing the Renilla luciferase gene or a mutant HCV genome with an 
altered SLVI also expressing the Renilla luciferase gene. The lysates were 
programmed with 15 nM of HCV RNA and 1.6 nM of capped firefly 
luciferase RNA. As previously, the Huh-7 cell lysates allowed for more 
efficient translation than the Huh-7.5 extracts. Huh-7 extracts permitted 
enhanced translation for both IRES- and cap-dependent templates. We again 
observed that IRES dependent translation was reduced in the presence of 
mutations altering SLV and SLVI (Figure 5.9). The capped RNA transcript 
was included as a control when measuring translation of the wild type and 
mutant HCV genomes, and therefore measured in two independent 
experiments (Figure 5.9).  When the extracts from Huh-7 and Huh-7.5 cells 
were mixed, translation only reached the level observed for the Huh-7.5 cell 
204
Figure 5.9. Huh-7.5 cells have a negative factor that reduces 
translation. Luciferase activity of Huh-7, Huh-7.5, and mixtures of 
Huh-7 and Huh-7,5 cell extracts programmed with a capped, 
polyadenylated firefly mRNA and HCV RNA expressing Renilla 
luciferase. Firefly luciferase activity is measured with A. wild type 
HCV RNA and C. mutant HCV RNA. Renilla luciferase is measured 
with B. wild type HCV RNA and D. mutant HCV RNA. E. Renilla 
luciferase of wild type and mutant HCV RNA over time.
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lysates or was even further compromised. The reduced ability of translation 
was evident in both IRES and cap dependent translation. This indicates a 
potential inhibitory factor is present in the Huh-7.5 cell lysates and not a 
positive factor in Huh-7 cells. Since both lysates were prepared under the 
same conditions, i.e. magnesium and potassium concentrations, and 
translation was conducted using identical reaction conditions, it is unlikely 
that the reduction in translation is due to unbalancing the optimized reaction.   
In all, the reduced capacity of Huh-7.5 cells to conduct in vitro 
translation of both IRES and capped RNAs, is in contrast to the high level of 
HCV replication supported by these cells.  
  
IRES mutations known to affect translation have a severe consequence on 
replication. 
 We have shown that translation of HCV genomes with the Stop 
1,2,3,4 mutations disrupting SLVI is reduced 25-50% (2- 3- fold reduction) 
of wild type, yet replication is reduced to an even greater extent to 1-2% of 
wild type (Chapter 4). The HCV IRES has been the focus of many research 
groups who have characterized mutations in the RNA sequence and structure 
of the IRES and their effect on translation. We compared the effects of these 
IRES mutants with the SLV and SLVI mutants for their ability to translate 
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and replicate. Two types of IRES mutations were engineered into the H-
JFH/Rluc genome. The mutant G266-268A substitutes three guanidines 
located on the loop of stem IIId with adenines (Figure 5.10). This mutant 
was studied for its ability to translate an HCV IRES driven firefly luciferase 
reporter gene and found to severely reduce translation to 8% of wild type in 
rabbit reticulocytes and to less than 5% of wild type in HeLa S10 lysates 98 
58. Despite being able to bind purified 40S subunits, studies of translation 
initiation kinetics map this defect to a complete absence of 40S formation, 
the initial complex that must form for translation to begin. The mutant IIId-
delE replaces loop E in stem III of the IRES with a helical segment (Figure 
5.10). Translation is only slightly reduced to 46% in rabbit reticulocytes 
lysates, but shows no translation defect in HeLa S10 lysates. This mutant 
IRES is highly active and can bind 40S as well as form the intermediate 
48S* and 80S complex, although the latter is formed slightly less frequently 
than wild type. 
 We measured these mutations in the context of H-JFH/Rluc genome 
for translation in rabbit reticulocyte lysates and for replication in Huh-7.5 
cells to determine the extent a defect in translation, however mild, would 
contribute to a reduction in replication. The mutant G266-268A was severely 
compromised for translation (Figure 5.11). After only 15 minutes, 
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Figure 5.10. Mutations in the IRES conferring defects in 
initiation. The mutants IIId-delE and G266-268A are tested 
in the H-JFH/Rluc genome for translation and replication.   




























































































































































































































































































































Figure 5.11. Mutations in the IRES that impair initiation confer 
severe defects in translation and replication assays. A. Luciferase 
expression in a translation assay using rabbit reticulocyte lysates 




















































translation was one-half logs below wild type, which is consistent with a 
defect in formation of the initial 40S complex. The mutant IIId-delE showed 
initiated translation equivalently to wild type, but luciferase levels failed to 
increase and only reached 2 logs below wild type levels (Figure 5.11). This 
mutant displayed a much greater defect in translation than in previous 
reports and may be due to the lower concentration of input RNA (15 nM as 
opposed to 100 nM) or reflect the further distance of translation required to 
express the luciferase gene located 2773 nucleotides away from the start site. 
Both IRES mutations caused a reduction in translation although not 
complete elimination of all activity. Even the most active IRES mutant able 
to form all three initiation complexes, IIId-delE, was translated an order of 
magnitude less than SLVI mutant genomes. The SLVI mutations may 
influence IRES driven translation, but at a less critical step in translation.   
 The IRES mutants displayed an obvious translation and replication 
defect in Huh-7.5 cells (Figure 5.11). After just 4H post transfection, both 
IRES mutants were 1-2 logs below both the wild type and pol- control 
genomes. Luciferase levels rapidly declined and never reached pol- levels. 
Even for the most active IRES mutant, replication could not be sustained, or 
perhaps launched in the face of such debilitating translation. The SLVI 
mutants did not show such a dramatic inability to initiate translation at the 
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4H time point, but did show a defect as replication was launched and nascent 
RNA underwent translation. This indicates the role of SLVI may act at the 
level of replication as well as influencing subsequent translation of newly 
made RNA.  
 
Does SLVI participate in a long range RNA-RNA interaction with the 
5’NTR? 
 The conservation of the 5’NTR and capsid sequence has led to 
predictions of numerous functions for this region, and in addition, a long 
range RNA-RNA interaction between the 5’NTR and the base of SLVI has 
been hypothesized. This interaction involves the unstructured region 
between SLI and SLII in the 5’NTR (24-38) and the left side basal region of 
SLVI (428-442) to form a 12 base complementary sequence (Figure 5.12). 
There is covariant support for this interaction; where most genotypes have 
an adenine-uridine base pair between bases 29 and 437, genotype 2a 
sequences contain a compensatory guanine-cytosine base pair at this 
location. The proposed role of this interaction was to negatively regulate 
translation. In the reported study, three substitutions were designed to 
disrupt the complementary interaction with the 5’NTR and base of SLVI and 

















Figure 5.12. Proposed interaction between the base of SLVI and the 
5’NTR. A. Diagram of the RNA structures of the 5’NTR and SLV and 
SLVI in the capsid gene. B. The 12 base paired interactions of the 




truncated CAT gene, was expressed by cap-dependent translation and the 
second cistron driven by the HCV IRES with either 85 or 101 nucleotides of 
the capsid gene fused to the downstream reporter, a full length CAT gene. 
Inclusion of the 101 nucleotides of the capsid gene was found to partially 
reduce in vitro translation in rabbit reticulocytes as measured by 
radiolabeled products visualized by autoradiography. Substitutions in the 
5’NTR designed to disrupt three base pairings of the proposed interaction 
with the capsid gene improved translation slightly above the parental 
genome, and the corresponding three mutations in the capsid gene improved 
translation to a higher level of 3 units above the parental. Translation was 
reduced, to levels below that of wild type, when all six mutations were 
included to compensate the 5’NTR and capsid gene interaction. The authors 
proposed that this interaction between the capsid sequence and 5’NTR is a 
regulatory mechanism that down regulates translation and allows replication 
to proceed. 
 The proposed region of the capsid gene that may interact with the 
5’NTR is located at the left base of SLVI. We have shown the apical stem of 
SLVI to influence translation and reduce replication. Previous replication 
studies have shown the base of SLVI to influence replication, but not to the 
same extent as the top region of SLVI (Chapter 4). To test if SLVI is acting 
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in concert with the 5’NTR to regulate translation, we introduced mutations 
identical to the published study in the 5’NTR and base of SLVI that would 
disrupt the proposed interaction in the parental genome of H-JFH/Rluc 
(Figure 5.13). The genome “5’NTR mut” contains mutations in the 5’NTR 
that would disrupt three predicted base pair interactions with the left side of 
SLVI in the capsid gene. Three silent mutations were introduced in the 
capsid gene to create genome “Base Left” that would also disrupt the 
interaction with the 5’NTR as well as base paired interactions within the 
base of SLVI. Together, “5’NTR mut/ Base Left”, these mutations should 
compensate the interaction with the 5’NTR and capsid sequence; however, 
the base of SLVI would remain disrupted. Previously, translation was 
measured in the context of only the first 101 nucleotides of the capsid gene, 
which contain only the left side of the basal stem of SLVI and not the entire 
stem structure present in the first 166 nucleotides of the capsid gene. Using a 
full length, monocistronic genome allowed a complete study of the entire 
stem of SLVI and any additional RNA elements that may also participate in 
translation. By including the entire HCV genome, we can determine if the 
competing right side of the base of SLVI has an effect as well as measure 
any consequences on replication. Mutations along the right side of SLVI, 
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5’NTR mut- / 
Base Left
Base Left
Figure 5.13. Mutations in the base of SLVI and 5’NTR designed to 
test the proposed interactions. A. Mutations in the base of SLVI of 
the H77 sequence. B. Mutations in thte 5’NTR designed to 




and in combination with mutations on the left side, Base Left, would 
predictably compensate the structure of SLVI, “Base Left/ Right”.  
 Translation was measured in rabbit reticulocyte lysates by quantifying 
Renilla luciferase expression from two independent preparations of RNA for 
each HCV genome (Figure 5.14). Reaction conditions were similar to the 
published study in which lysates were programmed with a 10 uM 
concentration of RNA in a 20uL reaction for 1H. We measured translation of 
two concentrations of input RNA at 7.5 nM and 0.75 nM over a time course 
of from 15 to180 minutes.  Data from the 7.5 nM reaction at 90 minutes is 
presented, yet both dilutions of RNA yield the same relative results. The 
proposed interaction between the 5’NTR and capsid gene was reported to 
negatively regulate translation with disruptive mutations in either location 
leading to an increase in translation. In the H-JFH/Rluc parent, mutations in 
the 5’NTR (5’NTR mut) and in the interacting partner of the capsid gene 
(Base Left) did not increase translation, but reduced translation to 87% and 
86% of wild type, respectively (Figure 5.14). Compensating the mutation 
sets in the 5’NTR and Base Left of the capsid (5’NTR mut/ Base Left) to 
restore the proposed interaction also reduced translation to 76% of wild type. 
Furthermore, mutations in the 5’NTR and the right side of the base of SLVI, 
the competing element for the Base Left, (5’NTR mut/ Base Right) also 
216
Figure 5.14. Translation of mutants designed to test the 5’NTR and 
Base of SLVI interaction in rabbit reticulocyte lysates. Translation was 
measured by luciferase activity at 90 minutes. Mutants permitting an 
interaction are designated with a “+” and mutants potentially 
disrupting an interaction is listed with a “-”. Compensatory mutation 
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reduced translation to 73% of wild type. In any context, disrupting the 
interaction between the 5’NTR and Base Left region of the capsid gene 
actually impaired translation, although only slightly, as opposed to 
improving translation as reported. This suggests there is not an interaction 
between the 5’NTR and left base of SLVI, which acts as a negative 
influence on translation.  
 Translation could, however, be influenced by the base of the SLVI 
structure itself. Where mutations along the left side (Base Left) minimally 
reduced translation to 87%, mutations on the right side of the basal structure, 
Base Right, impaired translation to 54%. Genomes harboring both sets of 
mutations, restoring the base of SLVI, compensated for the effect of Base 
Right alone to 86%. Disrupting the base of SLVI in the context of the 
5’NTR mutations also demonstrated that SLVI influences translation. The 
genome with the 5’NTR and Base Left mutations was impaired for 
translation to 76%. This result favors the SLVI structure having a role in 
translation, since compensating the 5’NTR and Base Left did not restore 
translation to wild type levels. Similarly, genomes with 5’NTR and Base 
Right mutations were reduced to 73%, again indicating that it is the 
disruption of SLVI that compromises translation. Restoring the base pairing 
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of SLVI, even in the presence of the 5’NTR mutations (5’NTR mut/ Base 
Left/ Right), improved translation to 90% of wild type. 
These data indicate SLVI participates in translation and does not 
indicate a role for the complementary sequences of the 5’NTR and capsid 
gene. The translation effects of the mutations in the basal region of SLVI 
results are consistent with the effects observed during replication. Mutations 
at the left base of SLVI (Left Base) reduced replication slightly, yet the 
mutations for the right side (Right Base) were more severe (see Chapter 4). 
Replication improved in the presence of both mutation sets that restored the 
base of SLVI. This replication defect could be a reflection of the reduced 
capacity for translation as well as indicate a role of the capsid protein as the 
mutations in Right Base also change an amino acid. The possible role of the 
capsid protein will be addressed in an upcoming section.  
 
Deletions of the 5’NTR reduce translation. 
 Point mutations introduced into the 5’NTR designed to disrupt a long 
range RNA-RNA interaction with the capsid gene proved to not increase 
translation as previously reported. Since individual base changes may have 
unanticipated effects on RNA structure and the predicted participating bases 
may be incorrect, we deleted the first 40 nucleotides in the parent genome of 
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H-JFH/Rluc to determine if translation was affected. This region of the 
5’NTR contains SLI at position 5-20 and the unstructured area bordering the 
5’ end of the IRES. Both regions have been shown to be required for 
replication and while deletion of SLI leads to an increase in translation, little 
is known about the unstructured area predicted to interact with the capsid 
gene 41. It is also unknown if the regions of SLVI involved with HCV 
replication are influenced by this region in the 5’NTR. We have shown that 
the base of SLVI can affect translation independently of the 5’NTR. It has 
also been shown that the basal stem of SLVI influences HCV replication, but 
that the apical stem is more critical for replication (Chapter 4). We were 
curious if the detrimental effects observed by mutations in the apical stem 
occur in the presence of the 5’NTR. The mutations conferring Stop 1,2,3,4 
and Stop 3,4 were introduced into the Delta40 construct with bases 1-40 
removed and translation compared in rabbit reticulocyte lysates at two 
different RNA concentrations. Enhanced translation was found in the 
Delta40 genome, confirming the previous findings for SLI. The mutations in 
SLVI suppress translation to 66% and 68% of wild type again indicating a 
role of this RNA structure in translation as well as replication (Figure 5.15). 
In the context of the Delta40 genome, the mutations of SLVI also showed a 




























































































































Figure 5.15. Translation of mutants designed to test the 5’NTR and 
Base of SLI interaction in rabbit reticulocytes. A. Translation at 




removal of the first 40 nucleotides. While SLI and the region 21-40 of the 
5’NTR did display an effect on translation, the mutations on SLVI in the 
capsid gene alter translation in an independent manner.  
 
Deletion of the capsid gene reduces translation. 
 The influence of the capsid gene on translation has been the subject of 
numerous studies predicting interactions with the 5’NTR, altering the 
stability of the IRES, and debate between the capsid protein or capsid 
sequence as being the component responsible. The HCV IRES requires 
sequence in the capsid-coding gene to function; the minimum length being 
33 nucleotides, though generally the first 16 amino acids of capsid are 
included in replicon and bicistronic constructs. It has been demonstrated that 
the region immediately downstream of the IRES must be devoid of RNA 
structure, presumably to not compete with the integrity of the IRES 
structure. Early studies of the IRES found that inclusion of additional 
sequences of the capsid gene led to a decrease in translation activity. Also 
the IRES varied in its ability to translate certain downstream reporter genes. 
Although the IRES does not require sequences beyond 33 nucleotides of the 
ORF to function, these results suggest that the efficiency of HCV IRES-
dependent translation can be influenced by sequence further downstream. 
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 The RNA structures of SLV and SLVI are located just 46 nucleotides 
from the AUG start codon and 13 nucleotides downstream of the minimal 3’ 
boundary of the IRES. Since the entire capsid gene has been shown to down 
regulate IRES activity, we compared translation in the presence of only SLV 
and SLVI and in the absence of both structures. In the parental construct of 
H-JFH/Rluc, we deleted the capsid gene either from amino acid 15 (position 
387) or amino acid 57 (position 513) to amino acid 171 (position 851), the 
start of the signal sequence of E1. A nine nucleotide linker that encodes 
three alanines was included at the deletion junction. The mutations of Stop 
1,2,3,4 were introduced to determine if SLVI influences translation in the 
absence of downstream capsid sequence. In an in vitro translation reaction, 
we found that removal of the capsid gene, Core Del 15-171, actually slightly 
decreased translation to 88% of wild type (Figure 5.16). This effect on 
translation is the opposite of what has been previously reported. Other 
translation studies of the capsid gene have utilized bicistronic constructs 
where the extended regions of the capsid gene were fused directly to a 
reporter and frequently lack other elements of the HCV genome such as the 
rest of the polyprotein and the 3’NTR. In this system, all elements of the 
HCV genome are present as a monocistronic construct, but with the partial 
deletion of the capsid gene. RNA structures originally downstream in the 
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genome are brought closer to the 5’NTR and may interfere with IRES 
function. Extending the region of the capsid gene to include the RNA 
structures of SLV and SLVI leads to a further reduction in translation, to 
80% of wild type (Figure 5.16). This is consistent with previous studies 
where RNA structures have been proposed to contribute a negative effect on 
translation. Inclusion of the silent mutations of SLV and SLVI compromised 
translation additionally to 65% of the parent genome. We have shown 
mutations in SLVI to reduce translation, and this study is consistent with 
those results, yet in addition, reveals that the role of SLVI in translation does 
not involve downstream elements.   
 
Genotype differences in the 5’NTR do not affect replication of the J6-JFH 
genome. 
 The 5’NTR sequence shows great conservation, yet there are several 
nucleotide differences that are genotype specific. It has been shown that the 
genotype 1b sequence conducts translation twofold less efficiently than 
genotype 1a sequence 55. The genotype 1b sequence contains two nucleotide 
differences, an AG at positions 34 and 35 (numbering based on H77 
sequence) whereas genotype 1a contains the dinucleotide GA. Exchanging 
the AG of genotype 1b with the GA of genotype 1a removed the two-fold 
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Figure 5.16. Translation of HCV genomes with deletions in the 
capsid gene is reduced. A. Domains of the capsid protein. B. 
Translation in rabbit reticulocyte lysates after 90 minutes as 











































































defect in translation.  It was also found that the increased genotype 1b 
translation was dependent on the presence of the capsid gene, therefore 
predicting a long range RNA-RNA interaction between the unstructured 
region of the 5’NTR and the capsid gene or the capsid protein 64. The 5’ 
NTR sequence of genotype 2a sequence is identical to the genotype 1a 
sequence at positions 34 and 35, yet there is a difference at position 29 (H77 
numbering) where most genotype 2a sequences contain a guanine and most 
other genotypes contain an adenine (Figure 5.17). This position was 
described in the previous section as being phylogenetic evidence for 
interacting with a partner sequence in the capsid gene. To address if these 
genotype differences contributed any effect on HCV replication, we 
introduced substitutions at position 29 and at positions 34 and 35 in a 
genotype 2a J6-JFH/Rluc genome. In this chimera, the 5’NTR sequence is 
from the JFH genome except for the J6-substitution of G301U.  In vitro 
transcribed RNA for the genomes with the G29A mutation (JFH 5’NTR 1a) 
and the dinucleotide mutations AG to GA at 34/35 (JFH 5’NTR 1b) were 
electroporated into Huh-7.5 cells and replication measured by luciferase 
expression. There was no difference at any time point between any of the 
genomes, indicating no effect of the genotype differences between the 
5’NTRs (Figure 5.17).   
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Figure 5.17. Genotypic differences in the 5’NTR do not affect 
replication. A. Alignment of genotype 1a, 1b, and 2a sequenced of 
the 5’NTR from position 1-43. B. HCV RNA measured by Real Time 


















































Mutations in the 5’NTR eliminate HCV replication. 
We have shown that mutations in the 5’NTR that would disrupt the 
predicted Watson-Crick base pair interaction with the capsid gene do not 
lead to an increase in translation. However we did discover that mutants in 
the predicted interacting partner, the left base of SLVI, did have both a 
translation and replication defect. To determine if there was any replication 
consequence of these changes in the 5’NTR in Huh-7.5 cells, the mutations, 
5’NTR mut-A, were engineered into the parent genome of H-JFH/Rluc and 
replication measured by luciferase expression (Figure 5.18). Although input 
RNA was translated, there was no replication as luciferase levels quickly fell 
below even levels for the pol- genome (Figure 5.19). This region of the 
5’NTR is known to be an essential element for replication; possibly because 
it forms the promoter for plus strand synthesis in the minus sense.  
The long range RNA-RNA interaction of the capsid gene and 5’NTR 
involves 9 base pairs at the 5’ end of the 5’NTR, a bulge of three bases each 
side, and 3 additional complementary nucleotides (Figure 5.18) 64. It has also 
been published that increasing the interaction between the 5’NTR and capsid 
gene by increasing the base pairing of the bulge region, further reduces 
translation. These three mutations, 5’NTR mut-B, involved the changes 
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Figure 5.18. The 5’NTR has been shown to interact with a 
microRNA and RNA sequences from the capsid gene. A. Positions 
1-43 of the 5’NTR of H77. B. The seed region for the interaction of 
miR122 and the 5’NTR. C. The interaction of the 5’NTR and the base 
of SLVI. D. Mutations introduced in the 5’NTR designed to disrupt 































Figure 5.19. Mutations in the 5’NTR affect HCV replication. All 
mutations introduced in the 5’NTR debilitate HCV replication with 
the exception of the single base change of mut-E, which lies outside 
of the miR122 seed region and would disrupt 1 out of 12 base 
pairings with the capsid gene. Two RNAs were tested for each 
genome and averages shown. 
Replication

























U33A, G34C, A35G and were tested for their ability to replicate in the H-
JFH/Rluc genome (Figure 5.19). Replication was eliminated in the presence 
of these mutations implying a lethal alteration of the 5’NTR or the minus 
strand promoter.    
 Another feature of this region in the 5’NTR is that it is a target for a 
microRNA and the recognition of this sequence has the unusual outcome of 
enhancing HCV replication 59. The microRNA, miR122, is very abundant in 
liver cells and is present in Huh-7 and Huh-7.5 cells. In fact Huh-7 cells and 
cell lines derived thereof are the only transformed liver cell line to have 
maintained their expression of miR122, leading to the hypothesis that 
miR122 expression is responsible for the ability of these cells to support 
HCV replication. It is still unknown how or at what stage miR122 is 
beneficial for replication. The seed region for miR122 shown to be critical 
for HCV replication is located between bases 22 and 29 of the 5’NTR 
(Figure 5.18). In addition to potentially disrupting the minus strand promoter 
mutations, the mutations of 5’NTR mut-A would also alter the target site of 
miR122. To disrupt the interaction between the 5’NTR and the capsid gene, 
without interfering with the miR122 seed region, a set of mutations, 5’NTR 
mut-C, D, E, F were generated in the 5’NTR and tested for their ability to 
replicate (Figure 5.19). All constructs were unable to replicate except 5’NTR 
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mut-E. This mutant contained only one substitution, A32U, which is outside 
of the miR122 seed area and could replicate efficiently. Unfortunately, this 
one base change may not completely abrogate an interaction with the capsid 
gene sequence, leaving that interaction untestable in a replication context. 
We did attempt to separate these two features by duplicating this 
overlapping region in the 5’NTR. We introduced a 6 base repeat at position 
29, which moves the interacting capsid region downstream from the miR122 
seed region. This genome, surprisingly, could efficiently translate and also 
could replicate, but to a much attenuated degree (Figure 5.20).  
 
Potential interactions of the capsid protein in trans. 
 The reduction of IRES directed translation in the presence of extended 
lengths of capsid gene has been the subject of numerous studies and debates 
as to whether the capsid sequence or the capsid protein acting in a regulatory 
fashion. Early biochemical studies of the capsid protein identified the amino 
terminus, residues 1-75, as capable of binding RNA 121. Given the highly 
basic amino acid composition and location in the genome, the capsid protein 
was predicted to be a structural component of the virion and was shown to 
bind RNA, although without specificity as it could bind HBV and ribosomal 
RNA as well as HCV RNA. Subsequently, the capsid protein was reported 
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Figure 5.20. Introduction of a repeated sequence predicted to base pair 
with the SLVI in the 5’NTR. A. In vitro translation of HCV with the 
repeated base of SLVI element shows no reduction in translation. B. 


















































to bind the 5’NTR and repress translation. Binding the HCV IRES has been 
described for the capsid protein expressed both in cis and in trans and using 
either purified recombinant protein in UV crosslinking and gel shift assays 
or recombinant baculovirus and mammalian systems expressing capsid 
protein in cell culture. Studies including other basic, virus capsid proteins, 
such as that from VEE have argued against the HCV capsid preferentially 
binding the IRES and interpret the reduced translation a consequence of 
downstream RNA structures, potentially SLV and SLVI. Increasing the 
length of capsid gene was shown to have a positive effect on replication of 
an HCV-poliovirus chimeric virus. Chimeric viruses with the longer regions 
of capsid gene were shown to have an improved replication and virus 
producing capacity than chimeric viruses harboring shorter capsid regions. It 
is unknown if the capsid sequence is used in virus assembly and packaging. 
To date, there have been no studies on the specific RNA structures of SLV 
and SLVI in the capsid gene and how they affect IRES activity and influence 
virus replication and infectivity.  
To study the effects of the capsid protein and capsid RNA structures 
on virus replication and infection, we compared replication and virus 
infectivity of genomes with deletions in the capsid gene. Using the parent H-
JFH/Rluc, the capsid gene was deleted from amino acids 15-171 which 
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includes the sequence necessary for IRES stability but removes SLV and 
SLVI as well as the majority of the capsid protein up to the hydrophobic 
E1signal sequence (Figure 5.21). To compare the effects on the presence of 
SLV and SLVI we extended the amount of capsid gene to amino acid 57 and 
deleted downstream sequence to residue 171. We also introduced the 
mutations Stop 1,2,3,4 into the capsid sequence to investigate if the structure 
of SLV and SLVI contributed to an effect. Previously we have shown that 
the deletion of the capsid gene slightly reduced the level of translation in 
vitro and the presence of mutated structures SLV and SLVI further 
compromised translation.  
To test if the capsid protein or sequence can act in trans to influence 
replication and virus production, we placed the HCV capsid gene in a 
recombinant Venezuelan equine encephalitis (VEE) virus expression system. 
Replication of the alphavirus, VEE, occurs entirely in the cytoplasm and 
independently of its structural proteins which are encoded from a 
subgenomic RNA transcribed from the minus strand replication 
intermediate. Due to the early and abundant expression of the structural 
proteins, expression vectors were developed that replace the alphavirus 
structural genes with heterologous genes for a protein of interest. 
Duplication of the subgenomic promoter allows expression of two 
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Figure 5.21. Transcomplementation assay. A. The HCV genomes with 
deletions in the capsid gene and/ or mutations in SLV and SLVI. B. 
Expression from VEE dual subgenomic promoters occurs after 
synthesis of minus sense genome and produces capped mRNA 
transcripts. C. HCV proteins expressed from a VEE subgenomic 
promoter.  
nsP1  nsP2  nsP3  nsP4 GFP pac
nsP1  nsP2  nsP3  nsP4 HCV Capsid pac
nsP1  nsP2  nsP3  nsP4 HCV   C  E1  E2  p7  NS2 pac
mRNAs
nsP1  nsP2  nsP3  nsP4 HCV Mut Capsid pac
nsP1  nsP2  nsP3  nsP4 GFP pac
C C E1     E2    p7     NS2 NS3        NS4A  NS4B     NS5A    NS5B
C C
C C
E1     E2    p7     NS2 NS3        NS4A  NS4B     NS5A    NS5B
E1     E2    p7     NS2 NS3        NS4A  NS4B     NS5A    NS5B
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heterologous proteins from independent mRNAs. Petrakova et al. selected 
for adaptive mutations that enable replication of a dual genomic VEE 
replicon without cytopathic effect in Huh-7 cells 101. We cloned the HCV 
capsid protein (residues 1-191) behind one subgenomic promoter of the 
adapted VEE replicon. The puromycin N-acetyl transferase gene, pac, was 
also included behind a second subgenomic promoter to allow for selection of 
cell lines harboring the VEE replicon.   
 We measured replication of HCV genomes containing the capsid 
deletions of: Del 15-171, Del 57-171, and Del 57-171/Stop 1,2,3,4 in Huh-
7.5 cells. After 72H, replication was severely impaired for the Del 15-171 
genome to levels of the pol- control (Figure 5.22).  Inclusion of the capsid 
structures SLV and SLVI in the genome Del 57-171, improved replication, 
but was still 59-fold lower than wild type. Disrupting SLV and SLVI 
furthermore limited replication and levels decreased to 807 fold below that 
of wild type. This impairment of replication is more dramatic than that 
observed for translation. While genomes with Del 15-171 showed only a 
slight reduction in translation (88% of wild type), replication was obviously 
compromised (Figure 5.22). This result was unexpected, as the capsid 
protein is not required for replication of subgenomic replicons. The minimal 
capsid sequence required for IRES activity was included; however, 
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Figure 5.22. Deletions in the capsid gene and mutations in SLV and 
SLVI confer a defect in replication.  Replication was measured by 
luciferase expression at 72H post electroporation. A. Replication in 
Huh-7.5 cells B. Replication in a VEE cell line expressing the HCV 
capsid protein. Values are averaged measurements from two 
electroporations of two independent preparations of RNAs each plated 
into two wells. The fold difference of luciferase levels below wild type 
is indicated above each bar. 








































































































































relocating downstream capsid sequence in closer proximity to the IRES may 
have affected as yet undefined replication elements in the 5’NTR. The 
presence of the capsid sequence containing SLV and SLVI was able to 
replicate more efficiently than the Del 15-171 genome despite showing a 
more defect in translation. Again it is surprising that replication was 
impaired, as the capsid gene was not believed to participate in replication. 
The reduced replication in the presence of the Stop 1,2,3,4 silent mutations 
indicate that it is the RNA structure and not protein that are affecting HCV 
replication. However, the genome Del 57-171 showed a significant decrease 
in replication ability, which might be due to capsid protein or additional 
RNA elements in the capsid gene. 
To determine if the capsid protein can restore the replication defect 
found in the deletion genomes, we established an Huh-7.5 cell line selected 
to harbor the VEE replicon expressing the capsid protein. We generated the 
cell line using a VEE replicon with the pac gene and the HCV capsid gene 
behind two subgenomic promoters. After the selection process, notable cell 
death was found in cells transfected with the VEE replicon containing the 
pac and HCV capsid gene. Cells transfected and selected for a VEE replicon 
expressing the pac gene and gene for GFP did not undergo such dramatic 
cell death and cytopathic effect. This indicates that over expression of the 
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HCV capsid conveys toxic effects on Huh-7.5 cells. We confirmed that the 
HCV capsid protein was expressed and was the appropriate size by 
immunofluorescence and western blot analysis (data not shown). At 72H 
post electroporation, replication levels of the parent construct, H-JFH/Rluc 
in the Huh-7.5-VEErepC cell line was found to be several logs below 
replication levels in Huh-7.5 cells, possibly due to adaptations in the cellular 
environment allowing replication of the VEE replicon or perhaps due to a 
down regulation of replication in the presence of large amounts of capsid 
protein.  Expression of capsid protein in trans did not restore replication for 
the genomes harboring deletions in the capsid gene. The Del 15-171 genome 
again was severely debilitated for replication and showed no benefit from 
the capsid expressed in the VEErepC cell line (Figure 5.23). As observed in 
the Huh-7.5 cells, replication was depressed for the Del 57-171 and Del 57-
171/Stop 1,2,3,4 genomes in the Huh-7.5-VEErepC cell lines. Again, the 
silent mutations in SLV and SLVI contributed to a further reduction in 
replication even in the presence of capsid protein in trans.  
Given the altered state of the Huh-7.5 cell selected with the VEErepC 
replicon and the reduced level of replication detected even in the parental 
genome, we decided to test for capsid complementation by delivering the 
HCV genome and VEE replicon simultaneously. We combined 1 µg of in 
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Figure 5.23. Coelectroporation of VEE replicon expressing HCV capsid 
and 15 amino acids of E1 can slightly improve replication of HCV 
genomes harboring deletions in the capsid gene. Replication is measure 
by luciferase expression at 72H post electroporation for two RNAs plated 
in duplicate wells. Averages are shown. 





































































































































vitro transcribed RNA for a VEE replicon expressing the capsid protein and 
the first 15 amino acids of E1 with 2 µg of HCV genomic RNA and 
coelectroporated RNAs into Huh-7.5 cells. To control for replication effects 
contributed by the VEE replicon, we included a VEE replicon expressing 
GFP instead of the capsid protein. Replication was measured by luciferase 
expression 72H post electroporation. Replication in the presence of a VEE 
replicon either expressing the capsid protein or GFP, resulted in a reduction 
of the wild type HCV genome to levels 33% and 29% as compared to 
replication of HCV alone (Figure 5.23). The genomes Del 15-171 and Del 
57-171 showed impaired levels of replication as previously observed; 
however replication was improved in the presence of expression of the 
capsid protein by the VEE replicon. For the Del 57-171 genome, a 200% 
increase in luciferase signal was observed in the presence of capsid protein. 
Replication of the Del 15-171 genome improved 277% with the capsid 
protein expressed by the VEE replicon, although the overall replication 
levels were very low. As compared to levels with the VEErepGFP, the wild 
type genome showed slightly improved replication by 113% when the capsid 
protein was provided in trans. This result indicates that the capsid protein 
acted in a stimulatory manner to improve HCV replication.  
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We next asked whether providing the capsid protein in trans could 
complement virus production by HCV genomes with the capsid gene 
deleted. After 72H post electroporation, media was collected and transferred 
onto naïve Huh-7.5 cell or the Huh-7.5 cell line containing the VEErepC 
replicon. At 48H, we measured luciferase to indicate infection, translation, 
and replication of packaged RNA produced from cells coelectroporated with 
the VEE replicon expressing the capsid protein or GFP and HCV genomes 
with the capsid protein removed. The Huh-7.5 VEErepC cell line was 
included to determine if infection, translation or replication is affected when 
the capsid protein is already abundantly present in the cell. None of the HCV 
genomes with deletions in the capsid gene could be trans complemented for 
virus infectivity (Figure 5.24). No virus infectivity was detected in either 
Huh-7.5 or the Huh-7.5 VEErepC cell line. The lack of detectable virus 
infectivity could be due to the inability of the capsid protein to package 
HCV RNA in trans or simply reflect the low level of virus replication in 
both the virus producer cells and the acceptor cells. 
We did discover that the capsid protein expressed in trans can 
increase virus infectivity of the replication uncompromised genome, H-JFH/ 
Rluc. The parental genome, H-JFH/ Rluc was able to release virus and infect 
both Huh-7.5 cells and the Huh-7.5-VEErepC cell line, although infection of 
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Figure 5.24. Coelectroporation of VEE replicon expressing HCV 
capsid and 15 amino acids of E1 increases virus infectivity in A. 
naive Huh-7.5 cells and in B. a Huh-7.5 cell line selected to 
harbor the VEE replicon expressing HCV capsid protein. 
Infectivity is measure by luciferase expression 48H post infection.
















































































































































































































































































the latter was reduced by 63% (Figure 5.24). Cells originally cotransfected 
with the wild type genome and VEErepGFP RNA could also produce virus 
that infected both cell lines, and similarly was reduced by 60% in the Huh-
7.5-VEErepC receptor cells. Infectivity of Huh-7.5 cells was 81% of that 
observed from cells transfected with the wild type RNA alone and may be a 
consequence of the lower amount of accumulated RNA in the producer cells 
due to the lower replication level (29% of wild type). An increase in 
infectivity was detected in both receiving cell lines when infected with virus 
produced from the cotransfection of wild type HCV RNA and VEErepC 
RNA. Cells harboring both wild type HCV RNA and the VEE replicon 
expressing HCV capsid produced 211% more virus infectivity in Huh-7.5 
cells than cells expressing HCV RNA alone. An increase of 168% over wild 
type alone was also measured in the VEErepC infected cells. This increase 
in infectivity is a direct result from an increase in the amount of capsid 
protein provided in trans in the virus producing cells. Replication levels of 
HCV RNA in the presence of VEE-expressed HCV capsid protein were 
reduced to 33% of HCV RNA replication alone. This reduced replication 
level is comparable to the level measured for HCV RNA replicating with 
VEE expressed GFP, yet infectivity was below that of wild type. An 
increase in infectivity of the VEErepC receiving cells was only observed for 
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virus produced in the presence of excess capsid, indicating no benefit from 
the capsid protein in the receiving cells.  
 
Translation and replication kinetics of HCV in the presence of HCV 
structural proteins expressed in trans.  
 Previous studies describing reduced translation in the presence of the 
capsid gene or protein were conducted using in vitro translation assays or 
transient expression systems in cell culture in the absence of a replication 
competent HCV genome. We have found the capsid protein to actually 
stimulate replication for both wild type and genomes harboring deletions in 
the capsid gene when expressed in trans. In addition, cells expressing the 
capsid protein from a VEE replicon increased virus infectivity from cells 
transfected with the replication competent, wild type genome. To further 
define the enhanced effect by the capsid protein, we measured translation 
and replication of HCV genomes containing deletions in the capsid gene 
(Del 15-171, Del 57-171, and Del 57-171/ Stop 1,2,3,4) in the H-JFH/ Rluc 
parent when cotransfected with VEE replicons encoding the capsid protein, 
structural proteins capsid-NS2, or a GFP control. Because the VEE replicon 
generates an independent mRNA transcript from each of its subgenomic 
promoters, the RNA sequence of the capsid gene is expressed in great 
246
abundance in trans. Since we have shown the capsid structures of SLV and 
SLVI affect HCV replication in cis, we wanted to determine if the RNA 
structures of the capsid gene or disrupted RNA structures contribute an 
effect in trans. We, therefore, introduced the silent mutations Stop 1,2,3,4 
into the VEErepC replicon.  
 We coelectroporated 3µg of VEE replicon RNA with 1 µg of HCV 
RNA, both generated by in vitro transcription, into Huh-7.5 cells and 
measured luciferase expression over time (Figure 5.25). Due to cell toxicity 
associated with expression of the VEE replicons in Huh-7.5 cells, we 
normalized Renilla luciferase levels to cellular ATP activity indicating cell 
viability. At 2H post electroporation, a difference was observed in 
translation between HCV genomes with deletions in the capsid gene (Figure 
5.25). This difference did not significantly vary with trans expression by the 
VEE replicon. The genome Del 15-171 was, on average, 48% of wild type 
and below the level of Del 57-171, which was reduced to 78% of wild type 
(Figure 5.25). The reduced translation of Del 15-171 is not consistent with 
translation measured in the in vitro translation assay showing only a slight 
inhibition of 88%, but does mirror the repeated replication defect observed 
for this genome. The reduced level of translation by genome Del 57-171/ 
Stop 1,2,3,4 (37% of wild type) is very consistent; again demonstrating a 
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Figure 5.25. (Next page). Transcomplementation of HCV 
genomes containing deletions in the capsid gene and/ or 
mutations in the RNA structures for replication over time. 
Coelectroporation of VEE replicon expressing HCV capsid, 
HCV capsid with Stop 1,2,3,4, HCV capsid to NS2, GFP, or no 
complement. Translation and replication is measured by 
luciferase expression normalized to cellular ATP activity. 
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Replication Huh7.5 cells G19y













































































































































































































































































































































functional significance of SLV and SLVI. The pol- genome displayed 
especially low levels of luciferase expression. Although each transfection 
was performed using two RNA preparations and luciferase measured for two 
independent wells for each combination, the low levels of pol- indicate a 
technical difficulty with these RNA preparations.  
By 8H, all HCV genomes had reached similar levels of luciferase 
expression (Figure 5.25) indicating the initial differences noted for 
translation was not due to variations in transfection. Notably, the Del 15-171 
genome peaked to levels within 0.5% difference of the wild type genome, 
and the genomes of Del 57-171 with and without mutations for SLV and 
SLVI were within a 1.6% difference. All combinations expressed luciferase 
within 38% of each other.  
 Replication differences became distinct by 24H. For the wild type 
genome, replication with any VEE replicon decreased luciferase expression, 
but a significant inhibition was caused by the VEErepC replicons, with and 
without RNA mutations (Figure 5.25). For the Del 15-171 genome, a 
marked improvement, above wild type, was found in the presence of C-NS2. 
Trans expression of the structural proteins also improved replication for the 
Del 57-171 and Del 57-171/ Stop 1,2,3,4 genomes. Replicon expression of 
the capsid protein alone hindered replication of all HCV genomes.  
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For the wild type HCV genome, replication differences became less 
apparent in the presence of all VEE replicons, yet remained one log below 
replication alone at 48H. Expression of the C-NS2 proteins led to an increase 
in replication by 153% above replication with expression of the capsid alone 
or GFP by the VEE replicon. A similar pattern was measured for the HCV 
genomes containing deletions in the capsid gene. Replication was 
suppressed when occurring with the capsid protein expressed in trans, yet an 
increase was observed for all HCV genomes when the C-NS2 proteins were 
present. For Del 15-171, expression of C-NS2 led to enhanced replication of 
164% above levels measured for replication in the presence of GFP. HCV 
genomes Del 57-171 and Del 57-171/ Stop 1,2,3,4 improved replication by 
129% and 147% when replicating with C-NS2 as opposed to GFP.  
 In this study, we monitored translation and replication of HCV 
genomes harboring deletions in the capsid gene and compared the ability of 
the capsid protein or the capsid protein with structural proteins to influence 
replication in trans. A clear translation defect of input RNA was detected at 
2H for genomes with deletions in the capsid gene and was more pronounced 
when the RNA structures of SLV and SLVI were disrupted. We did not find 
a significance difference in translation when the capsid protein was 
expressed, alone or with C-NS2, in either the wild type or capsid deletion 
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genomes indicating the capsid protein did not influence translation in trans. 
Since luciferase levels for all HCV genomes reached similar levels by 8H, 
the initial differences in translation were not lethal, but a compromise in the 
efficiency of an early event in translation or RNA localization to the host 
cell’s translation machinery. As replication accelerated for the wild type 
genome, a lag was observed for genomes with the capsid deletions. We 
detected additional repression in the presence of the capsid protein in trans 
for all HCV genomes. The capsid protein suppressed luciferase activity 
when expressed by both VEErepC and VEErepC/Stop 1,2,3,4 indicating no 
effect in trans by RNA structures of the capsid gene. However, HCV 
replication in the presence of the capsid protein in the context of E1-NS2 
was significantly more efficient for all HCV genomes. Either the capsid 
protein could not negatively interfere when expressed with the downstream 
structural proteins or E1-NS2 can positively influence HCV replication in 
trans. Expression of the C-NS2 proteins in trans improved luciferase 
activity to or above wild type levels for Del 15-171, Del 57-171, and Del 57-
171/ Stop 1,2,3,4. While expression of the capsid protein alone continued to 
suppress HCV replication and/ or translation, the presence of C-NS2 
significantly increased HCV activity.  
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Transcomplementation of point mutations in the capsid gene with the 
structural proteins can increase virus infectivity.  
 HCV genomes with deletions in the capsid were unable to be trans 
complemented for virus infectivity, probably a consequence of the 
significant reduced replication. To determine if the HCV structural proteins 
could trans complement virus infectivity, we tested HCV genomes harboring 
point mutations that convey no or little compromise in replication. We chose 
mutations previously generated to study the RNA structure of SLVI and 
their effects on HCV replication (Chapter 4) in the context of the H-JFH/ 
Rluc genome. The genome Base Right contains three point mutations that 
would disrupt the basal stem and shows a modest replication defect. The 
Open 3,4 mutations convey a more severe effect on replication and are 
predicted to disrupt the apical stem. The Mid Right Silent, Mid Right, and 
Mid Left mutation sets disrupt the middle stem region, while the genome 
with Mid Right/ Left mutations attempts to restore base pairing of the 
middle region. The Mut Loop SLVI introduces three base changes at in the 
loop of SLVI. Some of the mutations changed the amino acid sequence of 
the capsid protein, and the residue substitution is listed next to the mutant 
genome. Therefore, we compared replication in the presence of the VEE 
replicon expressing the C-NS2 structural proteins, VEErepC-NS2, and a 
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VEE replicon encoding GFP as a control, VEErepGFP to determine if the 
effect on replication was due to the amino acid difference or the altered 
RNA structure and if replication could be influenced in trans.  
 To reduce the toxicity conveyed by the VEE replicon, we 
coelectroporated a lower amount of VEE replicon RNA, 0.5 ug, with 2 ug of 
HCV RNA. At 48H post electroporation, we again observed a reduced 
ability of all HCV genomes to replicate in the presence of the VEE replicon 
(Figure 5.26). The genomes with mutations for Open 3,4 and Mid Right 
Silent showed the most pronounced replication defect, as previously, while 
the other mutations permitted replication within one log of wild type. An 
enhancement of replication was again observed with the expression in trans 
of C-NS2. In the presence of VEErepC-NS2, genomes with mutations for 
Open 3,4, Mid Left and Mid Right/Left showed an increase in luciferase 
activity 145% above levels measured for VEErepGFP (Figure 5.26). 
Genomes with mutations Mid Right Silent and Mid Right improved 
replication by 115% with the expression of C-NS2 as opposed to GFP. The 
increase in activity as a result of C-NS2 expression in trans did not correlate 
with a change in the amino acids of the capsid protein from the HCV 
genome.  
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Figure 5.26. Transcomplementation of HCV genomes containing point 
mutations in SLVI and amino acid changes in the capsid protein. A. 
Replication and C. virus infectivity are measured by luciferase at 48H. B. 
The percent of luciferase activity of activity measured when cotransfected 
with a GFP control. D. The percent of luciferase activity of activity when 




























































































































































































































































































































































































































































 We measured the ability of C-NS2 to trans complement virus 
infectivity of the mutant HCV genomes by incubating naïve Huh-7.5 cells 
with media harvested from transfected cells after 48H. After 48H incubation, 
the wild type genome produced the highest level of infectivity (Figure 5.26). 
Coexpression of the wild type genome with C-NS2 led to a moderate 
increase of virus infectivity, 140% of the infectivity produced when 
coexpressed with GFP (Figure 5.26). The Open 3,4 genome failed to 
establish an infection and could not be trans complemented, potentially a 
result of the low replication capacity of this genome. Despite modest levels 
of replication, the Mid Right genome could launch an infection, yet without 
any benefit when coexpressed with C-NS2. We detected a dramatic increase 
in infectivity for the genomes Base Right and Mid Right/ Left when both 
replicated in presence of trans expressed C-NS2. In the presence of 
VEErepC-NS2, the genome Base Right did not show an increase in 
replication; however, virus infectivity was significantly increased, to over 
600% of levels when replicating with C-NS2 versus GFP. Replication of the 
genome Mid Right/ Left was complemented by C-NS2 with a 150% increase 
over GFP, and yet we detected the largest improvement in infectivity by 
coexpression of this genome with C-NS2 in the virus producing cell. 
Replication of Mid Right/Left with VEErepC-NS2 resulted in an >2000% 
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increase in virus infectivity as compared to cells replicating the genome 
alone or with GFP. Both genomes Base Right and Mid Right/ Left harbor 
amino acid changes in their capsid proteins. The ability of both of these 
genomes to be trans complemented with the wild type capsid and structural 
proteins indicates the reduced level of infectivity was due to the amino acid 
mutation present in the mutant genomes. The genome Mid Left and genome 
Mid Right also harbor amino acid changes, L37F and A48G respectfully, in 
their capsid protein. Both show an increase in virus infectivity when 
replication and virus production occurred in the presence of replicon 
expressed C-NS2. The genome Mid Right/ Left contains both L37F and 
A48G mutations in the capsid protein and is the genome with the highest 
success of transcomplementation by authentic C-NS2.  
 
Mutations alter translation and replication at the single cell level. 
  We have examined the effects of mutations in SLVI by measuring the 
replication capacity at a population level. Replication was launched by 
electroporating equal amounts of HCV RNA into identical number of Huh-
7.5 cells; however the level of replication from HCV genomes containing 
mutations in SLVI was consistently found to be lower at early and late times 
after transfection. It was unclear if the lower level of replication was due to 
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fewer cells capable of replicating the mutant HCV genome or if replication 
was occurring at a reduced level in the population as a whole. Visualizing 
individual HCV positive cells by immunohistochemistry (IHC) and flow 
cytometry are routine assays used to quantitate differences between cells, but 
may not have the sensitivity to measure low levels of HCV antigen. After 
two days post electroporation of the mutant HCV RNA, it is apparent that, 
compared to the wild type, fewer cells are positive for HCV antigen by IHC 
(Figure 5.27). The presence of darker and light shades of antigen staining 
indicates variation of HCV protein expression in the population, but it is 
difficult to quantitate the degree of difference. Flow cytometry can measure 
a range of positive signal for individual cells, over a background of 
nonspecific immunoglobulin staining. Transfection with a wild type genome 
leads to a 70% positive population of Huh-7.5 cells (Figure 5.27). The wild 
type genome produces a distinct population of positive cells with a narrow 
range of antigen expression level. Analysis of the histogram for cells 
transfected with a SLVI mutant HCV RNA shows fewer positive cells and 
weaker antigen expression, indicated by a shoulder of positive cells near the 
background of nonspecific IgG2a controls. Flow cytometry of Huh-7.5 cell 
lines selectively harboring HCV replicons and bicistronic genomes 
expressing a drug selectable maker where, by definition, all cells should be 
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Figure 5.27. Fewer transfected Huh-7.5 cells with mutant 
genome are positive for HCV replication. A. IHC of NS5A 
positive Huh-7.5 cells after 2 days post electroporation. B. 
Flow cytometry of NS5A positive Huh-7.5 cells
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positive for HCV antigen, only yield a 50-70% positive population. This 
demonstrates the low level of sensitivity offered by flow cytometry to 
measure HCV protein expression. Both IHC and flow cytometry require a 
sufficient level of antigen expression for analysis, preventing early 
measurements of translation and replication differences. 
 Using a luciferase reporter, with high sensitivity and wide dynamic 
range, early differences of translation and replication can be monitored. We 
compared a wild type, pol-, and genome harboring the Stop 1,2,3,4 
mutations in SLV and SLVI in the parent genome of H-JFH/ Rluc. Huh-7.5 
cells were electroporated with HCV RNA and serially diluted with multiple 
replicates to allow comparisons of HCV activity to a single cell level and 
evaluate the heterogeneity of the population. We hypothesized that if the 
entire cell population could replicate the mutant HCV, yet at a low level, the 
luciferase signal would decline with the number of cells in a linear 
relationship. If the population were homogenous with respect to HCV 
replication, no significant differences between replicates at each dilution 
would be observed. If only a minor population of cells was capable of 
replicating the mutant genome, the luciferase signal would abruptly reach 
the background level as the small, positive cell population was diluted. 
Differences among the replicates would be apparent at the end point 
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dilution, as some wells received this minor population of cells capable of 
mutant replication while other did not.  
In a master plate, electroporated cells were diluted two fold and 8 
wells of a 96 well plate seeded at a beginning concentration of 40,000 cells 
per well. To ensure positive luciferase activity can be detected at a single 
cell at later time points, additional dilutions were performed for cells 
transfected with the wild type genome, seeding with starting dilutions of 
4,000 cells, 800 cells, and 400 cells per well. Cells electroporated with no 
RNA were diluted and seeded in the reverse order so that each well 
contained the same number of total cells. 
At 4H a linear association of luciferase expression and number of 
cells was observed for the wild type, mutant, and pol- genomes indicating 
equivalent levels of transfection and translation of the input RNA (Figure 
5.28). For the mutant and pol- genomes, luciferase activity could be detected 
to the last dilution of 39 cells/well. The wild type genome showed slightly 
less luciferase activity in wells seeded with fewer cells and the final positive 
detection of translation occurred at 125 cells/well. The theoretical line shows 
a two-fold dilution starting at the 40,000 value and is included as an 
orientation guide. By 12H, luciferase levels fell one log as input RNA and 
luciferase protein degrades. The reduction of luciferase activity is equivalent 
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for all three HCV genomes as well as the final positive signal at 313 
cells/well (Figure 5.28). At 24H, replication increased for the wild type 
genome. Dilutions of cells previously below the limit of detection for 
luciferase activity are now positive for replication. The mutant genome 
shows a reduced level of luciferase expression in both the cells positive for 
luciferase expression and in the number of positive cells. Luciferase activity 
indicting cells replicating the mutant RNA is positive for only 5000 
transfected cells/well while the wild type RNA could replicate with a 
minimum of 125 cells (Figure 5.28). This evidence suggests that despite 
being able to launch translation with equivalent amounts of HCV RNA, only 
a small proportion of cells were able to establish replication of a mutant 
genome. At the end point of dilution, the lower luciferase activity observed 
for the mutant genome indicates that replication was attenuated.  
At 72H, the wild type genome increased in luciferase expression. In 
all replicates of the first three wells seeded with a higher number of 
transfected cells, an additional increase is observed in luciferase expression. 
This could be due to a cooperative effect for HCV replication exuded from 
cells replicating at a particular level. Cells harboring the mutant genome also 
showed an increase in luciferase activity, but an average 2 logs below wild 
type. Where replication could be detected to 8 transfected cells in the wild 
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Figure 5.28. Translation and replication kinetics as measured in an 
end point dilution assay. Luciferase activity was measured in 8 
replicate wells for dilutions of transfected cells electroporated with 
wild type, mutant SLV and SVLI, or pol- HCV genomes over time. 
A theoretical line is provided for orientation. 
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type, the last point of detecting a positive signal for cells harboring the 
mutant genome is 313 cells. At this time point, the increase in number of 
positive cells could be due to virus spread increasing the amount of 
luciferase expression in the population.  
Comparing the number of cells capable of HCV replication over time, 
it is observed that more transfected cells are required to launch replication of 
a genome harboring mutations in SLV and SLVI. The end point was 
determined by the dilution having 50% of the wells positive for luciferase 
activity. Averaging the luciferase activity for the positive wells determines 
the RLU at the end point dilution. At 24H, the wild type genome required 
125 cells for an average of 2005 RLU (Figure 5.29). The mutant genome 
required 5000 transfected cells for an average luciferase signal of 916 RLU. 
The average background luciferase was 700 RLU. At 72H, the wild type 
genome required only 50 transfected cells to express an average luciferase 
unit of 5714 RLU. The mutant genome required 5000 transfected cells to 
express an average luciferase unit of 2316 RLU.  
This result implies either that a particular type or state of host cell is 
required to replicate a mutant HCV RNA or the mutant genome establishes 
replication very infrequently. For a cell to harbor HCV replication at 72H, 
the mutant genome required 100 times more transfected cells than the wild 
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Figure 5.29. Replication of the mutant HCV genome occurs less 
efficiently and in fewer transfected cells. A. Luciferase activity at the 
end point dilution. B. The number of transfected cells required to give 
a positive HCV signal at the end point dilution.   
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type. Either a particular host cell capable of mutant HCV replication is 
present in 1% of the population or mutant replication is launched 100 times 
less frequently than the wild type. The contribution of the host cell to mutant 
HCV replication is unknown, but whatever the function, it does not 
completely restore replication of the mutant RNA to wild type levels, as the 
average luciferase expression is reduced by half.  
 
The functions of SLV and SLVI are position-dependent. 
We have shown mutations in the RNA structures of SLV and SLVI 
result in a severe reduction in replication. These mutations also contribute to 
lower efficiency of translation as measured in transfection of Huh-7.5 cells 
and using in vitro translation assays of rabbit reticulocyte and Huh-7 cell 
extracts. These RNA structures are located in close proximity to the IRES 
and 5’NTR replication elements, and therefore we wanted to determine if the 
action of SLV and SLVI was dependent on the location within the genome. 
Previous translation and replication studies have compared the effects of 
mutations on SLVI and SLVI in the context of a monocistronic genome. To 
test the role of these structures outside of the context of the 5’NTR, we used 
a bicistronic genome of the genotype 1a H77 sequence with four adaptive 
mutations: Q1067R, K1691R, K2040R, S2204I. This bicistronic genome, H-
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neo/RRRI, contains the H77 5’NTR and the first 14 amino acids of the 
capsid gene fused to the neomycin phosphotransferase gene followed by the 
encephalomyocarditis virus (EMCV) IRES which drives translation of the 
complete H77 genome, capsid-NS5B. The mutations of Stop 1,2,3,4 were 
introduced into the capsid gene positioned behind the EMCV IRES. In vitro 
transcribed RNA was electroporated into Huh-7.5 cells and replication 
measured by Real Time qRT-PCR and selection of G418 resistant colonies. 
We found no defect in the ability of the H-neo/RRRI Stop 1,2,3,4 genome to 
replicate (Figure 5.30). Equivalent numbers of G418-resistant colonies were 
selected for both the parental genome and the genome with Stop 1,2,3,4 
(Figure 5.31). In addition, HCV RNA levels in transfected Huh-7.5 cells 
were slightly above levels of the parent genome at time points indicating 
active replication (Figure 5.30). These results demonstrate that the mutations 
of Stop 1,2,3,4 do not convey a replication defect when located apart from 
the 5’NTR and translation is dependent on the EMVC IRES.  
 
Independent expression of the replicase restores the replication for 
genomes with mutant SLVI. 
 The mutations in SLV and SLVI had no effect on replication when 
expression of the HCV polyprotein was driven by a heterologous IRES. We 
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Figure 5.30. Mutations in SLV and SLVI do not confer a 
replication defect when positioned behind the EMCV IRES in a 
bicistronic genome. A. Diagram of the bicistronic genome B. 
HCV RNA levels measured by Real Time qRT-PCR and 
normalized to cellular GADPH levels. 
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Figure 5.31. Mutations in SLV and SLVI do not 
reduce replication when positioned behind the 
EMCV IRES. G418 resistant colonies indicating 
HCV replication. The number of transfected cells is 





next wanted to examine if the mutations for SLV and SLVI could alter 
replication when located in their original position, but separate any effects of 
translation by expressing the replicase proteins from a heterologous IRES. 
We used a bicistronic genome consisting of the H77 sequence from the 
5’NTR thru NS2 followed by the EMCV IRES and NS3-3’NTR sequence 
from JFH-1. We introduced the mutation sets of Stop 3,4 and Open 3,4 into 
this parental genome, H-EI-JFH. Both mutation groups reduced replication 
to 2% of wild type in the context of the monocistronic genomes of genotype 
1a, H/L+I and in the genotype 1a/2a chimera, H-JFH/ Rluc. Replication was 
measured by Real Time qRT-PCR of HCV RNA over time. We 
distinguished between replicating HCV RNA and input RNA by comparing 
RNA levels with that of the pol- control. Given the robust replication ability 
of the JFH replicase, differences become noticeable after 20H, where the 
pol- RNA levels begin to decline (Figure 5.32). HCV RNA was quantiated 
and normalized as a percent of RNA at 4H to control for any differences in 
transfection. RNA levels for the parent genome began to rise after 14H and 
increased ~ 2 logs by 72H. RNA levels for the Stop 3,4 and Open 3,4 
bicistronic genomes did not initially increase and were at least 50% below 
wild type. After 30H, RNA levels increased, and finally approaching wild 
type levels at 72H. The restoration of replication indicates that the mutations 
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Figure 5.32. Replication is not reduced with mutations in SLV and 
SLVI when translation of the replicase is independent of the HCV 
IRES. A. Diagram of the bicistronic HCV genomes separating the 
replicase from the HCV IRES. B. HCV RNA measured by Real 
Time qRT-PCR. Values are normalized to the RNA level at 4H to 
control for transfection differences. C. Percent differences than 
wild type.
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of SLVI are most likely acting at the level of translation leading to an 
insufficient amount of replicase expression. By separating the expression of 
the replicase proteins from the HCV IRES and downstream structures SLV 
and SLVI, replication could proceed with only a slight delay. This delay in 
replication detected between 20H and 52H could be a consequence of 
additional functions of the RNA structures in replication, such as affecting 
RNA association with the replicase or influencing the minus strand 
promoter. Although the structural proteins of C-NS2 are not required for 
replicase activity, a reduction in their expression by mutations in SLVI could 
also possibly reduce the efficiency of the replicase. By independently 
translating the replicase, the mutations in SLVI have little effect and 
replication can proceed to almost wild type levels.   
 
Discussion. 
Translation is compromised by mutations in SLV and SLVI. 
 The capsid gene was previously thought to be unnecessary for HCV 
replication, yet we have shown mutations in RNA structures of SLV and 
SLVI contribute to a replication defect. Given the close proximity of the 
RNA structures to the HCV IRES, we tested if mutations in SLV and SLVI 
affected translation and thus led to reduced replication. Using a luciferase 
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reporter embedded within the NS5A gene of the polyprotein, we found that 
mutation of SLV and SLVI caused a reduction in translation, either in 
electroporated or lipid-mediated transfected Huh-7.5 cells. Since the 
luciferase insertion at NS5A does not allow replication, we were able to 
measure translation of only input HCV RNA.  
Translation was reduced 2 -4 fold in the presence of mutations 
previously shown to confer a severe replication defect, Stop 3,4 and Stop 
1,2,3,4 while mutations having no effect on replication, Stop 1,2, did not 
reduce translation. Despite the lower level of luciferase expression found at 
the early time points in the mutant genomes, translation could occur and 
luciferase expression eventually reached wild type levels. This lower 
efficiency of translation was also detected in cell free systems, where 
translation was launched by mutant genomes, but to levels 2-3 fold below 
wild type. The differences in translation were not due to preferential 
degradation of the mutant RNA.  
Translation of the HCV genomes containing mutations in SLV and 
SLVI was also assessed using cell lysates derived from Huh-7 and 
specialized Huh-7.5 cells. Both types of cell lysates were able to initially 
translate the mutant HCV RNA to similar levels of wild type, but mutant 
luciferase levels failed to reach wild type activity. We found that translation 
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extracts from Huh-7.5 cells had a reduced capacity to translate even wild 
type genomes. Combining extracts from Huh-7 and Huh-7.5 cells, 
translation remained below levels found for Huh-7 cell extracts indicating an 
inhibitory factor present in the Huh-7.5 cells. The reduced capacity for Huh-
7.5 cell extracts to conduct translation is in contrast to the enhanced ability 
of these cells to replicate HCV. This lower level of translation, although in a 
cell free system, may indicate a state where HCV replication benefits from 
less competition of the host cell translation machinery.  
The secondary structure of the HCV IRES has been characterized and 
the required cofactors and contacts points defined using the minimal 
sequence containing nucleotides 40-372 39. The downstream sequence of the 
capsid gene including SLV and SLVI was not included in these studies and 
is also absent in studies of the assembly of the intiation complex. We tested 
mutations in the IRES used to define the domains responsible for binding the 
initiation complex of 40S, ternary complex of eIF2-Met-tRNAiMet-GTP, and 
60S in our translation and replication assays. We found the mutations of 
G266-268A and IIId-delE to contribute to more severe defect in both 
translation and replication than that observed for mutations in SLVI. The 
mutant G266-268A is unable to efficiently form the 40S complex and an 
early reduction in translation and severe replication defect was observed. In 
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contrast, the mutant IIId-delE was reported to have high IRES activity with 
only a minimal reduction in translation. Despite being able to form the 
initiation complex, translation and replication were dramatically reduced. 
These results indicate that SLVI is not required for translation initiation, nor 
does it restrict assembly of the initiation complex, but may subtly influence 
the efficiency of intiation or affect subsequent steps in elongation or 
termination.  
Translation of SLV and SLVI mutant genomes was equivalently 
reduced, 2- 4 fold relative to wild type, in rabbit reticulocyte, Huh-7 and 
Huh-7.5 extracts, and in transfected Huh-7.5 cells. Translation was initiated 
in the mutant genomes, but proceeded with lower efficiency.  
 
The potential long range RNA-RNA interaction with the 5’NTR and base 
of SLVI does not affect translation.  
 The region between SLI and SLII of the 5’NTR is essential for HCV 
replication and is not required for IRES activity, but has been the focus of 
several research groups studying translation. Kim et al reported a 
complementary sequence of 12 nucleotides between the 5’NTR and the base 
of SLVI in the capsid gene that results in a decrease in translation 64. 
Mutations in either the 5’NTR or capsid gene designed to disrupt this 
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interaction led to an increase in translation of a bicistronic reporter. The 
capsid sequence thought to participate in this interaction involves the left 
side of the base of SLVI. In our studies, we tested the same mutations in the 
5’NTR and base of SLVI in translation and replication assays. We found 
mutations designed to interrupt the 5’NTR and capsid gene interaction 
actually slightly impaired translation. We used similar translation conditions 
as Kim et al., but included the sequence for the competing right side of SLVI 
in our analysis. In this context, we found the structure of SLVI to influence 
translation and not an interaction with the 5’NTR. Indeed, mutations in the 
basal region of SLVI impaired translation and replication of full length HCV 
genomes, and both activities were improved in genomes harboring the 
compensatory mutations restoring the base pairing of SLVI.  
 Previous reports suggested that differences between genotypes in the 
unstructured region of the 5’NTR contribute to a discrepancy in translation 
55.  We compared the 5’NTR sequences between genotype 1a, 1b and 2a and 
found no effect on translation or replication. In fact a genotype 1a/2a 
chimera genome that contains the 5’NTR from JFH-1, the capsid through 
NS2 genes from H77 and replicase to the 3’NTR from JFH-1 can replicate 
equally well as the H-JFH chimera where the entire 5’NTR is from the H77 
sequence (data not shown). This is in contrast to a recent report of a 
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genotype 1b/ 2a chimera displaying genotype specificity between the 
replicase proteins and the 5’NTR.  
Deletions were introduced into the 5’NTR and capsid gene to 
determine if the long-range interaction between these two regions controls 
translation. Deletion of the first 40 nucleotides of the 5’NTR resulted in an 
increase in translation, previously shown to be due to the removal of SLI. 
Mutations in SLVI conferred a decrease in translation in the presence of the 
deletion in the 5’NTR indicating the influence of SLVI on translation is 
independent of the 5’NTR. Deletions in the capsid gene reduced translation, 
with a more severe reduction observed when more capsid gene was deleted. 
Despite the low levels of translation, mutations in SLVI confer an additional 
translation defect in genomes with the downstream capsid gene deleted. This 
signifies that the role of SLVI in translation does not involved downstream 
elements in the capsid gene between amino acids 57 and 171. Branch et al. 
has proposed an RNA structure in the “terminal” region of the capsid gene. 
Since this region also overlaps the signal sequence for E1, it is present in 
these deletion constructs and therefore may have an effect. A role for the 




Transcomplementation with the capsid, E1, E2, p7 and NS2 in replication 
and virus infectivity. 
 Previous studies have shown the capsid gene and/or protein to 
negatively influence translation by acting either in cis or in trans. The 
modulation of translation by the capsid protein is reported to occur by 
directly binding the IRES. We found that deletions in the capsid gene 
slightly reduce translation, but considerably impair replication. We have 
made similar observations with mutants in SLVI that convey subtle effects 
in translation, yet dramatic effects on replication. This result is in contrast to 
previous assumptions that the capsid protein did not have a role in 
replication, at least in the context of the subgenomic replicon. The impact of 
the capsid protein or sequence acting as a translation repressor on replication 
has not yet been addressed. The adenine-rich region of the capsid sequence 
has been shown to interact with a cellular protein, NSAP1, to increase 
translation, and this sequence is present in all of the mutant genomes 63. If 
the capsid protein acts, as reported, to down regulate translation, this may 
consequently stimulate replication. Expression of the capsid protein in trans 
by a VEE replicon did moderately increase replication of the genomes 
harboring deletions in the capsid gene. Furthermore, virus production was 
increased in the wild type genome when replication occurred in the presence 
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of expression in trans of the capsid protein. The genomes with deletions in 
the capsid gene could not be trans complemented for virus production  
 The effects of expressing the capsid protein and polyprotein of capsid, 
E1, E2, p7 and NS2 on translation and replication of deleted capsid genomes 
were closely analyzed in a time course. Translation of the input RNA was 
compromised for Del 15-171 and Del 57-171 harboring mutations in SLVI, 
but no specific effect from trans expression of HCV proteins from the VEE 
replicon was observed. The capsid protein expressed alone or with the HCV 
structural proteins did not modulate translation in trans as previously 
reported. The reduced translation observed for Del 57-171/ Stop 1,2,3,4 is 
consistent with the findings in the in vitro translation study. For all HCV 
genomes, the differences in translation diminished by 8H indicating the 
defect in translation was not as severe as seen in the IRES initiation mutants. 
Coexpression of the VEE replicon led to a reduction in HCV replication.  
At 24H, luciferase differences become apparent between mutant and 
wild type genomes. At this time point, wild type luciferase levels begin their 
rapid increase indicating the launch of replication and translation of nascent 
HCV RNA.  Luciferase activity was enhanced in the presence of expression 
in trans of the capsid-NS2 polyprotein; however, luciferase activity was 
suppressed by expression in trans of the capsid protein alone. Expression of 
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the capsid protein in the context of the structural proteins may coordinate the 
localization of the capsid protein in the cell. This may lead to a lower 
amount of capsid protein to act in trans on HCV translation and replication. 
Also, the structural proteins of E1-NS2 may influence translation and 
replication by acting in trans. The expression of the capsid protein alone did 
reduce luciferase expression of even the wild type genome. The capsid 
protein could be repressing translation of the nascent HCV RNA and thus 
indirectly lower RNA synthesis or act directly against a component of 
replication.  The overlapping functions make a distinction of the defect 
impossible. Initial translation of input RNA was not affected by capsid in 
trans and luciferase levels did reach wild type, but perhaps translation after 
replication involves different factors than those used in translation of the 
incoming virus RNA. 
 In our initial study, we found the capsid protein to slightly enhance 
luciferase expression at 72H. In this study, the capsid protein was found to 
suppress luciferase activity, notably at 24H, but also at 48H. The disparity 
between the studies could be due to the amount of transfected VEE RNA. 
When the capsid protein was found to enhance replication, it was expressed 
at a low ratio of VEErepC to HCV RNA, 0.5 ug to 2 ug. When the capsid 
protein was found to suppress luciferase expression, the amount of 
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transfected VEE RNA had been increased to 3 ug and cotransfected with 1 
ug of HCV RNA. It could be that a lower amount of HCV capsid protein 
results in a slight increase in translation and/or replication. When the capsid 
protein is expressed in the context of HCV structural proteins less is 
available to repress translation/ replication and therefore acts in a 
stimulatory manner. HCV RNA naturally enters the cell encapsidated with 
the structural proteins of the capsid, E1, and E2. The presence of small 
amounts of capsid protein could act as a stimulant to initial translation. As 
replication proceeds and translation continues to express more HCV 
polyproteins, an increase in the localized amount of capsid protein could act 
as a repressor for translation of nascent RNA.  
 
Transcomplementation of silent and noisy point mutations in the capsid 
gene.  
 Expression of C-NS2 in trans was found to increase luciferase 
expression of HCV genomes harboring mutations in SLVI. Genomes with 
mutations that disrupted the top stem of SLVI, but not the loop increased 
their luciferase expression in the presence of C-NS2 in trans. Some of the 
mutations were silent; some changed the amino acid of the capsid protein. 
Expression of C-NS2 was found to transcomplement virus infectivity. 
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Genomes with mutations in the capsid protein sequence showed an increase 
in virus infectivity when packaged in cells coexpressing VEErepC-NS2. The 
most dramatic complementation was found in genomes with mutations in the 
base of SLVI, Base Right, and genomes with mutations in the middle of 
SLVI. All of the successful complemented genomes contained an amino acid 
change in the capsid protein. The transcomplementation for the mutant 
genome Base Right again shows no benefit at the level of replication, yet 
almost 1 log increase in infectivity when packaged in the presence of 
exogenous C-NS2. A slight increase in infectivity is detected again for the 
wild type genome.  
The contribution of C-NS2 in virus production is unknown. We have 
detected compensatory mutations p7 and NS2 that enable virus infectivity in 
the presence of a mutant capsid protein. Two second site reversions in p7 
and NS2 increased virus infectivity for a genome with an amino acid change 
in the capsid protein indicating either a cooperative interaction or a general 
improvement of replication or virus fitness. The mechanism of 
transcomplementation by the capsid, E1, E2, p7, and NS2 proteins in virus 
infectivity is unknown. The observation that these proteins cannot act in cis 
in the presence of a mutated capsid is intriguing. It could be the mutant 
capsid protein acts as a dominant-negative in virus production, and 
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overexpression of the structural proteins can overcome this effect. It would 
be interesting to know if individual expression of E1, E2, p7 or NS2 could 
restore virus infectivity. Individual expression of the capsid protein led to an 
inhibition of replication whereas an improvement in replication was detected 
when coexpressed with the structural proteins. The difference could be due 
to localization of the capsid protein. When expressed in the context of E1-
NS2, cis-acting interactions could prevent or reduce the amount of capsid 
protein interacting with HCV replication in trans.  
 
Analysis of HCV translation and replication by end point dilution. 
 Few cells transfected with HCV RNA with mutations in SLVI are 
positive for HCV antigen expression as measured by flow cytometry and 
IHC. Measuring replication at the population level has shown mutant HCV 
to replicate 1-2% of wild type. We questioned whether the mutant HCV is 
replicating at a low level throughout the population or if a subpopulation of 
cells can efficiently replicate the mutant RNA. Transfected Huh-7.5 cells 
were serially diluted to analyze replication at the single cell level. 
Replication at each dilution was monitored in multiple wells. Two types of 
events were expected to describe the population of cells replicating the 
mutant genome. In one case, luciferase values would decline in a linear 
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association with the cell numbers if all cells in a homogenous population 
could replicate the mutant genome. Alternatively, luciferase activity would 
not be observed to steadily decline with cell number, but rapidly fall as the 
small number of cells positive for HCV replication were seeded only in the 
higher dilution wells. For cells transfected with the genome containing 
mutations in SLV and SLVI, we observed the latter situation. Translation of 
the wild type, pol-, and mutant RNA was detected in a linear relationship 
consistent with the number of cells. A difference between the HCV genomes 
was detected as replication was launched. A larger proportion of the cell 
population could replicate the wild type genome than the mutant. At 24H, 
the mutant genome required 40 times the number of cells as the wild type to 
achieve half of the average luciferase units. At the height of replication, the 
mutant genome requires 100 times the number of transfected cells to achieve 
a replication level half of wild type.  
 This result indicates there is a small population of Huh-7.5 cells 
capable of replicating the mutant genome. One explanation for this 
observation is that this population is genetically distinct and contributes to 
HCV replication by an unknown host cell factor. Another explanation is that 
the mutant HCV can only launch replication at an infrequent rate. To 
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distinguish between these two possibilities, the following experiments could 
be performed. 
To determine if there is a beneficial host factor, cells harboring mutant 
HCV replication could be isolated and “cured” of replicating HCV by 
treatment with a replication inhibitor or interferon, and retransfect the cells 
with mutant HCV RNA. If replication of the mutant RNA was near wild 
type levels, it could be concluded that a host cell factor contributes to 
replication of a HCV with disrupted SLVI. If the small population of cells is 
a result of an infrequent event allowing mutant replication to launch, then 
transfecting more mutant RNA into Huh-7.5 cells may increase the number 
of replication-success events. The infrequency of launching replication could 
be due any numerous intrinsic/extrinsic variables of the cell state such as cell 
cycle, stress, growth factors, a state of a pathway, etc. Treatment of the cells 
to a variety of stimulants may trigger more cells in the population to exhibit 
the beneficial condition. The use of a fluorescent maker in the genome 
would also allow a visual distinction between HCV positive and negative 





The role of SLVI is dependent on the position within the genome and 
mutants of SLVI act to reduce translation. 
 We have shown mutations in SLVI to subtly reduce translation and 
severely impair replication. We tested if the effects of SLVI are dependent 
on its location within the genome. No change in replication was detected in a 
bicistronic genome where mutations of SLV and SLVI were introduced into 
the capsid gene of a polyprotein located behind the EMCV IRES. This 
indicates that the mutations in SLVI affect replication when located near the 
5’NTR and behind the HCV IRES. We tested if the mutations of SLVI 
reduce replication when in their original position, but expression of the 
replicase proteins independent of the HCV IRES and any effects on 
translation from the mutant SLVI. In a bicistronic genome where the 
replicase is expressed by the EMCV IRES, we found mutations for SLVI 
impair replication slightly between 20H and 52H; however, replication could 
reach wild type levels at 72H. This indicates the mutations of SLVI 
contribute to a reduced level of translation of the polyprotein and thus 
replicase proteins. The lower expression of replicase proteins leads to a 
drastic decline in the level of replication. The reduced replication at 20H ad 
30H may be due to an influence of the mutant SLVI on an additional 
component of replication or may act to reduce expression of C-NS2, and 
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thus lower the efficiency of replication. We have shown the mutant genome 
of Open 3,4 to be enhanced by expression of C-NS2 in trans. Even though 
C-NS2 are thought not to contribute to replication, they are expressed with 
equal ratio as the replicase proteins, and our data indicate they do have a 
positive effect on replication. In summary, mutations in SLV and SLVI were 
found to slightly reduce translation, yet dramatically reduce replication. 
The replication defect contributed by mutations in SLVI was restored by 
separating expression of the replicase proteins from the HCV IRES and 
mutant SLV and SLVI. These observations indicate that mutations in SLVI 

































Chapter 6.  Discussion. 
Predictions of a multifunctional capsid gene. 
 Phylogenetic studies have shown HCV to display great diversity; 
although the variation is not evenly distributed through the HCV genome, 
comparison of sequences from all 6 genotypes shows overall nucleotide 
differences of 30% 130. Regions of conservation indicate elements 
indispensable for the virus life cycle that cannot tolerate mutation without 
fitness being compromised. The 5’NTR and 3’NTR are the most conserved 
areas of the genome as they encode essential RNA structures. Studies of the 
synonymous/ nonsynonymous mutation rate and codon usage of the 
polyprotein coding region revealed exceptional sequence conservation for 
the capsid and polymerase genes 132, 153. These genes flank the polyprotein 
and are adjacent to the NTRs. The significance of this conservation was 
demonstrated by the presence of an RNA secondary structure in the coding 
region of NS5B that acts in a long range RNA-RNA kissing interaction with 
the 3’NTR to conduct HCV replication 40, 165. The sequence of the NS5B 
coding region is thus constrained to maintain both an essential protein and 
an essential RNA structure.  
 The capsid gene also displays great sequence conservation, which has 
led to predictions that this gene sequence possesses functions in addition to 
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simply encoding the capsid protein. All 6 HCV genotypes have a substantial 
open reading frame that overlaps the amino terminus of the capsid gene and 
could encode a 9-16kDa protein 153, 161. HCV patients have been shown to 
produce antibodies and cellular immune responses to peptides from this 
alternative reading frame indicating its expression during infection 66, 153, 161. 
Using phylogenetic analysis of covariant base change, RNA secondary 
structures have also been predicted to form in this region 133, 147. These 
structures, SLV and SVI, are positioned in the amino terminus of the capsid 
and ARF gene. The requirement for, and functions of, the ARF protein and 
the SLV and SLVI RNA elements in HCV infection and replication are the 
subject of this dissertation. 
 
Is the ARF essential in an HCV infection? 
 The chimpanzee model remains the gold standard for defining the 
essential genetic elements of the HCV genome, and describing the interplay 
between virus and the immune system. We therefore decided to test if the 
ARF was required for an HCV infection and if so, how the host’s immune 
system would respond to an ARF-ablated virus. We did detect an infection 
following inoculation of an H77 genome with mutations conferring Stop 
1,2,3,4 in the ARF. The peak of circulating HCV RNA was several logs 
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lower than previous chimpanzee infections launched with the parental H77 
sequence, and the duration of the acute infection was shorter. This suggested 
an attenuated infection, and we hypothesized that the absence of an ARF 
protein might contribute to a more robust immune response. We isolated 
CD8+ and CD4+ cells from both the periphery and the liver and found in both 
compartments, only a low frequency of T cells that recognized HCV-specific 
epitopes. Since it is thought that virus infection leads to recruitment of 
immunocytes that contribute to liver damage 19, 48, the absence of an elevated 
ALT also indicated low immune activity. The absolute number of 
CD4+/CD3+, CD8+/CD3+, CD56+/CD8+ and CD56+/CD4- cell populations in 
the circulation did not change during the HCV infection indicating a 
functional immune system. However, when we mapped the HCV-specific 
CD8+ and CD4+ epitopes, we found a diverse repertoire from a range of 
peptides from E2 to NS4B. In previous studies, this level of diversity was 
correlated with clearance of the virus infection while a limited repertoire of 
one or two HCV-specific epitopes was predictive of virus persistence and 
chronic infection 88. The appearance of HCV-specific lymphocytes at the 
cellular and humoral level coincided with virus decline in the circulation.  
The launch of an infection with the Stop 1,2,3,4 genome does prove 
that the ARF is not absolutely required for virus production. A diverse 
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immune response was stimulated indicating that virus replication did occur 
but, given the low ALT and low frequency of HCV-specific T cells, the 
infection was attenuated. As we later determined in cell culture studies, the 
replication of the Stop 1,2,3,4 genome was compromised and resulted in the 
attenuation. 
 
Are the Stop 1,2,3,4 mutations positively selected? 
 In a natural infection, HCV is present in a quasispecies. Launching the 
infection with a monoclonal genome allowed us to study the fitness of the 
specific input virus RNA sequence. Within 2 weeks of the infection we 
detected a reversion that removed the Stop 3 mutation. The appearance of 
this reversion corresponded with the launch of the acute phase and was the 
reversion quickly became fixed in the population. Using a sensitive nested 
RT-PCR, we could detect the original input sequence at week 1 in the 
circulation indicating replication and therefore creation of diverse HCV 
progeny. The fact that we could not detect the input sequence after week 1 
indicates a high selective pressure for the reversion. Numerous studies have 
investigated the evolution of HCV in natural and experimental infections. 
The dynamics of selective pressures on HCV have been described for the 
hypervariable region of E2 where amino acid mutation potentially allows for 
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antibody escape, CD8+ T cell escape, and resistance to interferon therapy 20, 
23, 143. Most of these studies have concluded selection to be positive selection 
where the rate of fixation exceeds the rate of mutation. This is the case for 
the selection of the reversion at Stop 3 where a bottleneck was apparent and 
only those genomes with the reversion survived in the population. Since 
protein expression from the ARF was still blocked in this revertent, this 
indicates a positive selection for the RNA secondary structure, as opposed to 
a restoration of the ARF. During the acute infection, the F and DF proteins 
remained blocked by the downstream Stop 4. A second reversion was 
positively selected within the first mutation conveying Stop 4. This second 
reversion occurred late, at week 10, and did remove the fourth stop codon, 
allowing the DF protein to be expressed, but did not alter the capsid protein. 
A third reversion (of the second mutation within Stop 4) was subsequently 
detected, but since this occurred in the context of a revertent that could 
already express the DF protein, this is indicative of selective pressure to 





Is replication compromised by the ablated ARF or disrupted RNA 
secondary structures in cell culture?  
 HCV genomes containing the mutations for Stop 1,2,3,4 were 
severely compromised for replication in Huh-7.5 cells. The replication 
defect was mapped to the mutations for Stop 3 and 4. Alone, the mutations 
of Stop 1 and 2 had no effect on replication; however, a synergistic 
reduction of replication was observed when combined with Stop 3 and 4 
mutations. Phylogenetic analysis of covariant base changes predicted this 
region to form the RNA structure SLVI 147. The sequence of top region of 
SLVI is highly conserved; the 473A mutation of Stop 3 is only present in 2 
of 1274 HCV sequences from all 6 genotypes, while the Stop 4 mutations 
480A and 482G are completely absent. The mutations of Stop 3 and 4 
disrupt three base pair interactions in a very conserved helical stem.  
 The mutations of Stop 1,2,3,4 are silent for the capsid, but do alter the 
codon usage. Mueller et al. found that recoding the capsid gene to 
suboptimal codons in poliovirus resulted in a complete loss of virus 
production 92. The defect was due to inefficient translation and consequently 
compromised replication. Recoding only portions of the capsid gene resulted 
in virus particles with a reduced infectivity. These mutant polioviruses were, 
however, capable of launching infection and causing pathology in the 
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poliovirus mouse model, but were found to produce fewer particles. The 
authors contend that since RNA viruses exist close to the error threshold, 
creating one suboptimal step in the virus pathway can lead to a dramatic 
attenuation of the virus fitness. The mutations for Stop 4 do not introduce a 
rare codon, but in fact exchange a CGC arginine codon for a more frequently 
used AGG. The mutation for Stop 3, however, does replace a leucine codon 
for a less frequent codon. So in addition to disrupting SLVI, translation 
could be attenuated by the rare leucine codon.  
We were able to measure replication of genomes containing other 
mutations in the same location of SLVI. The Open mutations allow 
expression of both the capsid and ARF proteins. Open 3 contains a mutation 
at the same nucleotide position as Stop 3 (473) and another substitution at 
471. The Open 3 genome was reduced in replication, yet the leucine codon 
was not the rare TTA as in the Stop 3, but a more frequently used CTC. This 
argues that the defect in replication is due to disruptions in SLVI as opposed 
to slow translation induced by usage of a rare codon.  
 Mutagenesis experiments showed that replication was most severely 
affected by mutations in the top stem of SLVI, the regions of 3 and 4 
mutations. Disruptions in the base of SLVI also reduced replication, but not 
with the same severity as with the apical stem. There was an additive 
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reduction in replication when mutations at the base and the top were 
combined. This suggests that the overall structure is important for SLVI 
function.  
 
Does the replication defect in Huh-7.5 cells explain the attenuated 
infection of the mutant genome Stop 1,2,3,4? 
 Passaging Huh-7.5 cells transfected with genomes containing Stop 
1,2,3,4 and Stop 3,4 resulted in selection of reversions that led to an increase 
in replication. The reversions at Stop 3 (473G) and the first base of Stop 4 
(480C) detected in Huh-7.5 cells were the identical to the reversions found 
during the chimpanzee infection. This suggests that the replication defect 
contributed by the Stop 3 and 4 mutations have similar deleterious effects in 
vivo and in vitro. Thus, the attenuation of the chimpanzee infection was 
consistent with the replication defect observed in cell culture. Interestingly, 
the reversion of Stop 3 and 480C of Stop 4 were found to have occurred on 
independent genomes in Huh-7.5 cells. The 480C revertant became more 
frequent in the population with passage. Replication of the Stop 1,2,3 
genome was more efficient than that of Stop 1,2,4,suggesting that the Stop 4 
mutation of 480A had an impact on fitness. A combination of both of the 
reversions observed in cell culture and the third reversion of Stop 4 (482C) 
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were required to increase fitness in the chimpanzee infection; a likely 
consequence of the substantial selective pressures during a natural infection. 
We did not observed any replication effect in genomes harboring the Stop 
1,2 mutations, the genome found at the conclusion of the chimpanzee 
infection.  
 
What defect in replication is caused by mutations in SLVI? 
 We found that mutations of SLVI reduced translation in both 
transfected Huh-7.5 cells and using cell free lysates. The base of SLV is just 
13 bases downstream of the proposed 3’ boundary of the IRES (position 
375) while the base of SLVI lies 53 nucleotides downstream of the IRES. 
We compared translation and replication of HCV genomes containing 
mutations in the IRES that impair translation initiation 98. Genomes with 
mutations that prevent 40S binding or reduce the transition from 48S* to 
80S were severely compromised in both assays. Measuring translation and 
replication with a luciferase reporter in Huh-7.5 cells revealed that the IRES 
mutant genomes were severely compromised for initial translation and levels 
of luciferase failed to reached even the polymerase defective control at all 
time points. The mutations in SLVI did not convey such a dramatic effect. In 
the context of replication defective genomes, a slight reduction of 2- 4 fold 
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below the wild type signal was measured for mutant SLVI genomes, both in 
cell free assays and after transfection. This indicates that mutant SLVI does 
not impede the association of the 40S, eIF3, ternary complex or 60S with the 
IRES. Instead, the mutant SLVI could influence IRES function, by forming 
a tertiary interaction with the IRES sequence. In previous reports, IRES 
structure, and the determination of initiation factor binding, was always 
studied in the absence of SLV and SLVI. Although the RNA complex is 
very large, NMR analysis of the IRES in the presence of SLV and SLVI 
could determine if an altered conformation is formed. Similarly, an 
assessment of the binding of initiation factors to the IRES, in the presence of 
SLV and SLVI, could help define a role for these RNA elements in the 
initiation of HCV IRES- mediated translation. 
 
Can the HCV structural proteins and NS2 act in trans to assist 
replication of mutant SLVI genomes? 
 Translation of the polyprotein is assumed to express each virus protein 
to equal amounts.  The structural proteins are first to be expressed, yet 
cannot assemble a virus until replication has synthesized a sufficient level of 
progeny virus RNA. The capsid protein has been reported to act as a 
translational repressor in addition to its role as a structural protein, and may 
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regulate the transition between translation and replication. Deletion of the 
capsid gene from amino acids 15- 171 reduced replication. In genomes 
where the capsid sequence of SLV and SVI was included, but downstream 
amino acids 57-171 were deleted, replication was improved, but not to wild 
type levels. Replication was further reduced when mutations were 
introduced in SLV and SLVI. To determine if the capsid protein or RNA 
elements in the capsid sequence could transcomplement these replication 
defects, we expressed the capsid protein alone or in the context of E1, E2, 
p7, and NS2. We found that expression of the capsid protein alone reduced 
translation and replication of the wild type and all mutant genomes. 
However, expression of C-NS2 led to an increase in replication of wild type 
and all mutants, after 24H post transfection. Despite the replication increase 
in the presence of C-NS2, replication of the mutant SLV and SLVI 
structures was still below wild type. The increase in translation and/or 
replication contributed by expression of C-NS2 was transitory; by 48H only 
a slight improvement was observed. Expression of the capsid protein alone 
however, continued to result in a lower level of luciferase expression.  
 The influence on translation and/ or replication by C-NS2 at the 24H 
time point implies a role for these proteins beyond virus assembly. Genomes 
containing deletions of the capsid gene, either with or without mutations in 
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SLV and SLVI, were shown to have a reduced translation in cell free 
extracts. This could indicate a threshold amount of C-NS2 proteins is 
required for efficient replication. Expression of the capsid protein in the 
context of the structural proteins and NS2 could tether the capsid location in 
the cell and thus reduce the amount of protein able to interact with the HCV 
genome. In addition, the C-NS2 complex could have a function in 
replication. Although there are many studies claiming the capsid protein 
affects cellular and virus functions when expressed alone, little is known of a 
function for C-NS2 beyond virus assembly.  
 
Is there a subpopulation of Huh-7.5 cells capable of supporting 
replication of SLVI mutants? 
 Observations of Huh-7.5 cells transfected with mutant SLVI genomes 
revealed a small number of cells positive for HCV antigen. We have shown 
that replication of SLVI mutants is impaired by measuring differences at the 
population level. It was unclear, however, if the low levels we detected were 
due to a few cells replicating the mutant to high levels or if most cells in the 
population were weakly replicating the mutant. We therefore measured the 
level of translation and replication of mutant genomes in a limiting dilution 
assay. We found that 100 times more transfected cells were required to 
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detect mutant replication than wild type. At the lowest points of dilution, the 
wild type luciferase level was twice that of the mutant. This indicated that a 
small population of Huh-7.5 cells was able to replicate the mutant genome, 
and that this subset of cells was able to replicate the mutant genome only 
half as well as wild type.  
 Clonal cell populations are known to display heterogeneity that results 
in “noise” when measuring biological pathways 33. Huh-7 cells are no 
exception and subclones have been isolated that differ from the parental line 
with respect to HCV permissivity. Subpopulations of Huh-7 cells capable of 
increased HCV replication were selected to establish the Huh-7.5 cell line 14. 
We observed that mutant HCV RNA was able to replicate in either a 
subpopulation of cells genetically distinct from the rest of the population or 
a small population of cells that were in a particular “state” that enabled the 
launch of mutant HCV replication. Numerous cellular factors have been 
described in HCV replication ranging in function from RNA binding 
proteins to interferon antagonists to lipid metabolism to most known cellular 
pathways. Cellular factors required for HCV replication have been shown to 
be limiting in Huh-7 and Huh-7.5 cell populations, although the identity of 
these factors and the extent of their cell-to-cell variation is unknown 7.  
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Are SLV and SLVI location dependent?  
 We found that the mutations in SLV and SLVI do not affect 
replication when located behind the EMCV IRES in a bicistronic genome. 
This implies that mutations in SLVI were acting in cis and interfere with 
either the IRES or a replication element in the 5’NTR. Finally, we 
discovered that we could rescue the defect in replication conferred by mutant 
SLVI by expressing the replicase complex independently of the HCV IRES. 
This is consistent with the hypothesis that mutation of SLVI reduces 
translation of the replicase proteins, leading to a reduction in HCV 
replication.  
 A similar reduction in translation and replication was shown for the 
flavivirus, BVDV. Replication of a subgenomic replicon of BVDV was 
found to be initially impaired, but improved upon passage in cell culture93. 
Adaptive mutations were identified that removed RNA secondary structure 
from sequence downstream of the BVDV IRES. The authors concluded that 
the presence of RNA structure partially inhibited 40S subunit binding. The 
result reduced translation slightly (8-10-fold), but dramatically reduced 
replication (10-100- fold). The BVDV IRES shares many similarities to the 
HCV IRES; in fact, the BVDV IRES can be functionally replaced by the 
HCV IRES. The selection for adaptive mutations that increase the efficiency 
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of translation relate again to the coupled processes of translation and 
replication and how virus fitness can be dramatically reduced if one stage is 
suboptimal 42.   
 
Model for the role of SLVI in replication 
 The following model is proposed for how SLVI influences HCV 
replication. Using the luciferase reporter genome as a guide of translation 
and replication, the following differences can be determined between wild 
type and mutant HCV RNA. Translation of transfected RNA is initiated in 
both genomes; however, the mutant genome is slightly impaired. For both 
the mutant and wild-type, the polyprotein is expressed and processed into 
the mature viral proteins. Translation continues and in the presence of a 
saturating amount of transfected RNA, little difference between wild type 
and mutant can be detected. Luciferase levels steadily increase and peak at 
8H. Quinket et al. quantitated the nonstructural proteins and plus and minus 
strand RNAs in a replicase complex 108. They determined that the molar ratio 
of nonstructural proteins to negative strand RNAs is 1000:1 and concluded 
that “excessive translation” must first occur before replication begins. In our 
assays, we cannot distinguish between input RNA and replicating RNA by 
qRT-PCR until 12H post electroporation. If a substantial amount of 
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nonstructural proteins must be expressed before replication can proceed, 
replication may not begin until hours after transfection. Upon reaching this 
threshold of protein concentration, the input RNA then enters the replication 
complex. Due to the defect in the efficiency of translation, the mutant may 
lag behind the wild type as it takes longer to achieve the critical amount of 
replicase complex expression.  
 A decline in luciferase expression is detected at 12H post transfection 
in the wild type, mutant, and polymerase defective genomes. The 
polymerase defective genome can express and assemble into a replicase 
complex; it is just nonfunctional. This decline in luciferase is then due, 
either to degradation, or to the input RNA entering the replicase complex 
and being sequestered from the translation machinery. This consistent 
decline in translation indicates a level of synchronicity. An obvious dip in 
luciferase activity was not detected at later time points, where RNA is either 
being replicated or translated. Perhaps additional measurements between 
24H and 72H would detect a trend or the decrease in luciferase is so 
apparent because of the large amount of translation that initially occurred 
without the noise of replication. The half-life of the Renilla luciferase 
protein is approximately 6H. Using a destabilized version might give a more 
accurate measure of the level of translation ongoing at particular time point.  
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 The replicase complex is thought form a membrane-associated 
compartment, which restricts entry of proteins from the cellular 
environment, yet can exchange nucleotides. Replication proceeds through 
synthesis of a minus strand intermediate. By qRT-PCR, an increase of wild 
type RNA levels above the input value can be detected at 12H post 
transfection. Using the luciferase reporter, activity begins to increase at 16H, 
presumably through translation of nascent HCV RNA. It is unknown if 
newly synthesized virus RNA is actively exported from the replicase 
complex or only released when the complex is turned over. The life of a 
replicase complex is though to be 11H to 16H, and the increase in translation 
could be due to a sudden decay of the initial replicase complexes 99, 103. A 
decrease in translation is detected for the polymerase defective genome as 
nascent RNA was not generated. Luciferase activity is lower for the mutant 
genome than the wild type at this time point. This lower level could be due 
to numerous factors. For example, although sufficient nonstructural proteins 
were expressed to initiate replication, the mutant RNA could have built 
fewer replicase complexes than the wild type, resulting in less synthesized 
RNA. The lag in building the replicase complexes could result in lower 
amounts of RNA generated at this time point. The mutant genome could be 
trapped in the replicase complex, perhaps because of an ineffective 
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interaction between a transport protein and the mutant RNA structure, or 
perhaps the replicase complex was built later and therefore will not degrade 
until later. Finally, the lower activity could simply be because translation of 
the newly synthesized RNA is attenuated.  
 Translation of newly synthesized RNA builds more replicase 
complexes. It is possible that, due to protein degradation, an “excessive 
amount” of translation must again occur to reach the amount of required 
nonstructural proteins. It has been observed that replicase complexes cannot 
be trans complemented. That is, a complex cannot replicate an RNA genome 
that it did not translate. Therefore, the nascent RNA must express and build 
its own replicase complex. Since the mutant genome is inefficiently 
translated, replicase complexes take longer to build, and a lag in the amount 
of mutant RNA is always detected. Alternatively, the mutant SLVI may also 
contribute to inefficient replication initiation and therefore reduce the 
amount of synthesized virus RNA. 
 Measuring replication using end point dilution, it was observed that 
fewer cells could replicate the mutant genome. If the mutant genome took 
too long in translation, a sufficient amount of nonstructural proteins would 
never be achieved, the replicase complex would never be built and virus 
RNA could never replicate. The cell would soon lose the HCV RNA. In a 
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minority cell population, however, this did not occur. Perhaps these cells 
express an abundance of translation machinery, are defective in protein or 
RNA degradation pathways, or express a factor that enables the mutant RNA 
to exit the replicase and undergo translation. The minor cell population does 
not, however, support replication of the mutant to wild type levels. It is 
possible that the mutant is also defective in an additional replication step. In 
the bicistronic construct where the replicase was expressed independently of 
the HCV IRES and mutant SLVI, RNA levels were restored to wild type 
levels, but only by 72H post transfection.  
 
Future Directions: 
 Mutations in SLVI attenuate translation and thus compromise 
replication. This reduction is most apparent between 16H and 24H using the 
luciferase system. During this time, initial replication and translation of 
nascent HCV RNA is occurring and the greatest differences between wild 
type and mutant are observed. Since we do not detect such a marked 
difference between the wild type and mutant after initial RNA transfection, I 
am curious if there are differences in translation between the translated RNA 
and recently synthesized virus RNA. To test if translation of the mutant is 
different from wild type after replication, translation could be compared, by 
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luciferase expression, after replication has been stopped by the addition of 
replication inhibitors. If performed at a time post transfection where input 
RNA has decayed, we would only detect translation of replicated HCV 
RNA. A reduction in translation could be a result of disruption of the IRES 
by the mutant SLVI or indicate an inability of the mutant RNA to associate 
with the translation machinery. The mutant RNA could be trapped in the 
replication complex. The replicase complex can be isolated by sucrose 
gradients and the amount of recovered HCV RNA compared. 
 Another remaining question concerns the observation that the liver 
abundant microRNA, miR122 can enhance HCV replication by an as yet 
undefined mechanism 59. In parallel to published results, we found mutations 
of the miR122 seed region in the 5’NTR eliminate HCV replication and yet 
could be restored by compensatory mutations of a lentivirus-expressed 
mutant miR122. The effect of miR122 on HCV replication is a novel 
observation for microRNA, which normally act to down-regulate translation 
of cellular RNA. MicroRNAs are thought to control mRNA expression by 
targeting the cellular RNAs to either processing bodies or stress granules. 
One hypothesis for a mechanism of miR122 in HCV replication is to test if 
HCV is localized to either stress granules or processing bodies, and if this 
action is required for replication. Studies of processing bodies (P bodies) 
308
have identified cellular scaffolding proteins required for their formation. 
Knocking down key proteins by siRNA disassembles the P bodies. 
Comparing HCV replication and virus production in Huh-7.5 cells with 
knocked down P body components would determine if these processes 
contribute to the HCV lifecycle and a role for miR122.  
Although the structure of SLV and SLVI has been probed by chemical 
and enzymatic analysis, a structure with higher resolution would benefit the 
genetic studies and potential interactions with other RNA or protein 
molecules. The size of the complete SLVI is rather large, 86 bases, but 
analysis with NMR, Cryo-EM or X-ray crystallography would provide 
greater detail of the stability of the structure and perhaps a similarity of other 
RNA structures with known function. Determination of the structure and 
interacting proteins of the IRES has not been studied in the context of SLV 
and SLVI. Repeating previous studies of structure and protein binding with 
additional capsid sequence including SLVI may alter the results and provide 
insight into how mutations in SLVI could reduce virus translation and 
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